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Abstract
Poxviruses, including smallpox virus, replicate their linear genomes by forming concatemers that must be
resolved into monomeric units in order to produce new virions. Poxviruses encode a resolvase enzyme that
cleaves 4-way junctions extruded at the concatemer junctions, a process that is essential for viral replication.
Given its important role in the viral life cycle, the resolvase is an attractive target for identifying small
molecule inhibitors of poxvirus infection. To provide a platform for interpreting and designing experiments
and to establish a framework for inhibitor design, we have determined the crystal structure of the canarypox
virus (CPV) resolvase. CPV resolvase is a RuvC-like dimer composed of RNaseH family folds, with an active
site lined by highly conserved, acidic, metal-binding residues. However, there are a number of intriguing
structural differences between resolvase and RuvC. A model of the CPV resolvase•HJ complex provides
insights into the likely consequences of these changes, including a plausible explanation for the weak sequence
specificity exhibited by the poxvirus enzymes. The model also explains why the poxvirus resolvases are more
promiscuous than RuvC, cleaving variety of branched, bulge, and flap-containing substrates. Comparing to
bacterial RuvC, poxvirus resolvase has one additional aspartic acid (Asp130) at the A site in the active site
pocket, which locates at a well-structured α helix. Asp130 side chain carboxylates hydrogen bonds to a water
molecule that coordinates the bound A site metal. Thus, Asp130 contributes indirectly to metal binding and
could be important for resolvase activity.
Based on the unique active site structure observed for CPV resolvase, we have carried out a series of
experiments designed to test divalent ion usage and preferences. We find that the two resolvase metal binding
sites have different preferences for Mg2+ vs. Mn2+ relative to their expected physiological concentrations.
Optimal resolvase activity is maintained with 5 �M Mn2+ and 100 �M Mg2+, concentrations that are well
below those required for either metal alone. The additional Asp130 increases the affinity for divalent ions by
10-15 folds and increases resolvase enzymatic activity. Biochemistry studies on the resolvase inhibitor
demonstrated that it inhibits resolvase activity in uncompetitive manner. Together, our findings provide
biochemical insights and structural models that will facilitate studying poxvirus replication and the search for
efficient poxvirus inhibitors.
We developed one novel method (Metal&EDTA) to purify RNaseH family members. This method takes full
advantage that RNaseH family members have different binding affinities to cationic exchange chromatography
column in the presence of EDTA and divalent ions. High purity of enzymes could be obtained in a two-step
purification using one SP-sepharose chromatography column. Metal&EDTA method has the potential to
purify all types of metal dependent nucleic acids enzymes and metalloproteinases.
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ABSTRACT 
STRUCTURE AND METAL BINDING PROPERTIES OF A POXVIRUS RESOLVASE 
Huiguang Li 
Gregory D. Van Duyne 
 
Poxviruses, including smallpox virus, replicate their linear genomes by forming 
concatemers that must be resolved into monomeric units in order to produce new virions.  
Poxviruses encode a resolvase enzyme that cleaves 4-way junctions extruded at the concatemer 
junctions, a process that is essential for viral replication.  Given its important role in the viral life 
cycle, the resolvase is an attractive target for identifying small molecule inhibitors of poxvirus 
infection.  To provide a platform for interpreting and designing experiments and to establish a 
framework for inhibitor design, we have determined the crystal structure of the canarypox virus 
(CPV) resolvase.  CPV resolvase is a RuvC-like dimer composed of RNaseH family folds, with an 
active site lined by highly conserved, acidic, metal-binding residues.  However, there are a 
number of intriguing structural differences between resolvase and RuvC.  A model of the CPV 
resolvase•HJ complex provides insights into the likely consequences of these changes, including 
a plausible explanation for the weak sequence specificity exhibited by the poxvirus enzymes.  
The model also explains why the poxvirus resolvases are more promiscuous than RuvC, cleaving 
variety of branched, bulge, and flap-containing substrates.  Comparing to bacterial RuvC, 
poxvirus resolvase has one additional aspartic acid (Asp130) at the A site in the active site pocket, 
which locates at a well-structured α helix.  Asp130 side chain carboxylates hydrogen bonds to a 
water molecule that coordinates the bound A site metal.  Thus, Asp130 contributes indirectly to 
metal binding and could be important for resolvase activity.  
Based on the unique active site structure observed for CPV resolvase, we have carried 
out a series of experiments designed to test divalent ion usage and preferences.  We find that the 
two resolvase metal binding sites have different preferences for Mg2+ vs.  Mn2+ relative to their 
expected physiological concentrations.  Optimal resolvase activity is maintained with 5 µM Mn2+ 
and 100 µM Mg2+, concentrations that are well below those required for either metal alone.  The 
vi 
 
additional Asp130 increases the affinity for divalent ions by 10-15 folds and increases resolvase 
enzymatic activity.  Biochemistry studies on the resolvase inhibitor demonstrated that it inhibits 
resolvase activity in uncompetitive manner.  Together, our findings provide biochemical insights 
and structural models that will facilitate studying poxvirus replication and the search for efficient 
poxvirus inhibitors.  
We developed one novel method (Metal&EDTA) to purify RNaseH family members.  This 
method takes full advantage that RNaseH family members have different binding affinities to 
cationic exchange chromatography column in the presence of EDTA and divalent ions. High 
purity of enzymes could be obtained in a two-step purification using one SP-sepharose 
chromatography column.  Metal&EDTA method has the potential to purify all types of metal 
dependent nucleic acids enzymes and metalloproteinases.   
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CHAPTER 1: Poxvirus resolvase Introduction 
Poxvirus and poxvirus resolvase 
Poxviruses are a large group of viruses which infects a very broad range of eukaryotic 
hosts, including mammals, birds, reptiles and insects.  These viruses have long, linear and 
double stranded DNA genomes that are replicated in the cytoplasm of infected cells (1), shown in 
Figure 1-1A.  The best known example is variola, the virus responsible for smallpox.  The 
vaccinia virus (VV), which had been used for many years as a naturally attenuated vaccine to 
eliminate smallpox, has served as the prototype poxvirus for laboratory research.  The VV 
genome is ~200 kb in length and encodes ~200 genes.  During poxvirus replication (Figure 1-1B), 
a viral DNA polymerase and several auxiliary factors generate concatemers of the linear genome 
using a rolling hairpin replication mechanism (2-4).  The concatemer junctions between unit 
genomes contain inverted repeat sequences which can be extruded as 4-way DNA junctions (5).  
These cruciform structures are cleaved by a viral resolvase, resulting in monomeric genomes that 
can ultimately be packaged into new virions (6,7). 
 
Figure 1-1.  Poxvirus replication.  Figure A shows vaccinia virus replication in human cell cytoplasm.  This Figure is 
adopted from reference (8). Figure B shows the vaccinia virus genome replication.  Black lines are single-stranded DNA.  
Half- arrows denote repeated sequences at the genome termini.  Bulges are unpaired DNA at the termini.  The replication 
has four steps: 1) genome replication and concatemer formation.  2). Concatemer isomerizes to form cruciform extrusion.  
3). the cruciform DNA is recognized and cleaved by resolvase.  4). DNA ligation seal the DNA ends. 
The VV resolvase (named A22) was originally identified based on weak similarity to 
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bacterial RuvC proteins (Figure 1-2) and is a member of the RNaseH superfamily (6).  Vaccinia 
virus A22 was the first poxvirus resolvase to be investigated.  Initial studies demonstrated that 
A22 binds Holliday Junction (HJ) substrates and cleaves them in a Mg2+ dependent manner in 
vitro (6).  In infected cells, A22 expression is required for concatemer resolution, viral replication, 
and production of virions, supporting an essential role in concatemer resolution for this enzyme 
(7).  Subsequent studies showed that A22 fusion with maltose-binding protein (MBP) is a stable 
dimer and that the enzyme has only weak sequence-specificity compared to E.coli RuvC (9,10). 
 
Figure 1-2.  Multiple sequence alignment of HJ resolvases from RNaseH family.  Only five conserved motifs are shown.  
The lengths of the poorly conserved spacers between the motifs are indicated by italic numbers.  The positions of the first 
and the last of the aligned amino acid residues in each sequence are also indicated.  The protein designation consists of 
the gene, an abbreviated species name, and the GenBank identification number (separated by underlines).  The multiple 
alignment is based on existing or predicted secondary structure.  E indicates β-sheet, and H indicates α-helix.  Species 
abbreviations: Bacteria: Ct, Chlamydia trachomatis; Ec, E.coli; Hp, Helicobacter pylori; Mtu, Mycobacterium tuberculosis; 
Rp, Rickettsia prowazekii; Ssp, Synechocystis sp; Tm, Thermotogamaritima; Tp, Treponemapallidum. Eukaryotic 
mitochondrial: Sc, Sac. cerevisiae; Sp, Sch.pombe.Viruses: biL66, LBPc2, Lactococcus lactis bacteriophages; CIV, Chilo 
iridescent virus; MCV, molluscum contagiosum virus; MSEPV, Melanoplus sanguinipes entomopoxvirus; Myx, myxoma 
virus; RFV, rabbit fibroma virus; VACC, vaccinia virus; YMV, Yaba monkey virus. Two arrows point to E.coli RuvC and 
vaccinia virus resolvase. This figure is adopted from reference (6). 
The RuvC-like resolvases use Mg2+ ions as co-factors, where two metal ions bind in an 
active site lined with conserved aspartic and glutamic acid residues (11).  During catalysis, the 
metals coordinate the scissile phosphate and the A site metal activates a water molecule for 
hydrolytic attack of the phosphodiester, leaving 5'-phosphate and 3-hydroxyl groups (12,13).   B 
site metal participates in transition state stabilization.  This two-metal ion mechanism is used in a 
broad range of nucleotidyl transfer reactions, including the RNaseH-like nucleases, transposases, 
retroviral integrases, DNA/RNA polymerases, and group I & II ribozymes (14,15). 
 Historically, smallpox has been a major threat to human health.  The virus is highly 
transmissible with infection typically resulting in 20%-30% mortality.  According to the World 
Health Organization (WHO), it has been estimated that 500 million people died of smallpox 
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infection in 20th century (16).  Although the smallpox virus has been eradicated, several reasons 
may cause the smallpox virus to come back.  First, terrorists may use smallpox as a weapon.  
Second, smallpox has been found in frozen mummies in Siberia and it is still infective (17).  When 
global warming intensifies, the contagious virus may infect humans.  Another concern is that 
cross-species virus transmission may infect humans such as monkeypox virus and cowpox virus 
(18).  There are few viral protein targets available for developing small molecule inhibitors as 
drugs except the poxvirus DNA polymerase (19).  Cidofovir has been developed as a inhibitor to 
poxvirus DNA polymerase (19), however, the poxvirus soon acquires the resistance the cidofovir 
(20).  It is clear that we still need other poxvirus enzymes to work as targets to develop drugs.  
Since humans have no homologue of poxvirus resolvase, it is a promising target to develop drugs 
against poxvirus.  Large scale inhibitor screens have been carried out, and several small 
compounds have shown promising inhibiting effect (21). 
RNaseH family members and RNaseH folding pattern 
In 1990, the crystal structure of E.coli RNaseH was determined by two research groups 
independently at same time (22,23).  The RNaseH shows a novel folding pattern with five beta 
strands sandwiched between alpha helices.  In the next several years, crystal structures for two 
other enzymes (HIV integrase and E.coli RuvC) involved DNA recombination have been 
determined (24,25).  Surprisingly, they share a similar folding pattern as RNaseH, although they 
function as dimers and do not show primary sequence homology.  Therefore, the folding pattern 
of RNaseH is called “RNaseH folding pattern” and this group is called the RNaseH family.  Since 
then, more crystal structures of enzymes involved in cleaving nucleic acid have been determined 
with the similar fold pattern.  Important members include transposase (26) which catalyzes 
transposon moving in host genome, argonaute (27) which plays critical role during RNA mediated 
gene silence and cas9 (28) which could introduce double stranded DNA break.  In general, 
RNaseH families are a large group of nucleases which digest double stranded nucleic acid, 
including double stranded DNA (examples is RuvC), double stranded RNA (examples is 
argonaute) and double stranded DNA/RNA duplex (examples is RNaseH).  Typical RNaseH 
family member structures are shown in Figure 1-3.  The oligomeric status of RNaseH family 
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members could be monomer or dimer depending on the number of cleavage sites on the 
substrate.  RNaseH needs only one cleavage thus it adopts a monomeric structure; RuvC and 
argonaute need two cleavages on their substrates, therefore, RuvC and argonaute adopt dimeric 
structures. 
 
Figure 1-3.  Catalytic core domain of RNaseH family members.  The central β-sheet (with numbered strands) and the 
conserved α-helix are shown in orange and yellow, respectively.  More divergent parts of the fold are shown in grey.  The 
active-site residues are shown in ball-and-stick representation.  The two metal ions observed in the Tn5 and RNaseH1 
structures are shown in purple.  The sites of insertions into the RNaseH fold are shown as dashed lines.  The direction of 
the last helix is indicated with an arrow.  HIV, human immunodeficiency virus; PDB, Protein Data Bank code; Tn5, 
transposon 5. This figure is adopted from reference (29). 
RNaseH binds to RNA/DNA hybrids in a sequence nonspecific manner and degrades the 
RNA strand.  Two groups of RNaseH have now been identified: RNaseH1 and RNaseH2 
enzymes.  RNaseH1 enzymes are present in all forms of life from bacteria to animals, as well as 
in retroviruses where they constitute a domain of reverse transcriptase.  RNaseH1 enzymes have 
been implicated in the removal of the RNA primers that are used to start the synthesis of Okazaki 
fragments during DNA replication (30).  RNaseH2 enzymes have different substrate specificity 
and biochemical properties.  Most importantly, RNaseH2 enzymes cleave preferentially at the 5' 
end of RNA in chimeric DNA–RNA–DNA/DNA hybrids.  They can hydrolyze this substrate even if 
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it contains only a single ribonucleotide, whereas RNaseH1 enzymes require at least four 
ribonucleotides (31).  Therefore, RNaseH2 enzymes are thought to be involved in the removal of 
single ribonucleotides misincorporated into DNA during replication(32). 
Although there is no detectable homology between the members of the RNaseH family, 
the structure of their catalytic RNaseH domains is highly conserved (33).  The central and most 
invariant element of this domain is a five stranded β-sheet and one α helix.  The first three 
strands are anti-parallel and usually run without any insertions. The shorter fourth and fifth 
strands run parallel to the first strand.  In addition to the central β-sheets, the fold contains α-
helices of variable position and arrangement.  The most conserved α-helix is located immediately 
after strand 3.  It is adjacent to one face of the β-sheet and runs across it. 
Table 1-I.  Enzymes that use two metal mechanism and possess an RNaseH folding pattern 
Enzymes activity Two-metal-mechanism RNaseH folding pattern 
Transferase activity   
     DNA polymerase (34) Yes  
     RNA polymerase (35) Yes  
     Reverse transcriptase (36) Yes Yes (RNaseH domain) 
Hydrolase activity   
     Restriction enzyme(37) Yes  
     RNaseH (23) Yes Yes 
     Bacteria Resolvase (24) Yes Yes 
     Dicer (38) Yes  
     Argonaute (27) Yes Yes (RNaseH domain) 
     Cas9 (28) Yes Yes (RNaseH domain) 
     Poxvirus resolvase Yes Yes 
     Bacteria UvrC (39) Yes Yes 
     Prp8 (40) Yes Yes (RNaseH domain) 
     Alkaline phosphatase (41) Yes  
Ligase activity   
     DNA ligase (42) Yes  
     RNA ligase (43) Yes  
Combined activity   
     Transposase (26) Yes Yes 
     Retroviral integrase (25) Yes Yes (RNaseH domain) 
Divalent ions are essential for catalysis.  The preferred ion is Mg2+, but Mn2+ also 
supports catalysis.  The crystal structures solved in the presence of nucleic acid (RNaseH1 
enzymes) indicated the involvement of two ions (12,44) and a general two-metal ion mechanism 
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(45).  In this mechanism, metal ions are located on two sides of the scissile phosphate: the A site 
Mg2+ ion activates the nucleophile; and the B site Mg2+ coordinates and stabilizes the transition 
state and the leaving group (Figure 1-4C).  The two-metal-ion mechanism is not only used by 
RNaseH family members, but also for most of the divalent ion dependent nucleic acid enzymes.  
Table 1-I lists the typical nucleic acid enzymes using a two-metal-mechanism to carry out their 
biological functions and possessing an RNaseH folding pattern.  The active sites of RNaseH 
members are composed predominantly of negatively charged carboxylate residues that 
coordinate the metal ions. 
 
Figure 1-4.  Crystal structure of RNaseH and RNaseH•DNA/RNA complex.  A) shows the E.coli RNaseH.  PDB code: 
1RNH. The critical amino acids are shown as sticks.  Conserved motifs are colored green, while divergent parts are 
colored purple. B) shows the Human RNaseH•DNA/RNA complex.  PDB code: 2QKK.  The critical amino acids are shown 
as sticks.  RNA strand is colored in red, while the DNA strand is colored in blue.  Two Mg2+ ions at the active site are 
shown as blue spheres.  Three water molecules interacting with A site metal are shown as red spheres.  C) shows the 
detail structure at the active site of panel B, adopted from reference (29). 
Two residues (two aspartates or one aspartate and one glutamate) are particularly 
important and are well conserved, as shown in Figure 1-4A.  The position of these two residues is 
also highly conserved: the first is in the middle or at the end of the first β-strand and the second is 
at the end of the fourth strand, adjacent to strand 1.  The first carboxylate is the only one that 
coordinates directly both metal ions and is located at the heart of the active site (12).  The second 
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residue coordinates metal ion B.  The third residue of the active site—the most C-terminal of the 
three coordinates metal ion A.  This residue is comparatively variable and can be an aspartate, a 
glutamate or a histidine (46).  Members possessing a histidine at the last C-terminal are often 
either located in the cytoplasm or are from archaea.  This residue is always located in a less 
conserved part of the core structure, after strand 5 of the central β-sheet.  This region usually 
forms a α-helix that is adjacent to the β-sheet, but in some species it exists as a loop.  The 
number of residues interacting with metal ion A also varies from two to four(24,47,48). 
Crystal structures of bacterial and human RNaseH1 enzymes bound to RNA/DNA hybrids 
have been determined (12,44).  The crystal structure of human RNaseH1•RNA/DNA complex is 
shown in Figure 1-4B.  In both cases, the nucleic acids adopt B from and were seen to interact 
with the active site.  Both bacterial and human RNaseH1 enzymes contain two grooves on their 
surface, each of which accommodates one strand of the RNA/DNA hybrid.  The RNA-strand 
groove contains the active site, and the RNA is specifically recognized by interactions with 2'-OH 
groups.  Two metal ions have been observed at the active sites of both bacterial and human 
RNaseH1 enzymes, which are coordinated not only by carboxylates from the active site but also 
by the backbone of the RNA. 
RuvC and HJ resolution 
Homologous recombination is a fundamental cellular process that rearranges genes 
within and between chromosomes, promotes DNA repair, and guides segregation of 
chromosomes at division.  More than 50 years ago, Holliday proposed a meiotic recombination in 
which homologous chromatids exchanges single DNA strands to form a joint molecule with a 
four-way junction at the point of exchange (49).  The four-way DNA strand exchange is reciprocal 
and generates a HJ.  Since then, enzymes responsible for resolving the four-way junction DNA 
have been identified in all kind of organisms, including bacteriophage T7 endonuclease I (endo-I) 
(50) (51), bacteriophage T4 endonuclease VII (endo-VII) (52), bacteria RuvC (53) and eukaryote 
Mus81-EME1 (54).  Among these junction resolvases, RuvC was extensively studied.  In early 
1990’s, the crystal structure of E.coli RuvC was determined (24).  It functions as a dimer, and 
shows a similar folding pattern to E.coli RNaseH, although they do not have primary sequence 
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homology, shown in Figure 1-5A 
 
Figure 1-5.  Crystal structure of E.coli RuvC and mechanism of RuvABC recognizing and cleaving HJs.  Figure A shows 
the crystal structure.  Critical amino acids are shown as sticks.  Figure B shows the cartoon diagram of RuvABC 
recognizing and cleaving HJ.  RuvA is colored in yellow, RuvB is color in blue and RuvC is colored in magenta.  Left 
Figure the top view and right Figure shows the side view.  Figure B was adopted from reference (55).  Two opposite 
Junction arms are pumped in from RuvAs, and the other two opposite arms are pumped out from RuvB. 
RuvC functions as a dimer, and each monomer has 5 conserved beta sheets sandwiched 
between alpha helices.  Four of critical amino acids comprise the active site.  The dimeric RuvC 
resolves the HJ into duplex products by the introduction of symmetrically related nicks in two of 
the four DNA strands.  It shows a preference for cleavage between the third and fourth positions 
of a tetra-nucleotide sequence with the consensus 5’-(A/T)TT↓(G/C)-3’ (56).  In the early study of 
the ruv gene region, scientists identified two other genes, RuvA and RuvB (57).  These two gene 
products are also involve in the homologous DNA repair pathway in E.coli.  Crystal structures of 
RuvA and RuvB have been determined (58,59), and RuvA has been further determined as a 
crystal structure with HJ (60).  A tetramer of the RuvA protein forms a grooved platform on which 
the HJ is held in a square planar configuration.  Each subunit binds one HJ arm and the four arms 
adopt a crossed configuration.  RuvB is an AAA enzyme (ATPase associated with various cellular 
9 
 
activities).  It functions as a hexamer, forming a ring shape with a central hole to hold HJ arms. 
Piecing these data together, researchers gradually formed a clear model to explain how 
RuvABC recognizes and cleaves the HJ in a concerted manner (55,61).  When RuvABC complex 
carries out its function, it uses a sequential process.  DNA HJ is first recognized and bound by 
RuvA.  Then one RuvB molecule is loaded on opposing arms of the junction via contacts with 
RuvA; five extra RuvB molecules polymerize to form a hexamer and wrap around the HJ arm.  
Finally, RuvC is loaded on the opposite side of RuvA.  Branch migration of the HJ is achieved by 
the RuvB helicase motor drawing the DNA through the complex, with each duplex arm rotating 
within the channels on the surface of RuvA.  DNA arms perform continuous open and anneal 
process at the junction center.  Meanwhile, RuvC scans the HJ to search for preferred sequence 
and carry out the cleavage. This model is shown in Figure 1-5B. 
For two decades, the attempt to crystallize E.coli RuvC with HJ was not successful.  In 
recent years, researchers switched their interests from E.coli to Thermus Thermophilus 
(T.thermophilus) and successfully obtained one high resolution crystal structure (1.28 Å) of RuvC 
alone (62) and one low resolution crystal structure of RuvC•HJ complex (3.75 Å) (63), as shown 
in Figure 1-6A, 1-6B.  The overall structure of T.thermophilus RuvC is similar to E.coli RuvC. 
Comparing the T.thermophilus RuvC structure between apo and complex forms, it adopts 
similar structural conformations.  The only differences locate at the β4-α2 loop and the α3-α4 loop 
region.  The β4-α2 loop adopts an asymmetric conformation in the apo form; however, it adopts a 
distinct conformation when RuvC forms a complex with HJ.  RuvC forms a symmetric 
conformation, moving along the junction center region to determine the substrate sequence 
specificity.  The α3-α4 loop region is flexible in the complex form.  The junction DNA in the 
complex is in an unfolded 2-fold symmetrical conformation, in which the four arms point toward 
the vertices of a tetrahedron.  The two arms during HJ resolution to be cleaved extend to the 
bottom two vertices, where they form numerous interactions with RuvC active sites and flanking 
regions.  The two uncleaved arms in the HJ resolution do not interact with RuvC, and extend to 
the upper two vertices. 
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Figure 1-6.  Structure of T.thermophilus RuvC and RuvC•HJ complex.  A) shows the crystal structure of T.thermophilus 
RuvC (PDB code: 4EP4).  B) shows the crystal structure of T.thermophilus RuvC•HJ complex.  (PDB code: 4LD0).  Uarm 
denotes the HJ arm which is not cleaved during HJ resolution;  Carm denotes the HJ arm which is cleaved during HJ 
resolution.  C) shows the crystal structure of endonuclease VII•HJ complex.  (PDB code: 2QNC).   D) shows the crystal 
structure of endonuclease I•HJ complex (PDB code: 2PFJ).  Critical amino acids are shown as sticks.  RuvC are shown in 
cyan while HJ DNA as colored in magenta.  Two monomers in endo-I and endo-VII are colored in green and red 
respectively.  HJ are shown as yellow ribbons in endoI•HJ and endoVII•HJ complex. 
Two other resolvase•HJ complexes have been reported.  They adopt different 
conformations to recognize and cleave HJ substrates.  One of them is bacteriophage T4 endo-
VII•HJ (Figure 1-6C).  In this complex, the HJ adopts a planar, un-stacked “X” conformation, and 
runs over one surface of endo-VII resolvase.  Endo-VII only approaches HJ from minor groove, 
and forms interactions with the sugar and phosphate moieties of HJ.  Another resolvase•HJ 
complex is bacteriophage T7 endo-I•HJ complex.  In this complex, the HJ adopts a different 
conformation from the HJ in bacteria RuvC and T4 endo-VII (Figure 1-6D).  Two adjacent arms 
stack together by aromatic interactions, and two halves of the junctions twist at 90° degree.  The 
HJ is recognized by two channels at the endo-I surface.  Similar to T4 endo-VII, endo-I only 
contacts HJ by sugar and phosphate moieties, which results in sequence non-specific cleavage. 
Purification of nucleic acid enzymes 
Purifying protein is labor and time consuming work since different proteins have different 
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properties and need different protocols. Nowadays, hundreds of nucleic acid enzymes have been 
cloned, expressed, purified and commercialized, which include DNA/RNA polymerases, 
nucleases, ligases and other (64). Several general methods have been developed to purify 
nucleic acid enzymes (65,66). The most often used chromatography resins are cellulose 
phosphate, SP-sepharose, heparin and hydroxyapatite (HAP) (65,67,68). In general, multiple 
chromatography steps are required for one protein to reach high purity. Fusing the protein of 
interest with an affinity tag could greatly facilitate downstream purification. However, adding tags 
may alter protein properties and cause some negative affects (69). Furthermore, adding a tag 
may also cause crystallization difficulty that hinders further structural study (70). Several cases 
have been reported where nice crystals could be only obtained from non-tag proteins (62,71). 
Thus, it is a general rule that the affinity tag should be removed before the protein of interest goes 
to crystallization trial (70).  
Nucleic acid enzymes use nucleic acids as substrate. Nucleic acids are negatively 
charged molecules. To carry out their biological function, the interface of nucleic acid enzymes to 
bind nucleic acid is heavy positively charged (72). This usually involves numerous positively 
charged residues, such as lysine and arginine (73).  For the divalent ion dependent nucleic acid 
enzymes, there are several negative charged residues at the active site which are surrounded by 
positive charged residues. Electrostatic potential maps of typical nucleic acid enzymes are shown 
in figure 1-7.  
 
Figure 1-7. Electrostatic potential map of typical nucleic acid enzymes. Negatively charged areas are colored red while 
positively charged areas are colored blue. A) shows Klenow enzyme (the large fragment of E.coli DNA polymerase I). B) 
shows the restriction enzyme BamHI. C) shows T7 DNA ligase. 
According to the two-metal-ion mechanism, two divalent ions, Mn2+ or Mg2+, bind at the 
active site (14). Two metal ions at the active site play different roles in the catalysis process. One 
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metal ion activates the attacking water or sugar hydroxyl, while the other metal ion coordinates 
and stabilizes the oxyanion leaving group (12,14,44). This mechanism was first observed in the 
crystal structure of DNA polymerase I from E.coli (74). Later, it was found that most divalent ion 
dependent nucleic acid enzymes, such as polymerases (75), nucleases (37) and ligases (42) use 
a the similar mechanism to carry out their biological functions. The shared surface and active site 
properties may help develop a universal protocol to purify this group of enzymes.   
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CHAPTER 2: Resolvase structure 
Contribution of this chapter pertaining to cell culture of Selenomethionine CPV resolvase were 
prepared by Young Hwang, a staff scientist in the Bushman lab.  The initial phasing and structure 
of CPV resolvase were obtained by Kay Perry, a stall scientist of Beamline NE-CAT at Advanced 
Photon Source. Gregory Van Duyne carried out final stage refinement of CPV resolvase structure 
and constructed the resolvase•HJ model. 
Abstract: 
Poxviruses encode a resolvase enzyme that cleaves 4-way junctions extruded at the 
concatemer junctions, a process that is essential for viral replication.  In this chapter, we solved 
crystal structure of canarypox virus (CPV) resolvase.  CPV resolvase crystals were obtained by 
micro-dialysis method and crystal structure were solved by combination of single wavelength 
anomalous dispersive and molecular replacement method.  CPV resolvase is a RuvC-like dimer 
composed of RNaseH family folds, with an active site lined by highly conserved, acidic, metal-
binding residues.  Comparison of CPV resolvase with E.coli RuvC reveals several structure 
differences. CPV resolvase has two shorter α2 helices than RuvC which constitute the major 
dimerization motif.  CPV resolvase has no α3 helix as RuvC, but has a much longer α4 helix than 
RuvC.  CPV resolvase has one additional aspartic acid in the active site.  A model of the CPV 
resolvase•HJ complex was constructed to study the effects of structure differences on CPV 
resolvase functions.  The long α2 helix in RuvC causes β4-α2 loop interacting with HJ center thus 
determines the HJ sequence specificity. In CPV resolvase, the short α2 helix leads to distance 
between β4-α2 loop and HJ center thus explains the lack of sequence specificity.  The N-terminal 
of CPV resolvase long α4 helix was docked into minor groove of HJ arm, suggesting that CPV 
primarily recognize HJ by four arms. In contrast, RuvC recognize HJ by two arms and junction 
central region.  An additional aspartic acid (Asp130) was identified in the CPV resolvase active 
site.  Asp130 help anchor Mg2+ ion at the active site through a water molecule, therefore, Asp130 
may increase resolvase activity by increasing Mg2+ binding affinity.  Further studies on the 
nucleases which are located in cytoplasm and digest double stranded nucleic acid indicated that 
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all of them have special structures features to maintain high metal affinity.   
Introduction 
Poxviruses carry out their life cycles in the host cytoplasm. Replication of poxvirus the 
genome involves formation of concatemers, and poxvirus resolvase plays an essential role to 
cleave the s to monomeric genome. Based on secondary structure prediction and critical amino 
acid mutation assays, poxvirus resolvase has a similar structure to bacterial RuvC and belongs to 
the RNaseH family. 
Compared to bacterial RuvC, poxvirus resolvase has low substrate specificity.  The 
substrate specificity includes substrate structure specificity and substrate sequence specificity.  
Earlier studies on E.coli RuvC and phage T4 endo-VII demonstrated that RuvC has strict 
substrate specificity, and only cleaves four-way junction DNA (76), while endo-VII cleaves has 
much wider substrate specificity including four-way junction DNA, three-way junction (Y junction) 
and bulged DNA.  The substrate structures are in Figure 2-1A, B and D.  Recent work on poxvirus 
resolvase by Culyba et al indicated that poxvirus resolvase has even wider range of substrates 
similar than those of T4 endo-VII (77).  In addition to the DNA substrates cleaved by endo-VII, 
The authors further found poxvirus resolvase was able to cleave flap DNA, as shown in Figure 2-
1C.  These alternative nuclease activities led to the suggestion that A22 could also participate in 
the initiation of replication and/or double-strand break repair pathways (78).   
 
Figure 2-1.  Structure diagram of poxvirus resolvase substrates.  Figures from left to right are: A) 4-way Holliday Junction; 
B), 3-way Holliday Junction; C), flap DNA; D), Bulged DNA.  T4 endo-VII cleaves substrates in Figure A, B and D.  E.coli 
RuvC only cleave HJ shown in Figure A. 
It is known that E.coli RuvC only recognizes and cleaves specific HJ DNA sequences 
(Figure 2-2A).  RuvC shows a preference for cleavage between the third and fourth positions of a 
tetra-nucleotide sequence with the consensus 5’-(A/T)TT↓(G/C)-3’  (53,56,79).  In contrast, 
vaccinia A22 weakly favors cleavage at the sequence 5’-(G/C)↓(A/T)-3’ (Figure 2-2B), and is 
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much less sequence specific than E.coli RuvC.  These two properties make poxvirus resolvase 
unique: it is structurally similar to RuvC but functionally similar to T4 endo-VII.  Although 
considerable progress has been made in poxvirus studies, our understanding of poxvirus 
resolvase is still very limited because lacking of structural information. 
 
Figure 2-2.  Substrate sequence specificity comparison among E.coli RuvC, phage T4 Endo-VII and fowlpox virus 
resolvase.  Figure A  is adopted from reference (80), and it shows the HJ cleavage by RuvC and endo-VII.  In the middle 
column, migratable HJ was cleaved by RuvC and endo-VII.  RuvC generates several distinct bands while endo-VII 
generates smear bands.  Both enzymes do not cleave linear DNA.  Figure B is adopted from reference (10), and it shows 
the HJ cleavage by RuvC and vaccinia resolvase A22R fused with maltose binding protein.  From left to right, the Figure 
shows the cleavage results on four DNA strands. 
RNaseH family members need different concentrations of Mg2+ to carry out their 
enzymatic functions.  Poxvirus resolvase is active when Mg2+ concentration reach 0.2 mM (10) 
(Figure 2-3A), while E.coli RuvC shows activity when Mg2+ reaches 1 mM (79) (Figure 2-3B) .  
HIV integrase needs a much higher concentration of Mg2+ (5 mM) to be functional (81) (Figure 2-
3C).  The Mg2+ concentration requirement is arranged in the order: poxvirus resolvase<bacteria 
RuvC<HIV integrase.  It is important to note that RNaseH family members often function in 
different cellular compartments.  The poxvirus life cycle, for example, is fully carried out in the 
host cell cytoplasm.  The HIV genome is integrated into the host genome in the nucleus.  RuvC 
functions in the bacterial cell.  Divalent ions are not evenly distributed in the eukaryotic cell.  Most 
divalent ions are located in the nucleus, and mitochondria, where they loosely associate with 
negatively charged macromolecules such as DNA.  According to Thiers’ study, the Mg2+ 
concentration in the nucleus is 60% higher than that in the cytoplasm in term of mass ratio of 
16 
 
magnesium/nitrogen (82).  In these three types of locations, the eukaryotic cell nucleus has the 
highest concentration of Mg2+; the bacterial cell is the next and eukaryotic cell cytoplasm has the 
lowest concentration of Mg2+.  The relative Mg2+ concentration distribution is: poxvirus 
resolvase<bacterial RuvC<HIV integrase.  It seems likely that the different concentration 
requirements of RNaseH family members adapt to their working environment.  It will be very 
interesting to know the structural basis of different RNaseH family members having different 
affinities to Mg2+. 
 
Figure 2-3.  The divalent ion requirement for RNase family members.  A) shows the poxvirus resolves cleavage of HJ 
substrate at the different concentration of Mg2+; B) shows the RuvC activity in the presence of different concentration of 
divalent metal ions.  C) shows the enzymatic activity of HIV integrase in the presence of Mg2+.  Figure A  is adopted from 
reference (10). Figure B  is adopted from reference (79). Figure C  is adopted from reference (81). 
Despite the substantial biochemical data now available for the VV and FPV resolvases, 
there are no structural models available for these proteins that could facilitate interpretation of 
existing data, guide new experiments, or enable structure-based poxvirus inhibitor design.  
Although crystal structures of bacterial RuvC and a yeast mitochondrial resolvase are known 
(24,48,62), the limited sequence similarities and distinct biochemical activities of the poxvirus 
enzymes have made it difficult to utilize homology-based models.  Determination the crystal 
structure of poxvirus resolvase will not only answer these questions, but also provide a platform 
for the design of drugs against poxviruses. 
In my thesis, I have determined the crystal structure of poxvirus resolvase, and 
established a structural basis for poxvirus resolvase possessing low substrate specificity and high 
metal binding affinity, and provided a solid platform for structure-based drug design against 
poxviruses. 
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Results 
CPV resolvase protein purification 
To initiate biochemical and structural studies of a poxvirus resolvase, we performed 
extensive crystallization of fowlpox virus (FPV) resolvase either alone or as a complex with 4-way 
junction DNA.  All of our attempts were unsuccessful.  Although FPV resolvase has improved 
solubility properties compared to the vaccinia virus (VV) resolvase, we found that FPV resolvase 
precipitated upon incubation at 4°C and 20°C, which may have contributed to the difficulties in 
obtaining crystals.  The selection of FPV resolvase as a model system was based on a 
comparison of five different poxvirus resolvase homologs that had been cloned and expressed 
(77).  We therefore expanded the search to include resolvases from five additional poxviruses 
(canarypox, crocodilepox, pseudocowpox, sheeppox, and swinepox) in an attempt to identify an 
ortholog that could be crystallized.  Each gene was codon optimized, synthesized by IDT 
(Integrated DNA Technologies) and cloned into pET21a between for bacteria expression.  We 
found that canarypox virus (CPV) resolvase could be over-expressed in BL21(DE3) cells.  CPV 
resolvase functions as a dimer with a molecular weight of 35 kDa and pI (isoelectric point) of 8.5.  
Detailed CPV resolvase properties are shown in appendix file.  We worked out one initial protocol 
to purify CPR resolvase by combining of two ion-exchange chromatography and one gel-filtration 
chromatography steps.  This protocol yielded CPV about 99% purity by SDS-PAGE.  The results 
are in shown in Figure 2-4. 
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Figure 2-4.  Initial protocol to purify CPV resolvase.  (A) and B) show the results of SP-sepharose chromatography.  A) 
shows the salt gradient elution profile.  B) shows the SDS-PAGE results of different fractions.  Lane 1: Ladder marker; 
Lane 2: lysate; Lane 3: supernatant; Lane 4: flow through; Lane 5 to 13 are evenly sampled from 44 ml to 84 ml.  C) and 
D) show the results of MonoS chromatography.  C) shows the salt gradient elution profile.  D) shows the SDS-PAGE 
results of different fractions.  Lane1: Ladder marker; Lane 2 to 12 are evenly sampled from 25 ml to 36 ml.  E) and F) 
show the results of gel-filtration chromatography.  E) shows the gel-filtration elution profile.  F) shows the SDS-PAGE 
results of different fractions.  Lane1: Ladder marker; Lane 2 to 7 are evenly sampled from 15 ml to 20 ml.  Arrows show a 
unknown protein tightly associated with CPV resolvase. 
We noticed that there is an unknown protein band with molecular weight around 20 kDa 
tightly associated with CPV resolvase.  This band could not be removed during ion exchange 
chromatography and gel-filtration chromatography. 
Large scale crystallization screens were performed using purified CPV resolvase protein 
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with lab-made and commercial available kits by hanging drop vapor diffusion.  One condition 
(0.16 M MgCl2, 0.08M Tris-HCl, pH8.5 24% PEG4000, 20% glycerol) gives needle crystals, 
shown in Figure 2-5A.  Based on this condition, we varied MgCl2, PEG4000, and glycerol 
concentration, and tried buffers with different pH.  However, this result is not easily reproducible 
with only occasional success.  We picked up the best crystal (Figure 2-5B) and tested its 
diffraction at room temperature by capillary mounting.  The crystal diffracts to 7~8 Å, with some 
spots that could be observed at 3.5 Å, as shown in Figure 2-5C. 
 
Figure 2-5.  Characterize CPV resolvase crystals.  A) shows the CPV resolvase crystals obtained from initial screen.  B) 
shows the optimized CPV resolvase crystal. An arrow points to the crystal.  C) shows the diffraction pattern of CPV 
resolvase crystal.  D) shows the SDS-PAGE results of CPV resolvase crystal and purified CPV resolvase. 
Since the final purified protein has two components, we did further experiments to 
characterize the crystals.  We spun down the crystal, dissolved them in SDS-PAGE loading buffer 
and ran electrophoresis to identify the crystal composition.  The result is shown in Figure 2-5D.  
This result confirms that the crystals we obtained are CPV resolvase.  Then it leaves us the 
question, what is the unknown band tightly associated with CPV resolvase? 
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Figure 2-6.  Protocol to purify CPV resolvase.  A) and B) show the results of SP-sepharose chromatography.  A) shows 
the salt gradient elution profile.  B) shows the SDS-PAGE results of different fractions.  Lane1: Ladder marker; Lane 2: 
before induction; Lane 3: Ladder marker; Lane 4: lysate; Lane 5: supernatant; Lane 6: flow through; Lane 7 to 15 are 
evenly sampled from 64 ml to 96 ml.  C) and D) show the results of MonoS chromatography.  C) shows the salt gradient 
elution profile.  D) shows the SDS-PAGE results of different fractions.  Lane1: Ladder marker; Lane 2 to 11 are evenly 
sampled from 25 ml to 34 ml.  E) and F) show the results of gel-filtration chromatography.  E) shows the gel-filtration 
elution profile.  F) shows the SDS-PAGE results of different fractions.  Lane1: Ladder marker; Lane 2 to 8 are evenly 
sampled from 15 ml to 21 ml. 
We did further experiments to characterize both bands to determine their primary 
sequences by mass spectrometry.  These results indicated that the lower band is full length CPV 
resolvase.  To our surprise, the band with larger molecular weight is also CPV resolvase, but only 
matches the N-terminal 147 amino acids.  The additional residues are not resolvase-derived.  We 
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noted that there are 8 adenosine bases in a row after the F147 (AAA-AAA-AAC, coding for KKN), 
suggesting that a translational frameshift could occur here.  A similar translational frameshift of 
adenosine repeats occurs in HIV Gag-Pol translation (83).  Therefore, we changed the codon 
AAA-AAA-AAC to AAG-AAG-AAC without affecting the primary protein sequence and repeated 
the expression and purification.  The purification results are shown in Figure 2-6.  The protein 
tightly associated with CPV resolvase was gone, and the purity was greatly improved. 
The removal of the higher molecular weight band generated an immediate effect.  When we 
crystallized CPV resolvase with the same conditions as described above, each drop contained 
several to several dozen resolvase crystals.  In addition, the crystal quality improved: the crystal 
size increased and the crystals were more single. 
Structure determination 
After we removed the CPV resolvase impurity band, we optimized crystallization 
condition in an attempt to obtain more single and bigger crystals.  Crystals with a larger size could 
be obtained with conditions around 0.15~1.20 M MgCl2, pH7.0~9.0, and 10%~20% PEG4000.  
However, we encountered another problem.  There were several cracks on the crystal surface, 
and some cracks ran through the crystals, as shown in Figure 2-7A and 2-7B.  When we tried to 
cryo-protect crystals by adding glycerol, they broke into thousands of small pieces in seconds.  
We could not even perform a capillary mounting and test its diffraction at room temperature.  The 
observation that glycerol could not be used to cryo-protect these crystals suggests that high 
concentration of glycerol may also have a negative effect on crystal growth, such as crack 
formation.  However, we must keep a high concentration of glycerol to make CPV resolvase 
soluble.  The micro-dialysis method allows more control over the crystallization condition.  
Therefore, we switched from the hanging drop vapor diffusion method to the micro-dialysis 
method. 
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Figure 2-7.  Crystal images of CPV resolvase.  Figures A, B show the CPV resolvase crystals obtained by hanging drop 
evaporation method.  Cracks are visible on crystal surfaces and edges.  Figure C shows the CPV resolvase crystals 
obtained by micro-dialysis method. 
The final crystallization condition of the micro-dialysis method is determined by the 
reservoir/dialysis solution.  Therefore, we decreased NaCl concentration to 0.35 ~ 0.50 M, and 
removed glycerol.  We further found that adding sodium potassium tartrate could help crystal 
growth through an additive screen.  The final condition to grow CPV resolvase crystal was: 10μl 
of 10mg/ml resolvase in 20 mM Tris-HCl (pH 7.4), 15% glycerol, 1 M NaCl and 0.01% NaN3 
dialyzed against 1.5 ml of 50 mM Tris-HCl (pH 8.5), 180 mM MgCl2, 150 mM sodium-potassium 
tartrate, 0.35-0.50 M NaCl at 22°C.  CPV resolvase crystals usually appear in one week and 
continue to grow for another week.  Crystals have the shape of long pyramids, and typical 
crystals reached dimensions of 0.1x0.1x0.5 mm, as shown in Figure 2-7C. 
Various cryo-protectants were tested their effects; however, most of them did not work.  
Resolvase crystals tended to crack or break to pieces.  Fortunately, we found that sucrose could 
effectively cryo-protect CPV resolvase crystals without damaging the diffraction quality.  The 
results of testing different cryo-protection buffers and their effects are listed in Table 2-I. 
Table 2-I.  Summary of cryo-protection of CPV resolvase crystals 
Cryo-protectant  5% 10% 15% 20% 25% 30% 50% 
Glycerol  OK OK Crack Crack Broken   
EG  OK OK OK Crack Broken   
PEG400  OK OK OK Crack Broken   
MPD  OK Broken      
EG/PEG400 OK OK OK Broken    
Sucrose  OK OK OK OK OK OK OK 
Salt concentration 0.5 M 1.0 M 1.5 M 2.0 M 2.5 M 3.0 M 3.5M 
Malonate OK OK Crack Broken    
NaCl OK OK OK OK OK Almost OK Crack 
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We collected one Se-Met dataset and one high resolution native dataset at Advanced 
Photon Source.  Typical images are shown in Figure 2-8.  Se-Met CPV resolvase crystals decay 
quickly during data collection.  The resolvase crystals have the shape of long pyramids, and this 
feature has the advantage that we could shoot crystals along the long dimension without 
changing the crystal orientation.  Therefore, we were able to collect a full dataset using one single 
crystal by translating the crystal.  Native crystals could last longer during data collection, and one 
full dataset could be collected by one single crystal.  The native resolvase diffraction data 
exhibited anisotropy with diffraction limits of 2.3 Å along c* but 2.7 Å along a* and b*.  The data 
were ellipsoidally truncated, anisotropically scaled, and used at 2.6 Å for final refinement.  There 
is one resolvase dimer in asymmetric unit.  CPV resolvase crystals have a Matthews coefficient of 
3.3, and solvent comprises 63% of total cell volume. 
 
Figure 2-8.  Diffraction pattern of CPV resolvase crystals.  The left panel shows the SeMet CPV resolvase, and the right 
panel shows the native CPV resolvase diffraction pattern.  SeMet CPV resolvase diffracts to 3.2Å, and native CPV 
resolvase diffracts to 2.6Å. 
The SeMet dataset extend to 3.2 Å, however, the anomalous signal could only be used to 
5 Å.  Two Se sites were located, and a phased map was calculated.  But, the resulting SAD-
phased map could not be readily interpreted.  We used the HJ resolvase from S.pombe 
mitochondria as a model (Protein Data Bank code: 1KCF), and combined the phasing from 
molecular replacement and Se-Met SAD to obtain an interpretable map.  The diffraction data 
collection and final structure statistics are shown in Table 2-II.  Canarypox virus resolvase has 
152 amino acids.  In our final structure, the N-terminal methionine, and the C-terminal amino 
acids after 145 were disordered.  Residues 114-127 of both subunits are also disordered, but 
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were fit into weak density to provide approximate locations for modeling studies. 
Table 2-II.  Summary of data collection and refinement statistics 
 
Rmerge=Σ|Ih - <Ih>|Σ Ih, where <Ih> is the average intensity over symmetry equivalent measurements; R-factor, Σ|Fobs – 
Fcalc|/ ΣFobs, where summation is data used in refinement.  Numbers in parentheses represent values in the highest-
resolution shell.  *Rfree was calculated with 5% of the data. 
Overall architecture of CPV resolvase 
CPV resolvase is an elongated dimer with a dimension of 40x44x74Å, as shown in Figure 
2-9A.  Each subunit has five beta sheets and four alpha helices.  Five beta sheets are 
sandwiched between two pairs of alpha helices.  β1 to β3 strands run anti-parallel and β1, β4 and 
β5 strands run parallel.  α1 and α2 helices are located in the middle of the dimer forming the 
dimerization motif, while α4 are located at the outside regions.  The active site, defined by a 
cluster of conserved acidic residues, is located in a cleft formed between the β-sheet and the 
α4/α5 helices.  There is one Mg2+ ion identified in the active site pocket.  The dimer has two-fold 
Crystal Native resolvase Se-Met(Peak) 
Space Group P43212 P43212 
Unit Cell a=b=89.1Å, c=117.9Å a=b=89.3Å, c=118.2Å 
 α=β=γ=90° α=β=γ=90° 
Wavelength (Å) 0.97918 0.97947 
Resolution (Å) 50-2.6 50-3.2 
Completeness (%) 99.7(99.9) 99.9(100) 
Rmerge 0.09(0.99) 0.156(0.922) 
Mean I/σ 14.5(1.4) 23.9(3.3) 
Redundancy 3.4(3.2) 13.6(11.7) 
Unique Reflections 18685 8250 
SAD phasing   
Se sites  2 
Resolution (Å)  5.0 
SeMet/Model Phase combination  
Figure of merit 0.669 
Final total log likelihood gradient map -86084 
Molecular replacement   
Model 1KCF  
Resolution (Å) 2.9  
Refinement   
Rfree* 0.264  
Rwork 0.198  
Number of atoms   
Protein 2342  
Mg2+ 2  
Tartrate 10  
Solvent 35  
RMSD   
Bond length (Å) 0.008  
Bond Angles (°) 1.270  
Ramachandran plot (%)   
Favored 94.4  
Allowed 5.6  
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symmetry, generated by interactions between the α1 and α2 helices.  However, their 
conformations are not exactly identical.  The overall rmsd between the two subunits is 0.330 Å.  
The β4-α2 loop region (residues 60-67) adopts different conformations, and has a higher rmsd of 
1.471 Å (Figure 2-11H).  The asymmetric structure at these loop regions is also observed in 
RuvC from E.coli and T.thermophilus. They are involved the sequential cleavage of HJ substrates 
at the two cleavage sites (62,63). 
The electrostatic potential of CPV resolvase is unevenly distributed.  One side bearing 
the active sites is rich in positively charged residues, making it a positively charged.  This face 
binds HJ substrate.  Only the active site forms a small patch of negatively charged area, with a 
function to bind divalent ions as cofactor.  The opposite side is rich in negatively charged residues, 
making it a negatively charged surface.  The electrostatic potential map is shown in Figure 2-9B. 
 
Figure 2-9.  The overall structure of poxvirus resolvase and its electrostatic potential map.  A), Resolvase structures are 
shown in cartoon.  Left panel shows the side view of CPV resolvase and right panel shows the top view (bearing the 
active sites).  The critical amino acids at the active site pocket are shown in sticks.  Mg2+ ions are shown as blue spheres.  
B) shows the surface electrostatic potential map. Negatively charged area is colored in red and positively charged area is 
colored in blue. Left panel shows the surface without active sites and right panel shows the surface bearing active sites. 
Poxvirus resolvase belongs to the RNaseH family.  We performed a primary and 
secondary structure alignment with other resolvases from the RNaseH family, including fowlpox 
virus resolvase, vaccinia virus resolvase, S.pombe mitochondria resolvase (Ydc2), and 
T.thermophilus and E.coli RuvC, shown in Figure 2-10.  The results show that they have a similar 
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number of secondary structure elements.  All of them have 5 beta sheets and several alpha 
helices.  Importantly, the critical amino acids for enzyme activity are well conserved (22-24,47). 
 
Figure 2-10. Secondary structure alignment of RuvC family resolvases.  Active site residues are shaded yellow, and 
residues identical in three or more of the sequences are shaded gray.  α helices are shown as pink rectangles and β 
strands are shown as green arrows. Ydc2, Schizosaccharomyces pombe; Tth, T. thermophilus; Ec, E.coli 
Comparison between poxvirus resolvase and RuvC from E.coli 
When CPV resolvase and E.coli RuvC dimers are compared, several differences stand 
out (Figure 2-11).  First, the α1 and α2 helices are both longer in RuvC, resulting in a more 
extensive dimerization interface.  For the RuvC, the dimer interface has total area of 953 Å2.  In 
the dimer, the α2-α2 interface only contributes 429 Å2 (45%), while the interface between α1-α1, 
α1-α2 contributes 524Å2 (55%).  Non-polar interaction comprises 22.5% and polar interaction 
comprises 77.5% of total interactions.  The interface comprises numerous of hydrophobic side 
chains, such as A74, A77, L78, L80, L44, L40, I88, L47, and V89. The only aromatic stacking 
comes from Tyr 48 of two subunits, shown in Figure 2-11F.  The overall shape of the RuvC 
dimerization domain resembles a  reversed “V” where the vertex goes into and contacts DNA HJ. 
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Figure 2-11.  Structure comparison between CPV resolvase and E.coli RuvC.  A). Cartoon expression of canarypox virus 
resolvase.  B). Cartoon expression of E.coli RuvC.  Critical amino acids for the catalysis are shown as sticks.  In all panels, 
poxvirus resolvases are colored in green, RuvCs are colored in cyan.  The critical amino acids in resolvase are shown as 
red sticks, and the critical amino acid in RuvC are shown as yellow sticks. Two Mg2+ ions in the active sites are shown as 
blue spheres.   C) and D). Superimposition of resolvase and RuvC.  Resolvase and RuvC were aligned as dimer.   E). 
Zoom in the dimerization motif of resolvase and alpha helix from two monomers are colored in green and light green 
respectively.  Amino acids involved in the dimerization are shown as sticks.  F). Zoom in the dimerization motif of RuvC 
and structures from different monomers are colored as cyan and light cyan.  G), Superimposition of poxvirus resolvase 
monomer and RuvC monomer.  H), Superimposition of two monomers in CPV resolvase.  Side chains of β4-α2 loop are 
shown as sticks. 
In poxvirus resolvase, dimerization is primarily contributed by α2 helix.  We calculated the 
total interface area between two monomer of resolvase is 663 Å2, and 594 Å2 (90%) of them is 
located at α2-α2 interface.  The α1-α2 interface only contributes 69 Å2 (10%).  In this case, polar 
interactions comprise 75%, while non-polar comprise 25%.  The major non-polar interaction is 
aromatic ring contacts with a side chain from other subunit.  The hydrophobic interactions include 
from top to bottom: R64(A, molecule A)-R64(B, Molecule B), P66(A)-Y63(B), K69(A)-Y72(B), 
Y72(A)-K69(B), F73(A)-K75(B), K75(A)-F73(B), F77(A)-Y79(B) and F79(A)-Y77(B), shown in 
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Figure 2-11E.  The overall shape of poxvirus resolvase dimerization domain also resembles a “V” 
with two α2 fragments meeting at the bottom.  Despite the modest self-interaction surface, CPV 
resolvase elutes as a single dimeric peak on size exclusion columns, consistent with the dimeric 
properties of VV resolvase when expressed as a maltose-binding protein fusion (9).   
A second conspicuous difference between the viral and bacterial resolvases is that CPV 
resolvase does not have the α3 helix found in RuvC, and the α4 helix is longer than the similarly 
positioned helix in RuvC.  As discussed below, the shorter α2 and extended α4 helices in CPV 
resolvase suggest that different structural elements may be used to recognize branched DNA 
substrates compared with RuvC. 
Superimposition was performed to compare CPV resolvase and RuvC, as shown in 
Figure 2-11C and 2-11D.  When we compare resolvase and RuvC homology as dimer, it gives a 
rmsd of 8.5 Å, and even the active sites could not be nicely aligned.  However, if we only align the 
core domain (five beta sheet and α4 helix), the rmsd drops to 1.4 Å (Figure 2-11G), suggesting 
that the active site pockets of RuvC and poxvirus resolvase are quite similar. 
Comparison of a bacterial RuvC•HJ structure with a poxvirus resolvase•HJ model 
The crystal structure of T.thermophilus RuvC bound to a DNA four-way junction has 
provided a framework for considering how the bacterial enzyme recognizes this branched 
substrate (63).  Given the common features of the dimeric E.coli (and T. thermophilus) RuvC and 
CPV resolvase structures, we reasoned that the modes of substrate recognition are also likely to 
be similar.  However, there are also some important differences between the two enzyme dimer 
structures, as discussed previously and highlighted in Figure 2-11.  To help visualize the potential 
consequences of these differences in the context of substrate binding, we constructed a model of 
the CPV resolvase•HJ complex by superposition of the CPV resolvase dimer onto the 
T.thermophilus RuvC dimer in the RuvC•HJ complex structure.  For both models, we extended 
the four-way junction arms to lengths of 10 bp using standard B-DNA, leaving the core DNA 
structure unchanged. 
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Figure 2-12.  Comparison of RuvC•HJ complex (PDB code: 4DL0) and resolvase•HJ complex model.  A), T.Th crystal 
structure of RuvC•HJ complex.  RuvC are colored in cyan and synthetic HJ molecule is colored in magenta.  Critical 
amino acids located at the active pocket are shown as yellow sticks.  B), Model of poxvirus resolvase and HJ complex.  
The resolvase was shown in green and HJ was shown in magenta.  Critical amino acids at the active pocket are shown as 
sticks. 
The CPV resolvase•HJ model and RuvC•HJ structure are compared in Figure 2-12.  The 
DNA junction arms extend in directions that approximate tetrahedral geometry, but the four DNA 
strands are not stereo chemically equivalent.  The two “continuous” strands have a B-DNA-like 
backbone conformation at the branch point, whereas the two “crossing” strands have a sharp kink 
at the branch point, similar to that seen in the Cre•HJ complex (84).  The continuous strands of 
the HJ substrate are positioned near the enzyme active sites, consistent with the established 
strand cleavage preference for RuvC (85).  Overall, the enzyme-bound DNA junction adopts a 
confirmation that is distinct from the planar, 2-fold symmetric form found in the Cre•HJ complex 
(84), the stacked-X form found in the T7 endonuclease I•HJ complex (86), and the 2-fold 
symmetric unstacked X form found in the T4 endonuclease VII•HJ complex  (87). 
The RuvC/resolvase dimers engage the minor grooves of the DNA arms as they 
converge at the center of the junction, consistent with biochemical data for FPV resolvase (88).  
The most extensive interactions are with the DNA duplex arms that will be cleaved, which we 
refer to here as the “C arms.” RuvC makes very few contacts to the DNA arms that are not 
cleaved (the “U arms”), except at the very center of the junction (63).  Here, HJ nucleotides in a 
given strand are numbered -10...-1, 1...10, where the branch point phosphate is indicated by -
1:+1. 
An obvious difference between the two complexes shown in Figure 2-12 involves the 
protein-DNA interactions present at the center of the junction.  The α2 helix in RuvC extends into 
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the center of the junction, where side chain from α2 and the β4-α2 loop are well positioned to 
interact with both the backbone and the +1 and +2 base pairs of each arm.  In the CPV resolvase 
model, the α2 helix is shorter, and the enzyme can only contact the sugar and phosphate 
backbone at the junction center.  These observations are consistent with and may explain the 
relative lack of sequence specificity near the junction branch point for the poxvirus enzymes 
(9,10), compared with the strong preferences observed for E.coli RuvC (56,89). 
 
Figure 2-13. Arg100 and Lys101 are conserved throughout poxvirus resolvase. Critical amino acids at the active pocket 
are shown as sticks.  Mg2+ ions are shown as blue spheres.  Arg100 and Lys101 are shown as red spheres. 
A second difference involves the α4 helix, which is longer in CPV resolvase compared 
with RuvC.  The α3-α4 region of RuvC makes only minimal contact with the DNA junction, 
although the disordered loop connecting these helices could potentially form backbone contacts 
to the U arm.  In the CPV resolvase•HJ model, the N terminus of α4 is docked at the minor 
groove of the extended U-arm in each subunit, where resolvase-DNA backbone interactions 
involving both α4 and residue in the β5-α4 loop can be formed.  Arg100 and Lys101 are located 
on the DNA binding surface of α4 and are highly conserved among the poxvirus enzymes, shown 
in Figure 2-13.  Lys101 is essential for activity in FPV resolvase (88), supporting the importance 
of these inferred protein-DNA contacts.  Indeed, Lys101 is also strongly conserved among the 
RuvC-like enzymes (Figure 2-10).  Unlike RuvC, the model predicts that poxvirus resolvases 
make substantial interactions with all four arms of the four-way junction. 
The third difference we observed involves the extent of enzyme-DNA interactions on the 
C-arms of the junction.  RuvC makes a relatively small number of DNA backbone interactions 
after the +1 and +2 nucleotides, with contacts possibly extending to the +6 and +7 positions.  
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CPV resolvase, however, docks in the major groove of the C-arm adjacent to the cleavage site, 
where a complex network of interactions could potentially be formed.  In addition, the disordered 
α4-α5 loop is positioned where it could form backbone interactions in the adjacent minor groove, 
extending potential C-arm contacts to +8/+9 base pairs from the branch point.  The more 
extensive C-arm contacts predicted for the poxvirus enzyme may explain the broad range of 
branched substrates that can be efficiently cleaved (77).  Unlike RuvC, which interacts primarily 
with the center of the four-way junction, resolvase is predicted to interact primarily with the 
junction arms.  Bulged, flap-containing, and alternative junction substrates could each adopt 
conformations in which two duplex segments are bent into a structure resembling the C-arms 
shown in Figure 2-12.  This observation may explain why activity-based screens for poxvirus 
resolvase inhibitors work so well with bulged DNA substrates (21). 
Active site organization 
Two active sites are located at the clefts of the resolvase dimer.  Each active site 
comprises of five conserved negatively charged amino acids (Appendix A), as shown in Figure 2-
14A.  In which, Asp8 is located at the C-terminal end of β1, and Glu59 is located at the C-terminal 
end of β4.  These two negatively charged amino acids are conserved throughout the RNaseH 
family enzymes.  Three other aspartic acids Asp130, Asp131, Asp134 are located at the N-
terminus of the α4 helix.  There is a huge electron density between Asp8 and Asp131, which 
corresponds to one Mg2+ and three water molecules.  The Mg2+ ion forms interactions with the 
carboxyl oxygen of Asp8 and Asp131.  It further interacts with three water molecules in the active 
site pocket.  Water 1 forms a bridge between Asp130, Asp134 and Mg2+.  Waters 2, 3 and 4 only 
forms interaction with Mg2+ and fill the metal coordination sites.  One of waters functions as a 
nucleophile to perform the nucleophilic attack of the scissile phosphate.  The B site (as defined in 
Chapter 1, Figure 1-4 ), where Glu59 is expected to coordinate a second metal ion in the 
presence of substrate, is not occupied in the crystal structure despite the high concentration of 
Mg2+ that is present. This suggests that the resolvase B site has a low affinity for divalent metal 
ions. 
Yang and co-workers (12,13,44) have crystallized a series of RNase H1•DNA-RNA 
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complexes and visualized snapshots of active sites thought to represent the two-metal ion 
catalytic mechanism in progress. A comparison of the CPV resolvase active site with the active 
site from the RNase H1 complexes provides useful insights into how a DNA substrate strand 
could be engaged for hydrolytic attack by resolvase (Figure 2-14B and C). One of the Mg2+ 
coordinated water molecules in the CPV resolvase structure (W3 in Figure 2-14B) may serve as a 
surrogate for the scissile phosphate oxygen atom that bridges between the A site and B site 
bound metals in an active resolvase-substrate complex.  
 
Figure 2-14.  Active site of CPV resolvase. A), stereo view of active site electron density (2mFo-DFc; contoured at 1 ) 
showing theMg2+ water cluster bound at site A and the five acidic active site residues. B) and C), active sites of CPV 
resolvase B) and RNase H1 C) bound to a DNA-RNA hybrid (PDB code 2QKK). Metal coordination and Asp-water 
hydrogen bonds are drawn as dashed lines. The substrate scissile phosphate is expected to displace one of the water 
molecules coordinated to Mg2+ in the CPV resolvase A site. Asp130 and Asp134 stabilize a Mg2+ bound water through 
hydrogen bonding.  
Resolvase has an additional aspartic acid in the active site 
We compared the active sites among CPV resolvase and other typical RNaseH family 
members, including E.coli RuvC, T.thermophilus RuvC, S.pombe Ydc2, HIV integrase and E.coli 
RNaseH, shown in Figure 2-15.  RNaseH family members have different critical residues in their 
active sites.  The numbers range from three to five.  HIV integrase only has three residues; E.coli 
RuvC has four residues while CPV resolvase have five residues.  The critical residues numbers 
have an inverse correlation with Mg2+ concentration requirements for enzyme activity as 
described in the introduction. 
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For each of the four HJ resolvases, three residues are involved in the B site metal binding.  
The difference in active site residues is located at the A site.  CPV resolvase has one extra 
aspartic acid in the A site compared to E.coli RuvC.  Which one is the extra, Asp130 or Asp131?  
In Figure 2-14, it seems amino acid Asp131 is the extra one.  The Bushman lab has 
systematically studied the function of amino acids function in the active site of the related fowlpox 
virus resolvase (88).  Their results suggested that Asp8, Glu59, Asp131, and Asp134 (numbers 
refer to CPV resolvase) are critical amino acids which are required for the resolvase activity.  Our 
enzymatic studies also showed that the D131A mutation abolished the resolvase function (The 
experiment is shown in Appendix A).  We believe Asp130 is the extra aspartic acid in the active 
site, since Mg2+ directly interacts with Asp131, but indirectly interacts with Asp130.  Four residues 
in CPV resolvases form a shape of square, in which the Mg2+ interacts with Asp8 and Asp131, 
and indirectly interacts with Asp130 and Asp134 through a well-anchored water molecule.  This 
H-bond and salt bond network does not work for Ydc2, since the corresponding residues adopts 
the shape of a rhombus. 
RNaseH has 4 critical amino acids in the active site pocket, where the orientation of 
active pocket arrangement rotates by 90° (Figure 2-15F).  E48 is unique to RNaseH and it 
provides enzyme the ability to recognize the RNA strand in an RNA/DNA duplex (44). 
 
Figure 2-15.  Active sites of typical RNaseH family members.  Amino acids in red dashed line box are the amino acids 
forming the A sites, while the amino acids in green dashed line box are the amino acids forming B sites. 
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Double stranded nucleic acid nucleases in the cytoplasm have special structural features 
to maintain high metal binding affinity to Mg2+ 
Poxvirus resolvase has one extra Asp in the active site, and this increases metal binding 
affinity by 10-15 fold.  Considering that divalent ions  are not evenly distributed in eukaryotic cells 
and most ions are located in the nucleus (82), we suggest that Asp130 enhances poxvirus 
resolvase function and is required for poxvirus resolvase to functions efficiently in the cytoplasm.  
To seek support for this idea, we looked for examples of double stranded nucleases in the 
cytoplasm possessing high metal binding affinity. 
These nucleases should satisfy three requirements: 1) they should cleave double 
stranded nucleic acids.  These substrates could be double-stranded DNA, RNA or DNA/RNA 
duplex; 2) the enzymes should be divalent ion dependent; 3) They should carry out their 
biological function in the cytoplasm.  The ideal candidates should either have a different folding 
pattern to achieve high affinity binding to divalent ion, or have structures like CPV resolvase 
which possesses an extra aspartic acid to provide high metal affinity, or have other special 
structural features to reach high metal affinity.  Unfortunately, not many double stranded nucleic 
acid nucleases are located at the cytoplasm.  The most well-studied example, bovine pancreatic 
ribonuclease, is located in the cytoplasm.  However, it is not divalent ion dependent, and it only 
digests singe-stranded RNA (90). 
Two enzymes involved in the RNA interference digest double stranded RNA.  One is 
Dicer, and the other is Argonaute (27).  Dicer cleaves double stranded pre-microRNA into short 
double stranded RNA fragments called micro-RNAs.  The exact Mg2+ concentration requirement 
for Dicer has not been reported.  However, from the Provost et al study (91), when Mg2+ reaches 
1 mM, the Dicer reaches its maximum velocity, suggesting the real Mg2+ requirement is much 
lower than 1 mM  (Figure 2-16C).  The crystal structure of human Dicer has been solved (92).  
Dicer has a very different folding pattern than RNaseH, suggesting that different folds also 
support high affinity biding to metal ions (Figure 2-16A and B).  Interestingly, the Dicer crystals 
were obtained in the presence of 20 mM MgCl2, much lower than CPV resolvase crystals (180 
mM MgCl2).  We also noticed that in the A site, Mg2+ coordinates with three negatively charged 
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amino acids, and three water molecules.  Together, these data support the idea that Dicer uses 
different folding pattern to obtain high metal affinity in cytoplasm. 
 
Figure 2-16.  Human dicer has a special folding pattern to obtain high metal affinity.  A) shows the crystal structure of 
human Dicer (92).  B) shows the active site of human Dicer (PDB: 2EB1).  Mg2+ are shown as blue spheres, water 
molecules are shown as red spheres and negatively charged amino acids are shown as sticks.  Salt or hydrogen bonds 
are shown as dashed lines.  C) shows human Dicer enzymatic activity in the presence of different concentration of Mg2+.   
Figure C is adopted from reference (91). 
Next we carefully studied the structure of the PIWI domain of human argonaute.  The 
PIWI domain shares a similar folding pattern as RNaseH, and is responsible for the double 
stranded RNA cleavage in RNA interference.  We found that the last critical amino acid, located in 
an alpha helix, is a histidine, not an aspartic acid as in E.coli RNaseH (93) (Figure 2-17A and B).  
Since divalent ions could be coordinated by the δ-1 nitrogen atom of histidine, this suggests that 
histidine in the PIWI domain serves a similar role as an aspartic acid in RNaseH. This finding 
inspired us to search all eukaryotic species and compare the primary sequences of argonautes  It 
is very interesting that all eukaryotic argonautes have a histidine at the last alpha helix of the 
PIWI domain (Figure 2-17D).  As a comparison, most prokaryotic species have an aspartic acid at 
the same position (94) (Figure 2-17C).  Interestingly, some extreme thermophiles also have a 
histidine in the argonaute active site, as shown in the Figure 2-17D.  The histidine in this position 
may help stabilize Mg2+ at higher temperature. 
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Figure 2-17.  PIWI domain of Argonautes from eukaryotes and some thermophile prokaryotes have special structure 
composition to get high metal affinity.  A) shows the crystal structure of PIWI domain of human argonaute.  B) shows the 
crystal structure of E.coli RNaseH.  Box with red dashed lines shows the A site and boxes with green dashed lines shows 
the B site.  C) shows the primary sequence of argonaute from Cyanobacteria Calothrix sp.  D) shows primary sequence 
alignment of PIWI of typical eukaryote Argonautes and some thermophile species of some prokaryotes.  Protein ID in the 
alignment: Calothrix sp: WP_019497030; Methanotrorris Formicius: WP_007044032; Pyrococcus furiosus: 62738879; 
Thermococcus barophilus: WP_013468138; Arabidopsis-thaliana: AEE32289; Caenorhabditis-elegans: NP_500994; 
Danio rerio: NP_001289151; Drosophila melanogaster: NP_730054; Homo sapiens: NP_004755; Mus Musculus: 
DAA00372; Schizosaccharomyces P: CAA19275; Xenopus laevis: ACA52290. Critical amino acids form active sites are 
shadowed in yellow. 
Metalloproteinases use two histidines and one glutamate to achieve high affinity for 
divalent ions 
We found that the number of histidines in the active site, is correlated with the affinity to 
metal that they bond.  Examples are divalent ion dependent metalloproteinases (Figure 2-18).  
Unlike nucleic acid enzymes, which use two metal ions at their active sites, metalloproteinases 
only need one divalent ion at their active sites (95).  Three critical amino acids form the active site.  
One of them is glutamate, and the other two amino acids are histidines.  These three amino acids 
form one salt bond and two dipolar bonds with Zn2+.  One water molecule also binds to Zn2+, 
which is activated by Zn2+, and performs nucleophilic attack against the substrate peptide bond.  
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Most metalloproteinases use Zn2+ as their cofactor, but some metalloproteinases prefer to use 
other divalent ions, such as Mn2+, Cu2+, or Co2+ based on the subtle difference at the active site 
(96).  Metalloproteinases have extremely high affinity for their cofactor, which could often reaches 
nano-molar levels (97). 
 
Figure 2-18.  The active site of bovine pancreas carboxypeptidase (BPC) has special structural feature to maintain high 
affinity to Zn2+.  A) shows the overall structure of BPC at 1.2 Å resolution (PDB: 1M4L).  B) shows the active site 
composition.  Salt bonds or dipolar bonds are shown as dashed lines. 
The affinity of metalloproteinases to metal is so strong that once the metalloproteinase 
has been activated, divalent ion is always sitting at the active site, and ready for the nucleophilic 
attack.  The divalent ion could only be removed by harsh conditions, such as adding EDTA to 
chelate the metal, or changing pH from neutral to acidic conditions.  
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CHAPTER 3: Resolvase biochemistry 
This chapter focuses on poxvirus resolvase biochemistry study.  Young Hwang, a staff scientist in 
the Bushman lab, made various contributions which included providing fluorescence labeled 
bulged and Holliday Junction DNA, helping enzymatic experiment and providing resolvase 
inhibitors. 
Abstract 
The structure of CPV resolvase and the model of CPV resolvase•HJ complex have 
important implications for understanding how CPV resolvase recognizes and cleaves HJ 
substrate.  In this chapter, we carried out serial experiments to study the how the resolvase 
structure adapts to its function.  The structure model of CPV resolvase•HJ suggests that N-
terminal α4 helix docks into minor groove of HJ arms.  Our truncation assay demonstrated that α4 
helix increases HJ binding affinity by 1000 folds.  This result supports that CPV resolvase 
recognizes HJ primarily by four arms, while RuvC recognizes HJ primarily by two arms and 
junction central region.  We symmetrically studied the metal binding property of CPV resolvase 
and the effect of Mg2+ and Mn2+ as cofactors. When using Mn2+ as cofactor, resolvase is much 
more active than Mg2+.  When both Mg2+ and Mn2+ are present, optimum activity could be 
reached at low concentration of both Mg2+ and Mn2+.  The additional aspartic acid in the active 
site, Asp130, increases resolvase activity by 10-15 folds.  This property likely adapts to low Mg2+ 
concentration in cytoplasm.  Preliminary studies on resolvase inhibitor indicated that it does not 
bind resolvase alone, but binds resolvase•HJ complex. These results suggest that the resolvase 
inhibitor may inhibit resolvase activity in an uncompetitive manner.   
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Results 
α4 helix enables resolvase to preferentially bind HJ substrates 
Based on the CPV resolvase and HJ structural model, the N-terminal end of the α4 helix 
likely interacts with the HJ substrate arms.  To study the contribution of the α4 helix to HJ binding, 
we made a truncated version that we call ∆7-resolvase (the first seven amino acids at the N-
terminal of α4 helix were deleted: YSDRKKQ), and compared its affinity for HJ substrates with 
wild-type resolvase.  The N-terminus of α4 helix comprises residues frequently observed to 
interact with DNA (98).  We first determined the binding affinity of wild-type resolvase to HJs by 
electrophoretic mobility shift assay (EMSA).  CPV resolvase has a Kd value of about 50 nM for 
the immobile HJ substrate used in our studies (shown in Figure 3-1A).  We then determined the 
binding affinity of ∆7-resolvase to HJ, as shown in Figure 3-1B.  The maximum concentration of 
∆7-resolvase in the experiment resulted in shifting only one fourth of the total HJ.  We estimated 
that ∆7-resolvase has a HJ-binding Kd value of about 50 μM.  These experiments indicate that α4 
increases the binding affinity of resolvase to HJs by 1000-fold, strongly suggesting that the α4 
helix interacts directly with the HJ DNA.  These experiments support the idea that CPV resolvase 
recognizes HJs by interacting with all four arms of the junction rather than just two. 
We next measured the wild-type resolvase and ∆7-resolvase affinities for duplex DNA.  
These results are shown in Figure 3-1C and 3-1D.  Wild-type resolvase has a binding affinity of 1 
μM (Kd) to DNA duplex, while ∆7-resolvase has an estimated binding affinity of 10 μM (Kd) to 
duplex DNA. (The maximum concentration of ∆7-resolvase in the experiment could only bind 
roughly half of total DNA, so this Kd is an estimate).  The binding affinity of resolvase to DNA 
duplex is only 10 times higher than ∆7-resolvase.  Considering the binding affinity of resolvase to 
HJ is 1000 times higher than ∆7-resolvase, we suggest that α4 provides poxvirus resolvase the 
capability to preferentially to recognize HJ substrates.  We also tested the enzymatic activity of 
∆7-resolvase.  The results indicated that ∆7-resolvase does not cleave bulged DNA or only has 
very weak enzymatic activity, suggesting α4 helix is essential to resolvase function (shown in 
Appendix A).  Truncation of N-terminal of α4 helix does not change resolvase property.  ∆7-
resolvase could be over-expressed and purified as wild resolvase. 
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Figure 3-1.  Electrophoretic mobility shift assay to determine the binding affinity of wild resolvase or ∆7-resolvase to HJ or 
DNA duplex.  Figure A shows the structural model of wild CPV resolvase•HJ complex, and Figure B shows the structural 
model of ∆7-resolvase•HJ complex.  Resolvase is shown in green, aphla4 helix is colored in red.  HJ DNA are shown in 
magenta.  Figure C shows the result of HJ affinity to resolvase, while the Figure D shows ∆7-resolvase affinity to HJ.  
Fluorescein labeled HJ was fixed at 5 nM.  Resolvase and ∆7-resolvase concentration are 0 nM, 10 nM, 100 nM, 1 μM 
and 10 μM through lane 1 to lane 5.  Figure E shows the result of resolvase affinity to DNA duplex, while the Figure F 
shows ∆7-resolvase affinity to DNA duplex.  Fluorescein labeled DNA duplex was fixed at 5 nM.  Resolvase and ∆7-
resolvase concentration are 0 nM, 10 nM, 100 nM, 1 μM and 10 μM through lane 1 to lane 5. 
Metal binding properties of CPV resolvase 
The observation of a bound Mg2+ ion, together with a potential role for Asp130 in 
stabilizing the A site metal, prompted us to investigate Mg2+ and Mn2+ binding to CPV resolvase.  
We used isothermal titration calorimetry (ITC) to measure the binding affinities, where metal ions 
were titrated into a solution of resolvase.  These results are shown in Figure 3-2.  CPV resolvase 
has affinities of 108±27 mM (estimated value) and 1.19±0.03 mM to Mg2+ and Mn2+ respectively.  
These results are quite surprising, since the cellular concentration of Mg2+ and Mn2+ are at sub-
milli and micro-molar level (99).  These values would appear to be too high for resolvase to 
function if metal binding to the apo-enzyme is required.  Therefore, poxvirus resolvase must have 
a way to deal with the low concentration of divalent ion.  One possible strategy is that metal 
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affinity is higher to the enzyme-HJ complex and metal binds following the binding of HJ substrate. 
 
Figure 3-2.  ITC experiment to determine the CPV resolvase metal affinity.  Figure A shows the result of titration of 
resolvase buffer with Mn2+; Figure B shows the result of titration of resolvase with Mn2+; Figure C shows the result of 
titration of resolvase buffer with Mg2+; Figure D shows the result of titration of resolvase with Mg2+. Kd of Mg2+ for CPV 
resolvase is a estimated value, since titration profile is not sigmoidal. 
We next used ITC to measure the binding affinities of metal ions to the resolvase•HJ 
complex.  We limited metal binding to a single site and eliminated cleavage activity by using site-
specific resolvase catalytic mutants.  The resolvase E59A mutant was used to measure metal-
binding affinity at A site, since Glu59 is remote from the A site and does not participate in A site 
metal binding (Figure 2-14).  The D131A mutant was used to measure the metal affinity at B site, 
based on similar reasoning.  Both mutants have been previously shown to eliminate cleavage 
activity but bind HJ substrates with wild-type affinities (Kd< 50 nM) for the nearly identical FPV 
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resolvase (88).  As a negative control, we titrated metal ions into a resolvase 
E59A/D130A/D131A/D134A•HJ complex where both metal binding sites were eliminated.  This 
mutant still binds HJ substrates tightly, but the complex does not bind Mg2+ or Mn2+, indicating 
that there are no high affinity binding sites located outside of the enzyme active site.  These 
results are shown in Figure 3-3 and a summary of binding data is given in Table 3-I. 
 
Figure 3-3.  ITC experiment to determine the CPV resolvase•HJ complex metal affinity.  Figure A shows the result of 
titration of Tetra-Mut•HJ with Mg2+; Figure B shows the result of titration of E59A•HJ with Mg2+; Figure C show the results 
of titration of D131A•HJ with Mg2+; Figure D shows the result of titration of Tetra-Mut•HJ with Mn2+.  Figure D shows the 
result of titration of Tetra-Mut•HJ with Mn2+; Figure E shows the result of titration of E59A•HJ with Mn2+; Figure C show the 
results of titration of D131A•HJ with Mn2+; Figure D shows the result of titration of Tetra-Mut•HJ with Mn2+.  Figure BE 
measure the metal affinity at A site of poxvirus resolvase to bind metal; Figure CF measure the metal affinity at the B site 
of poxvirus resolvase to bind metal. 
Mn2+ binds to the A site with Kd=24.7±0.8 μM and to the B site with Kd=5.8±0.2 μM.  The 
surprisingly high affinity of Mn2+ for the metal binding sites of CPV resolvase suggests that this 
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metal ion could be used in vivo, if present at micro-molar concentrations in the cytoplasm of 
poxvirus-infected cells.  When we titrated Mg2+ into the same complex, we found weaker binding, 
with Kd values of 277±14 and 392±16 μM for sites A and B, respectively.  In these experiments, 
the stoichiometries were fixed at N=2 sites per dimer and the affinities were determined from 
standard hyperbolic binding curves, since sigmoidal binding (allowing experimental determination 
of N) would require using concentrations of resolvase•HJ complex greater than 1 mM (79 mg/ml). 
Table 3-I.  Summary of Mn2+ and Mg2+ affinity to apo-poxvirus and resolvase*HJ complex 
 Mg2+ Mn2+ 
Wild-type resolvase (A site)   
Kd (mM) 108±26.7 1.185±0.031 
∆H (kcal/mol) -8.75±0.19 -6.14±0.05 
Wild-type resolvase (B site)    
Kd (μM) N.D. N.D. 
E59A•HJ complex (A site)   
Kd (μM) 277 ± 14 24.7±0.8 
∆H (kcal/mol) 3.93±0.08 2.76±0.02 
D131A•HJ complex (B site)   
Kd (μM) 392±16 5.75±0.21 
∆H (kcal/mol) 4.52±0.08 8.11±0.04 
Cellular Concentration (mM) 0.2~0.7 (100-102) 0.01~0.04 (103,104) (105) 
Surprisingly, CPV resolvase has different metal-binding enthalpies for apo vs 
resolvase•HJ complex.  Mn2+ binds to resolvase with Kd=1.19±0.03 mM and with ∆H=-6.14±0.05 
kcal/mol.  Mg2+ binding to resolvase alone was too weak to be measured under the buffer 
conditions, but we estimated that it has Kd=108±26.7 mM and with ∆H=-8.75±0.19 kcal/mol.  
These results are consistent with other RNaseH family members (106-108).  We discuss the 
implications of these binding enthalpies below in the context of a resolvase•HJ model. 
Another interesting phenomenon is that Mg2+ and Mn2+ have distinct affinity pattern at the 
A site and B Site.  Mn2+ has a 4.3 fold higher affinity to B site than A site, while Mg2+ has a 
roughly similar affinity to A site and B site (A site is little bit higher, 1.4 fold).  The titration of 
resolvase to other divalent ions (Fe2+, Co2+, Ni2+, Cu2+ and Zn2+) could not be performed since the 
all of them will precipitate the resolvase•HJ complex. 
Catalytic efficiencies of Mg2+ and Mn2+ 
The results of ITC experiments suggest that Mn2+ should be an effective co-factor for 
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resolvase cleavage at much lower concentrations than Mg2+.  This is consistent with previous 
findings that Mn2+ is effective at 0.5 mM in HJ-cleavage assays for FPV resolvase.  To 
characterize metal utilization further, we measured Km values for Mg2+ and Mn2+ using a bulged 
DNA substrate (Figure 3-4A and B).  Unlike HJ substrates, which suffer from slow product 
dissociation rates, bulged DNA substrates are both efficiently cleaved and rapidly released by 
resolvase (14, 16). Therefore, bulged DNA was used as substrate for enzymatic assays. 
 
Figure 3-4.  Determination of Vmax and Km value of poxvirus resolvase using Mg2+ or Mn2+ as cofactor.  A), using Mg2+ as 
the cofactor to determine the resolvase maximum velocity and Km value of substrate.  B), using Mn2+ as the cofactor to 
determine the resolvase maximum velocity and Km value of substrate.  C), using Mg2+ as cofactor to determine the Km 
value of Mg2+.  D), using Mn2+ as cofactor to determine the Km value of Mn2+.  In Figure C and D, the substrate levels 
were fixed at 268nM and 395nM respectively. 
Using a fluorescence polarization assay previously developed for screening small 
molecules for inhibitory activity against FPV resolvase (16), we first determined approximate Km 
values for the bulged substrate in the presence of saturating Mg2+ and Mn2+.  The maximum 
velocity measured for CPV resolvase was slightly higher when Mn2+ vs. Mg2+ was used as co-
factor, with kcat(Mn2+)/kcat(Mg2+) ~ 1.7 and substrate Km values of 395±91 nM and 268±58 nM, 
respectively.  Basically, when Mg2+ and Mn2+ concentrations are not limiting factor, resolvase has 
the similar enzymatic activity.  We then measured Km values for Mg2+ and Mn2+ using fixed 
concentrations of bulged substrate at their Km values (Figure 3-4C and D).  As anticipated from 
the ITC experiments, the Km values are quite different for the two metals, with Km=50±17 μM for 
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Mn2+ and Km=750±330 μM for Mg2+.  Mn2+ is more than 10 times as active than Mg2+.  These 
results suggested that when Mg2+ and Mn2+ are limiting factor, their concentrations have 
considerable effects on resolvase activity.  Considering that the physiological concentration of 
Mg2+ and Mn2+ is below or around Km values (99,103), the concentrations  Mg2+ and Mn2+ will play 
a critical role in cleavage of the HJ substrate. 
Resolvase activity in the presence of both Mn2+ and Mg2+ 
Our experiments have thus far indicated that Mg2+ and Mn2+ support resolvase cleavage 
activity, but Mn2+ requires concentrations that may not be available under physiological conditions 
for efficient function at the A site.  Our ITC experiments demonstrate that the two sites at poxvirus 
resolvase active pocket have different binding patterns to Mg2+ and Mn2+.  The A site prefers to 
bind Mg2+, while the B site prefers to bind Mn2+.  We therefore asked whether a combination of 
Mg2+ and Mn2+ would be effective at concentrations lower than are required for either metal ion 
alone.  To address this, we measured the amount of HJ cleaved in a 30 min reaction by CPV 
resolvase using different concentrations of metal ions (Figure 3-5A and B).  When they are the 
only source of divalent ion, 200 μM Mg2+ and 20 μM Mn2+ are required to cleave half of the 
substrate.  When both ions are present, however, the requirements for cleavage of half of the 
substrate are quite different (Figure 3-5C).  At 5 μM Mn2+, the Mg2+ requirement drops to ~100 μM 
and at 10 μM Mn2+, 50-100 μM Mg2+ is sufficient.  These experiments indicate that a combination 
of 5-9 μM Mn2+ and 50-100 μM Mg2+ is sufficient for highly efficient resolvase-mediated HJ 
cleavage. 
Estimates of free cytosolic Mg2+ range from 0.2-1.0 mM in mammalian cells, suggesting 
that use of Mn2+ by poxvirus resolvases may be unnecessary (37).  The cellular concentration of 
Mn2+ has not been investigated nearly as extensively as for Mg2+, but in rat hepatocytes, the free 
and total concentrations have been measured as 0.7±0.1 μM and 34±4 μM, respectively (38).  At 
these concentrations, Mn2+ would be expected to contribute to poxvirus resolvase catalysis.  We 
suggest that in some cell types, and/or under some physiological conditions, the free cytosolic 
concentration of Mg2+ may be limiting and poxviruses could exploit the μM concentrations of Mn2+ 
available to maintain high viral replication activity. 
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Figure 3-5.  Determine the metal concentration requirement for resolvase activity.  A), shows the results using Mg2+ as 
cofactor; B), Shows the results using Mn2+ as cofactor; C).  Shows the different concentration combination of Mg2+ and 
Mn2+; S arrow shows the position of HJ before cleavage, and P arrow shows the position of HJ after cleavage. 
Asp130 increases metal binding affinity and promotes resolvase enzymatic activity 
Poxvirus and mitochondrial resolvases have a fifth acidic active site residue that is not 
conserved among the eubacterial RuvC enzymes (Figure 2-15).  For CPV resolvase, this is 
Asp130.  In the CPV resolvase structure, the Asp130 and Asp134 side chain carboxylates 
hydrogen bond to a water molecule that coordinates the bound A site metal (Figure 2-14).  Thus, 
Asp130 contributes indirectly to metal binding and could be important for resolvase activity.  To 
test this hypothesis, we purified the CPV resolvase D130N mutant and measured HJ cleavage 
activities in the presence of Mg2+ and Mn2+.  The concentrations of Mg2+ and Mn2+ required to 
cleave half of the HJ substrate in a 30 min reaction increase to 3 mM and 200 μM, respectively, 
compared to 200 μM and 20 μM for the wild-type enzyme (Figure 3-6B).  To directly measure 
metal binding to the resolvase A site, we purified the CPV resolvase D130N/E59A protein in 
which B-site binding is blocked and carried out ITC experiments on the mutant resolvase•HJ 
complex.  The Mn2+ Kd for A site increased from 25 μM (Table 3-I) for wild-type resolvase to ~ 
170 μM (Figure 3-6C) for the D130N/E59A mutant, in broad agreement with the cleavage activity 
measurements.  Binding of Mg2+ to the resolvase D130N/E59A•HJ complex was too weak to 
measure reliably using ITC.  We estimated that it is around 5 mM (Figure 3-6D).  These results 
demonstrated D130 increases metal binding affinity by 10~15 fold. 
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Figure 3-6.  The effect of Asp130 on resolvase activity and metal binding affinity.  A), structure model of D130N resolvase 
active site.  B), metal concentration requirement of D130N resolvase cleaving substrate.  C), ITC titration of Mn2+ binding 
affinity of D130N-E59A resolvase at A site at the active pocket. D), ITC titration of Mg2+ binding affinity of D130N-E59A 
resolvase at A site at the active pocket. 
Crystallization of the resolvase•HJ complex 
We made considerable progress in obtaining CPV resolvase•HJ complex and their 
crystals.  We found that the solubility of resolvase•HJ complex is much better than resolvase 
alone.  Resolvase is soluble only in high concentrations of salt and glycerol (1 M NaCl and 15% 
v/v glycerol).  As a comparison, resolvase•HJ complex is highly soluble in 20 mM Tris-HCl (pH 
7.4), 0.1 M NaCl.  E59A resolvase was used to form a complex with HJ substrate to prevent HJ 
cleavage.  We screened for CPV resolvase•HJ complex crystals with commercial and lab-made 
crystallization screen.  Dozens of conditions has shown small crystals, as shown in Figure 3-7.  
All of four arms of the HJ DNA are 15 bp.  These results provide a good starting point to optimize 
crystallization conditions and obtain large single crystals suitable for structure determination. 
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Figure 3-7.  Resolvase•HJ crystals were obtained by the hanging drop vapor diffusion method.  Crystals are shown as the 
same relative size.  A) was obtained in buffer containing 0.1M Tris-HCl (pH8.5), 3M NaCl; B) was obtained in buffer 
containing 0.2 M MgCl2, 0.1M Tris-HCl (pH 8.5), 25% PEG3350; C) and D)  were obtained in buffer containing 0.2 M 
sodium formate, 20% PEG3350. 
Resolvase inhibitor inhibits resolvase activity in an uncompetitive manner 
We carried out preliminary experiments on a previously identified poxvirus resolvase 
inhibitor (1,4-dihydroxy-3-phenyl-6-(4-(trifluoromethyl)phenethyl)-1,8-naphthyridin-2(1H)-one, DPTPN,   
shown in figure 3-8B).  The small molecule inhibits HJ cleavage with an IC50 of 4μM (21).  We 
tried to co-crystallize CPV resolvase with inhibitor, and also soaked resolvase crystals with 
inhibitors.  However, no extra electron density was observed in the crystal structure 
corresponding to inhibitor, although inhibitors clearly diffused into resolvase crystals (inhibitor is 
brown colored and crystals changed to dark brown upon adding inhibitors) (Figure 3-8A).  
Therefore we carried out ITC experiments to measure the affinity between resolvase and the 
inhibitor.  No such experiments had been done previously, since the inhibitors were identified in 
activity-based screens and were not further characterized (21) .The results are shown in Figure 3-
8B.  To our surprise, resolvase does not show measurable affinity to the resolvase inhibitor.  An 
alternative explanation is that binding is purely entropic, which would lead to no heat changes 
during the ITC experiment.  Next, we repeated the ITC experiment measuring the affinity between 
resolvase•HJ complex and inhibitor.  The result is shown in Figure 3-8C.  The inhibitor shows 
weak binding to the resolvase•HJ complex.  Although the dissociation constant and the 
stoichiometry value could not be exactly determined, we roughly estimated resolvase•HJ complex 
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has Kd about mM level and stoichiometry between 1 and 2.  In this experiment, the heat changes 
measured during the titration are very small, indicating a small enthalpic contribution to the free 
energy and the need to perform the experiment at higher concentration of complex.  
Unfortunately, we are limited in the amount of resolvase-HJ complex that we can use.  This was 
also the case for the weak Mg2+ binding experiments described earlier.  ITC therefore does not 
explain the IC50 values observed in the in vitro activity assays of resolvase.  
 
Figure 3-8.  CPV resolvase interaction with inhibitor. A) shows the CPV resolvase crystals soaked with inhibitor. B) shows 
the resolvase inhibitor structure of 1,4-dihydroxy-3-phenyl-6-(4-(trifluoromethyl)phenethyl)-1,8-naphthyridin-
2(1H)-one, DPTPN. The naphthyridin core structure is dash-line circled.  C) shows ITC experiment to determine 
the affinity of CPV resolvase to inhibitor and CPV resolvase•HJ complex.  Left shows the result of inhibitor to resolvase 
and right shows the result of inhibitor.   
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Chapter 4: Resolvase discussion and future directions 
Discussion 
Poxviruses use a special mechanism to replicate their DNA genomes, and this process 
needs the involvement of resolvase.  In this thesis, I solved the crystal structure of resolvase from 
canary poxvirus.  Poxvirus resolvase has a similar folding pattern as RuvC and it belongs to the 
RNaseH family.  However, poxvirus resolvase has considerable functional and structural 
differences from RuvC.  First, their biological roles are different. Poxvirus resolvases plays an 
essential role in the poxvirus life cycle.  When resolvase is deleted, the virus particle is not viable 
(7).  In contrast, RuvC plays a less important role, since it only benefits bacterial growth by 
participating in DNA repair pathways, but is not required for bacterial viability (109) and its 
function could be replaced by other enzymes, such as RecG (110). Second, their enzymatic 
properties are different. Poxvirus resolvase cleaves a variety of nucleic acid substrates aside from 
HJs, while RuvC is specific to HJs. Poxvirus resolvase has less substrate sequence specificity 
than RuvC. In addition, poxvirus resolvase requires lower concentrations of divalent ions to 
function than RuvC. These enzymatic features make poxvirus resolvase one of the most active 
enzymes in the resolvase family, and likely adapt to poxvirus resolvase function.   
In this thesis, I considered several interesting questions and reached some conclusions 
which are unique to CPV resolvase and other poxvirus resolvases. Some of them may also apply 
to other nucleic acid enzymes. Here, I discuss them in detail.  
Structural basis of CPV resolvase’s low substrate sequence specificity 
Of the available resolvase•HJ complex structures, including Endo-VII•HJ from phage T4 
(87) and Endo-I•HJ from phage T7 (86,111),  both of them have no substrate sequence specificity.  
These endo-nucleases exclusively approach HJ from DNA backbones, which explain the lack of 
sequence specificity, as shown in Figure 4-1A and 4-1B.  The eukaryotic counterpart, Mus81-
Eme1, was crystallized as complex with flap DNA substrates.  Similar to the phage resolvases, it 
only interacts with DNA backbones (112).  Bacterial RuvC seems to be an exception since it 
requires a specific junction sequence for the cleavage.  For all the sequence specific 
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recombinases (including Cre recombinase shown in Figure 4-1C, λ integrase, γδ resolvase and 
large serine recombinases), they forms numerous interactions with nucleo bases in the DNA 
major grooves (84,113-115).  In the crystal structure of the RuvC•HJ complex, the β4-α2 loop, 
has close contacts with the HJ central region, thus it provides the substrate sequence specificity.  
Since RuvC shares a similar folding pattern with poxvirus resolvase, we believe that poxvirus 
resolvase should have a similar mechanism to recognize and cleave the HJ. 
 
Figure 4-1.  A), the diagram structure of T4 endoVII•HJ.  Protein is shown in red and green (different monomer as different 
colors).  B), the diagram structure of T7 endo-I•HJ.  Proteins are shown in red and green (different monomer as different 
colors).  C), the cartoon expression of Cre•HJ complex.  T4 endo-VII and T7 endo-I only contact with HJ at backbone.  
Cre forms numerous interactions with DNA bases. 
However, poxvirus resolvase has no or very low substrate sequence specificity.  In our 
resolvase•HJ model, there is about 10Å distance between the β4-α2 loop and HJ.  This region 
could only contact the backbone sugar or phosphate group, but could not interact with nucleo 
bases.  Therefore, poxvirus resolvase avoids forming interactions with the bases from the HJ 
center, and retains low or no substrate specificity.  If this region of the enzyme does not interact 
with the HJ, could the affinity between resolvase and HJ substrate be greatly weakened? Earlier 
experiments show that poxvirus resolvase has the similar binding affinity to HJ as E.coli RuvC 
(77).  In our resolvase•HJ complex model, the α4 helices of resolvase are inserted into the minor 
groove of HJ DNA and interact with substrate.  The extra interaction of α4 with the HJ minor 
groove may compensate for the shorter α2 in poxvirus resolvase.  The putative α4 interaction with 
the HJ may be responsible for very effective HJ cleavage.  Two arms of the HJ are engaged by 
α4, while the other two arms are bound by the active sites and flanking residues, including the 
distant α4-α5 loop.  The interaction between the α4 helix and HJ arm is supported by previous a 
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mutation study on fowlpox virus resolvase (88) and our α4 truncation assay described earlier.  In 
the RuvC•HJ complex, the active sites and flanking residues stabilize two arms; the β4-α2 loop 
stabilizes the junction center region with the other two arms left free.  Therefore, bacterial RuvC 
uses a less effective way to recognize and cleave HJs than poxvirus resolvase. 
HJs and Mg2+ bind to CPV resolvase in a sequential manner 
The binding sequence of HJ and Mg to resolvase has not been carefully studied.  It is 
generally assumed that HJ and Mg randomly bind to resolvase.  Here, we determined the 
Mg2+/Mn2+ affinity to apo resolvase and resolvase•HJ complex.  Based on our ITC and kinetics 
results, I suggest that CPV resolvase recognizes and cleaves HJ substrates in a sequential 
manner, as shown in Figure 4-2A -E.  Our observed results indicate that apo CPV resolvase 
binds to Mg2+ around 100 mM level (only A site binding was observed; B site could not be 
detected because of extremely low binding affinity).  However, CPV resolvase has an affinity to 
HJs around 50 nM in the absence of divalent ions. When resolvase binds to HJs under these 
conditions, it has no activity.  As we have shown, the resolvase•HJ complex greatly improves the 
affinity to Mg2+, and Mg2+ concentration in the cell is high enough so that it could bind at the active 
site.  When the three components form a tertiary complex, cleavage occurs.  After the cleavage, 
the affinity of resolvase to DNA drops to that of double-stranded-DNA level, then DNA dissociates.  
After DNA dissociates, resolvase affinity to Mg2+ also drops, then Mg2+ leaves.  This mechanism 
of resolvase recognizing and cleavage HJs substrate is very different from metalloproteinase 
cleaving protein or peptide substrates, as shown in Figure 4-2F-H.  The affinity of 
metalloproteinase to metal is so strong that it must be synthesized as a zymogen (116-118).  
Once metalloproteinase is has been activated, the metal is always sitting at the active site, and 
ready for the cleavage of substrate. 
53 
 
 
Figure 4-2.  CPV resolvase  and bovine pancreas carboxypeptidase (BPC) use distinct mechanisms to cleave substrates.  
Figure A-E show the model of CPV resolvase cleaves HJ substrate.  HJ and resolvase form complex, then four Mg2+ ions 
join and form tertiary complex.  After cleavage, HJ leave first, and then followed by four Mn2+.  Figure F to G show the 
model of BPC cleaves peptide.  BPC and Zn2+ exist as holoenzyme.  Substrate peptide comes in, is cleaved, then leaves. 
Some nucleic acid enzymes have high affinity for divalent ions, including Cce1, T7 endo-I 
and Methanococcus jannaschii RNase HII.  The role of high affinity binding is in most cases to 
match the free Mg2+ concentration found in the cytoplasm (106-108).  However, these examples 
only have high affinity to Mg2+ at one metal binding site (the A site).  The affinity between 
restriction enzyme and substrate DNA has been intensively studied. In the absence of Mg2+, 
restriction enzyme has relatively weak non-specific binding to nonspecific DNA in the μM range 
(119), and strong specific-binding specific DNA in the nM to pM range (120). The exact affinity to 
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divalent ion has not been studied for apo restriction enzyme. I found one example of 
endonuclease domain of the influenza virus polymerase PA subunit, which is a member of the 
PD-(D/E)XK family of nucleases that use divalent metal ions for nucleic acid cleavage. The PD-
(D/E)XK structure motif is shared by most of restriction enzymes (64). Endonuclease domain of 
the influenza virus polymerase has affinity to Mg2+ at 0.148 and 4mM: suggesting physiological 
Mg2+ concentration could saturate one site, but not both sites (121).   I did not find examples 
which possess sub-millimolar affinity for both the A site and the B site.  Physiological 
concentrations of Mg2+ or Mn2+ do not saturate both the A site and B site for nucleic acid apo 
enzymes as a general rule.  In our studies, we found the expected Mg2+ concentration is high 
enough for CPV resolvase to carry out its biological function.  This conclusion is based on the fact 
that CPV resolvase readily forms a complex with its substrate, and the substrate is well 
positioned and ready for cleavage.  After Mg2+ binds, the nucleophilic water molecule will be 
activated for cleavage.  This mechanism may help resolvase to find the proper substrate and 
prevent wrong or random cleavage of other nucleic acid structures. 
Asp130 functions in poxvirus resolvase and poxvirus replication 
Poxvirus resolvase belongs to the RNaseH family.  Each member has several negatively 
charged amino acids located at the active site.  The number ranges from 3 to 5: HIV integrase 
has only three; E.coli RuvC has four, and poxvirus resolvase has five.  It seems that the aspartic 
or glutamic acid number closely correlates with enzyme activity.  As described in the introduction, 
the Mg2+ concentration requirement for these three members is different, with a sequential order: 
HIV integrase > E.coli RuvC > poxvirus resolvase.  The number of negatively charged amino 
acids is inversely correlated with in vitro Mg2+ concentration requirements for high activity and 
with the available Mg2+ concentration in their cellular environments. 
Comparing to E.coli RuvC, poxvirus resolvase has one extra aspartic acid (Asp130) at 
the active site.  What’s the function of Asp130 in poxvirus resolvase and in poxvirus life? The best 
example to compare with poxvirus resolvase is E.coli RuvC.  Both of them have three negatively 
charged amino acids at the B site, suggesting that CPV resolvase and E.coli RuvC may have 
similar metal affinity at the B site.  Our ITC titration results demonstrated that the B site of CPV 
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resolvase has a Kd value of 0.392 mM for Mg2+, which is in the range of the physiological level in 
eukaryotic cytoplasm.  Therefore, we could conclude that Mg2+ concentration in the cell is not a 
problem for the B site. 
The extra Asp130 is located in the A site.  Now, the question narrows down to the A site.  
When Asp130 was replaced by asparagine, resolvase is still active, but requires a high 
concentration of Mn2+ or Mg2+ to cleave HJ substrate.  Wild-type resolvase needs 0.2 mM Mg2+ to 
be active, while D130N resolvase needs 2.5 mM Mg2+ to be active.  The mutant assay indicates 
that Asp130 is not essential amino acid for resolvase activity.  There is no doubt that Asp130 
increases poxvirus resolvase’s affinity for divalent ion, thus increasing the resolvase’s enzymatic 
activity.  What we are really interested in is whether this feature is required for poxvirus viability.  
Considering that the eukaryotic cell cytoplasm has a lower free divalent ion concentration than in 
the nucleus, it seems unlikely that Mg2+ concentration could not reach 2.5 mM in the cytoplasm.  
Therefore, Asp130 is likely essential for poxvirus resolvase to function in vivo. 
This conclusion is further supported by the observation that available divalent ion 
dependent, double nucleic acids enzymes located in eukaryotic cytoplasm have special features 
to reach high metal-binding affinity.  These features could be different folding patterns or 
replacement of aspartic acid with histidine or addition of an extra aspartic acid at the active site.  
Poxvirus resolvase is one example of possessing an extra aspartic acid to reach high metal-
binding affinity. 
Homologues of RuvC accessory proteins may be not required for poxvirus resolvase 
In E.coli, RuvC works together with RuvA and RuvB as a complex (122-124).  RuvABC is 
a very complicated system, where each member plays a different role.  RuvA functions as a 
sliding frame, supporting four strand of DNA branch-migrating on its surface.  RuvB is an ATPase, 
which pumps out DNA through the RuvA scaffold by hydrolyzing ATP and drives branch migration.  
RuvC scans the HJ DNA sequence and cleaves the substrate when it encounters the preferred 
sequence.  RuvB and RuvC form direct interaction and could be cross-linked by chemical reagent 
(125,126).  In poxvirus, no protein associated with resolvase has been identified (127,128).  I 
doubt that there are resolvase accessory proteins.  Several lines of evidences support the idea 
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that poxvirus resolvase can accomplish HJ resolution alone. 
One line of evidence comes from the simple genome of poxvirus genome.  Poxviruses 
encode about 200 genes, and most of the gene products have been assigned a biological 
function (4).  No protein was identified working together with resolvase.  The second line of 
evidence comes from structural differences between bacterial RuvC and CPV resolvase.  
Bacterial RuvC interacts with HJs primarily by two arms and the junction central region, while 
poxvirus resolvase interacts with HJs by binding to all four junction arms.  Importantly, HJ 
recognition is initiated by RuvA in bacteria, which fixes the HJ configuration as the square planar 
“cross” shape.  We have suggested that poxvirus resolvase first recognizes HJ by the four 
junction arms, and converts to a more planar conformation of the arms upon divalent ion binding 
(129), as discussed further below.  The third line of evidence comes from the fact that poxvirus 
resolvase has higher affinity for HJs than bacterial RuvC.  From our studies and Culyba’s studies 
(77), poxvirus resolvase has an affinity of 20-50 nM (Kd value) in the absence of divalent ions; 
Iwasaki measured the affinity of RuvC to HJ greater than 140 nM (Kd value) (53).  However, the 
affinity of RuvC to HJ could be increased to 20 nM in the presence of 0.5 mM MgCl2 (130).  In the 
real situation, the RuvABC system is very complicated, for the affinity of RuvC to HJ may be 
further strengthened by interacting with RuvB (125). 
The HJ conformation in the active resolvase complex 
Whereas there has been general agreement regarding the sequence specificity of E.coli 
RuvC, the question of where that sequence is positioned on a given branch point isomer that is 
cleaved by RuvC has been more difficult.  Bennett & West (131) used methylphosphonates to 
bias HJ substrates towards specific branch point isomers and concluded that RuvC cleaves the -
1:+1 and +1:+2 phosphates, with a small preference for the branch point position.  Using 
immobile junctions, Fogg et al. (132) found an even higher preference for the branch point 
phosphate.  In contrast, Sha et al (133) used intramolecular torsional restraints to bias the HJ 
isomers formed in solution and concluded that cleavage at the +1:+2 position is strongly preferred.  
For the VV resolvase, Garcia et al (9) found that an immobile HJ substrate was cleaved at both 
the +1:+2 and +2:+3 phosphates.   
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To address this question in the context of CPV resolvase and the model shown in Figure 
2-12B, we first marked the expected locations of scissile phosphates in the enzyme active sites, 
using the highly conserved DDE residues (Asp8, Asp134, and Glu59) and the corresponding 
residues from a high resolution RNaseH1•DNA•RNA complex structure (12), as shown in Figure 
2-14B. Based on these positions, the expected distance between scissile phosphates in the CPV 
resolvase dimer is 36.4 Å.  Assuming that the resolvase dimer remains relatively rigid and the HJ 
substrate is remodeled to fit the enzyme during binding and catalysis, a distance of ~36 Å is 
required between HJ scissile phosphate positions in order to be engaged by both of the enzyme 
active sites.  In the HJ conformer observed in the RuvC•HJ crystal structure, the distance 
between continuous strand branch point (-1:+1) phosphates is 30.8 Å and the distance between 
+1:+2 phosphates is 24.7 A.  Thus, the observed HJ conformation cannot be the one that is 
cleaved by either CPV resolvase or RuvC, assuming a symmetric or nearly symmetric 
mechanism.  The branch point and +1:+2 phosphates are each ~6.5 A from the expected scissile 
phosphate positions in the CPV resolvase active sites, further indicating that the HJ in this model 
does not represent an active conformation.   
To estimate the distances that would be available in alternative HJ conformers (134), we 
calculated the same inter-phosphate distances in the Cre (84), T4 endo-VII (87), and T7 endo-I 
(86) HJ complexes.  For continuous strand branch point phosphates in these structures the 
values are 31.9, 31.6, and 32.0 A, respectively, leading to the surprising conclusion that the RuvC 
enzymes appear incapable of cleaving symmetrically at this position for any known HJ 
conformation.  For the +1:+2 phosphates, the corresponding distances are 34.9, 37.3, and 35.6 A, 
all of which are much closer to the expected distance than that found in the RuvC•HJ complex.  
The Cre and T4 endo-VII HJ conformations are closely related to one another, differing primarily 
by their inter-arm angles and small out of plane deviations in the T4 endo-VII HJ arms.  An HJ 
conformation intermediate between the Cre and T4 endonuclease-bound HJ forms could be 
obtained by 'flattening' the HJ conformers shown in Figure 2-12, while maintaining general 
features of the resolvase-DNA interactions.  The resulting Cre/T4-endonuclease HJ conformation 
would have the correct inter-phosphate distance, would be more closely related to the HJs 
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observed in RuvABC resolvasome studies (135), and would be more consistent with the well-
established conformation of RuvC•HJ and FPV resolvase•HJ complexes in solution (88,136).  
Indeed, the yeast mitochondrial resolvase Cce1 binds to a nearly square planar form of the HJ 
(137).  Additional work will be required to establish the detailed structure of the active RuvC and 
resolvase•HJ complexes. 
Thermodynamic signature of a structural reorganization upon metal binding 
The metal binding enthalpies summarized in Table 1-III support the idea that the poxvirus 
resolvase•HJ complex adopts distinct structural conformations in the presence vs absence of 
divalent ions.  Previous reports have indicated exothermic binding of Mg2+ and/or Mn2+ to RuvC-
like resolvases, as expected from the ionic nature of the coordination complexes that are formed 
(106-108).  Indeed, Mn2+ binding to CPV resolvase is also exothermic.  However, I have shown 
here that binding of Mg2+ and Mn2+ to the resolvase•HJ complex is endothermic, and is therefore 
entropically driven.  These observations can be explained by a model in which a substantial 
number of solvent molecules are bound within the resolvase•HJ interface upon initial complex 
formation but released when divalent ions bind to the complex.  The resulting redistribution of 
solvent would provide both a positive enthalpic contribution (due to 'melting' of water) and a 
favorable entropic contribution.  Additional structural changes may contribute as well and would 
presumably be revealed by high resolution structural models of resolvase•HJ complexes. 
Future directions 
Poxvirus resolvase shares a similar folding pattern with bacterial RuvC; however, it 
possesses considerable structural differences, such as the ability to bind variety of substrates 
preference and high metal-binding affinity.  This leaves several unanswered questions regarding 
poxvirus resolvase’s mechanism of action.  Does the poxvirus resolvase structure adapt to its 
biological functions? What is the three dimensional structure of the resolvase•HJ complex? Does 
it have a similar conformation as the RuvC•HJ complex prior to divalent metal binding? What is 
the nature of the conformational change upon binding of Mg2+?  Where do the currently known 
resolvase inhibitor binds in resolvase•HJ complex? What is the mechanism of inhibition of 
poxvirus resolvase? Can we improve the inhibitory effects of resolvase inhibitors? 
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In this section, I have designed serial experiments to address the above questions.  This 
section is presented in three parts.  The first part addresses how the poxvirus resolvase structure 
is adapted to its function.  The second part aims to determine the three dimensional structure of 
CPV resolvase•HJ complex.  The final part will address the mechanism and kinetics of current 
resolvase inhibitors and develop more efficient inhibitors. 
Study the molecular basis of poxvirus resolvase adapting to its biological function 
1). The first biochemical assay is to study the mechanism of poxvirus resolvase only 
possessing low substrate sequence specificity.  Based on the CPV resolvase•HJ model and 
RuvC•HJ structure, we found that the RuvC α2 helix is much longer than that of CPV-resolvase, 
making the β4-α2 loop deep into the center region of the HJ.  I speculate that the loop moves 
along the HJ surface to form numerous interaction with the HJ, thus determining the substrate 
sequence specificity. 
I have designed two strategies to study whether the long α2 helix determines E.coli RuvC 
specificity.  The first strategy is decreasing the α2 helix at the N terminal end by one turn in the 
E.coli RuvC structure (Figure 4-3A and B).  Thus the close interactions between β4-α2 loop 
region and HJ substrate will be abolished. I expect that RuvC will lose substrate sequence 
specificity.  EMSAs will be used to determine the affinity change.  We expect that the shorter α2 
helix will make the loop region unable to interact with HJ center region (becoming more similar to 
the interaction between CPV resolvase and HJ), thus it will also weak the RuvC•HJ interaction 
affinity.  Another experiment will be carried out on CPV resolvase.  We will extend the resolvase 
α2 helix at the N terminal end by one turn (Figure 4-3C and D), making the β4-α2 loop region 
reach closer into HJ central region.  Thus, the linker will form interactions with the HJ junction 
central region (like the interaction between E.coli RuvC and HJ).  In this way, the CPV resolvase 
may show a certain level of sequence preference cleavage of HJ DNA.  We expect that extension 
of the α2 helix will strengthen the CPV resolvase•HJ interaction affinity.  EMSA will be used to 
measure the affinity change. 
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Figure 4-3.  Planned experiments on resolvase substrate sequence specificity assay.  A) shows the structural model of 
E.coli RuvC•HJ complex, and B) shows the structural model of E.coli RuvC•HJ complex with truncated α2 helix.  C) shows 
the structural model of CPV resolvase•HJ complex, and D) shows the structural model of CPV resolvase•HJ complex with 
extended α2 helix.  Both α2 helices in RuvC and CPV resolvase are colored in red. 
2). Study the interaction between the α4 helix, α4-α5 loop, and HJ DNA arm.  Based on 
our structural model and our truncation experiment, the N-terminal end of α4 forms interacts with 
the HJ uncleaved arm.  However, it is not clear how many amino acids are involved in the 
interaction.  The possible number is much more than one.  Culyba et al has shown that Lys102 
forms interactions with the HJ, and is essential for resolvase activity.  In fact, we identified four 
amino acids in the N-terminal end of α4 helix (Tyr97, Arg100, Lys101 and Lys102) that are good 
candidates.  Among these four amino acids, Tyr97, Arg100 and Lys101 are facing the inner side 
of resolvase, which is also the interface between the α4 helix and the HJ arm.  All of these amino 
acids have a high frequency to interact with nucleic acids.  We plan to mutate each of them to Ala, 
study their effects on the binding affinity to HJs, and measure their enzymatic activity.  We expect 
that all of them should have lower affinity to HJs compared to wild type resolvase.  Some of them 
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may retain enzymatic activity, but the activity may drop substantially.  Another region is the huge 
loop region between α4 and α5.  This region is docked into the minor groove of cleavable arms of 
the HJ.  I plan to delete the central part, but still maintain a length to make sure that the loop still 
connects α4 and α5 without disrupting the resolvase fold.  I expect that the deletion will weaken 
the affinity of CPV-resolvase to HJs, but may not completely abolish the resolvase activity. 
 
Figure 4-4.  Planned experiment on α4 and linker region between α4 and α5.  A) shows the structural model resolvase to 
half HJ DNA.  The regions docked to DNA minor groove are colored in red.  B) shows the detailed structure of N-terminal 
of α4, which possibly interacts with Junction DNA.  C) shows truncated loop region connecting α4 and α5.  Figure B and 
Figure C are shown in the same orientation as Figure A. 
3). Study the structural basis of poxvirus possessing higher metal affinity than other 
RNaseH members.  Poxviruses carry out their whole life cycle in the host cell cytoplasm.  This 
raises the question of how resolvase structure adapts to low Mg2+ concentrations in the 
cytoplasm.  Poxvirus resolvase has one extra aspartic acid (Asp130) in the active site.  This 
residue interacts with the cofactor Mg2+ through a water molecule.  Here I designed following 
experiment, and will determine whether Asp130 is required for poxvirus viability.  Vaccinia virus 
will be used instead of canarypox virus, since vaccinia virus has been extensively studied and 
there is a well-established protocol to culture and work with the virus (138).  Since Asp130 is well 
conserved through all the poxvirus family, using any poxvirus strain should provide the same 
result. 
I will use vaccinia virus to infect mammalian cell strain (Baby hamster kidney cells (BHK-
21); ATCC#: CCL-10) to test poxvirus resolvase activity.  Endogenous resolvase will be 
eliminated by RNA interference.  Then VV infected cells will be transfected respectively with wild-
type A22R and D140N/A22R expression plasmid (D140 in vaccinia virus resolvase occupies the 
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same position of Asp130 in canarypox virus resolvase).  Structure models are shown in Figure 4-
5.  The expected results are that supplying wild-type A22R will rescue VV particle production, 
while D140N/A22R will not.  D140N/A22R enzymatic activity will be also be studied in vitro using 
synthetic HJs as substrate. This experiment aims to probe that D140 is required for VV viability 
but not for poxvirus enzymatic activity.  Since eukaryote argonautes have one histidine in the last 
active site α helix, and this structure provides high metal affinity, we will also test the two other 
A22R mutants based on replacing aspartic acid with histidine.  We will transfect cells with D140H-
D141A, and D140A-D141H A22R respectively after depleting endogenous A22R expression, 
shown in Figure 4-5.  We expect both constructs will yield viable VV particles. 
 
Figure 4-5.  Planned experiment to study the effect of D140 on VV viability.  A) shows the structure model of A22R 
resolvase active site.  B) shows the structure model of D140N resolvase.  C) and D) show the D140H-D140A, D140A-
D141H resolvase respectively.  Red dashed box shows the A site, and green dashed box shows the B site. 
Determine the three dimensional structure of resolvase•HJ complex 
The overall structure of poxvirus resolvase is similar to bacterial RuvC, but with several 
distinct differences which are involved in the substrate recognition.  Determing the three 
dimensional structure of a resolvase•HJ complex will greatly enrich our understanding of poxvirus 
resolvase and provide a structural platform to develop antiviral drugs. 
1). Determine the crystal structure of a resolvase•HJ complex.  The crystal structure of 
the resolvase•HJ complex would be most informative to understand the mechanism of resolvase 
recognizing and cleaving HJ DNA.  The crystal structure of resolvase will be used to guide HJ 
design to crystallize the resolvase•HJ complex.  The initial resolvase•HJ complex crystals 
described earlier in this thesis were obtained by using HJ DNA with 15-bp arms.  However, the 
63 
 
quality of these crystals is not high enough to solve the structure.  Based on the CPV 
resolvase•HJ model, CPV resolvase binds HJ DNA in an asymmetrical manner.  Resolvase binds 
to the cleavable arms by about 10bp, and binds to uncleaved arms contacting about 5~6 bp.  
Thus, trimming the uncleaved arms to smaller sizes may help the complex grow high quality 
crystals.  I will screen resolvase•HJ complexes with different HJ arm sizes, and aim to obtain 
single and larger crystals to solve the structure.  D59A resolvase will be used to form a complex 
with HJ DNA to prevent substrate cleavage.  We expect that the overall structure of CPV 
resolvase•HJ will be similar to the complex of T.thermophilus RuvC•HJ and thus to our model 
which is shown again below in Figure 4-6A. 
 
Figure 4-6.  The structural model CPV resolvase•HJ complex in the absence /presence of divalent ion.  Figure A shows 
the model in the absence of divalent ion.  HJ arms have different sizes.  The cleavable arms has 10bp, while extended 
arms has 6bp.  Figure B shows the model in the presence of divalent ion.  All four arms have 10bp. 
2). Study the conformational change between the binding and cleaving states of CPV 
resolvase•HJ complex.  It has been long realized that E.coli RuvC binding and cleavage of 
substrate are distinct steps (130).  There are considerable conformational changes associated 
within this process.  In our structural model of the resolvase•HJ complex, the two active site are 
separated by a distance of 36 Å.  However, the distance between the target phosphodiesters is 
24 Å.  This suggests that structural model is more likely an initially bonding state, but not cleaving 
state.  The four-way junction substrate could extend the phosphate-phosphate distance by 
flattening the HJ conformer.  We expect that HJ will adopt more flat planar structure when forming 
a complex with resolvase in the presence of divalent ions, shown in Figure 4-6B.  This 
conformation would be more properly configured for cleavage: thus we call this the cleaving state.   
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Resolvase uses a two-metal-ion mechanism to carry out its enzymatic activity.  Addition 
of divalent ions may promote the conformation change.  Another evidence which supports CPV 
resolvase undergoing a large conformational change upon divalent ion binding comes from the 
enthalpy change.  I estimated up to 10 H-bond or ordered water molecules are broken or 
squeezed out when CVP resolvase•HJ transition from the binding state to cleavage state (Table 
4-I).  Ca2+ binds to the resolvase active site to coordinate with HJ substrate, but inhibits cleavage 
(88).  Thus, Ca2+ will be added to resolvase•HJ complexes to promote formation of a flat 
conformation.  The conformation will be determined by X-ray crystallography and small angle X-
ray scattering (SAXS) method. 
Table 4-I. Estimation broken H-bonds during CPV-Res•HJ transition from binding to cleavage state 
Events Number of bonds ∆H (kcal/mol) 
Mn2+ : CPV-Res•HJ  ~ 10.87 
Mn2+ to CPV-Res•HJ (A site)  2.76 ± 0.02 
Mn2+ to CPV-Res•HJ (B site)  8.11 ± 0.38 
Mn2+ total contribution At least 14 Est: -21.49 
Mn2+ : CPV-Res At least 8 Est: -12.28 
Mn2+ : CPV-Res (A site) 2 x 2 -6.14 ± 0.22 
Mn2+ : CPV-Res (B site)* At least 2 x 2 Est: -6.14 
Mn2+ : HJ (as CPV-Res•HJ) At least 6 Est: -9.21 
Mn2+ : HJ (A site)* At least 1 x 2 Est: -3.07 
Mn2+ : HJ (B site)* At least 2 x 2 Est: -6.14 
Conformation change upon 
Mn2+ bind CPV-Res•HJ 
 ~ 10.87-(-21.49) 
= 32.36 
Energy to break one CPV-Res•HJ 
or ordered Water H-bond 
1 ~ 3 
Energy to break intramolecular 
or ordered Water H-bond 
1 ~ 7 (139) 
Energy to form H-bond with solvent 2 ~ -2 (140) 
H-bonds broken upon Mn2+ binding ~ 10  
* Bond energy is calculated as same value as Mn2+ binding to A site. According the two-metal-ion theory (12), metal at A 
site will form at least two bonds with resolvase and at least one bond with HJ; metal at B site will form at least two bonds 
with resolvase and at least two bonds with HJ. 
Study the mechanism of resolvase inhibitor and develop more efficient inhibitors 
Culyba et al used fowlpox virus resolvase and screened the several small compound 
libraries, identifying several promising compounds which could potentially be used as resolvase 
inhibitors (21).  In this part of my future plan, I focus on studying the mechanism of resolvase 
inhibition, and developing more efficient inhibitors based on the current inhibitor structure.  
Based on our ITC experiment, inhibitor (showed in Figure 4-7B) does not show 
measureable binding affinity to resolvase alone, suggesting it does not simply bind to active site 
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pocket.  However, the inhibitor shows binding affinity to the CPV-resolvase•HJ complex, 
suggesting that the inhibitor might bind to both the CPV resolvase and HJ substrate.  We found 
that there is about a 10Å distance between the resolvase β4-α2 loop and the HJ.  The inhibitor 
core moiety has been docked to this interface (Figure 4-7A), where it could potentially block the 
conformational change of HJ required to assemble the active site.  If the inhibitor behaves exactly 
as we expect, it should inhibit CPV resolvase in an uncompetitive manner.  Therefore, CPV 
resolvase will have smaller value of Km and Vmax.  (They are the properties of uncompetitive 
inhibition) 
 
Figure 4-7.  Structural model of resolvase inhibitor mechanism and inhibitor structures.  A) shows structural model of CPV 
resolvase•HJ•inhibitor tertiary complex.  B) shows the resolvase inhibitor structure, DPTPN. Inhibitor core  is shown in 
dashed  circle.  C): R1 and R2 moieties are variable groups in resolvase inhibitors.  D) shows the minimum compound we 
will try.  Figure E and F show two compounds with R1 moiety being changed to hydroxyl and acetate groups. 
We will carry out experiments as described by Culyba et al (21) and our published results 
to study the mechanism and kinetics of DPTPN to inhibit CPV resolvase.  When DPTPN binds 
into the interface between CPV resolvase and HJ, it will be sandwiched between resolvase Tyr63 
and HJ bases.  Therefore, it might increase the binding affinity between resolvase and HJ DNA.  
EMSA experiments will be applied to study the affinity between resolvase and HJ complex.  We 
will measure the affinity change of resolvase and HJ in the presence and absence of inhibitors. 
Another important area is developing more effective inhibitors against poxvirus resolvase.  
The interface between the β4-α2 loop of CPV resolvase and the HJ DNA has limited space: it 
could fit a core structure of DPTPN, but not the whole molecule.  The R1 and R2 moieties are 
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predicted will to cause steric clashes for DPTPN to bind in that area.  Thus, we will remove the 
R1 and R2 group (Figure 4-7C) to and test the binding affinity.  I predict that the core structure 
(Figure 4-7D) of DPTPN will have a stronger affinity than the intact structure.  I further note that 
the R1 and R2 groups are extremely hydrophobic, contributing to poor solubility of the inhibitor.  
Thus, it will be very difficult to deliver such an inhibitor to the infected tissues.   
In our structural model, the inhibitor binds to the interface between CPV-resolvase and 
HJ.  This is an open position, not an enclosed hydrophobic cavity.  The major core structure of 
the inhibitor is two aromatic rings. The R groups could be modified by adding hydrophilic groups 
to increase its solubility, possibly resulting in efficient delivery to the resolvase.  I plan to change 
the R1 moiety to hydroxyl and acetate groups (shown in Figure 4-7E, F).  These modifications 
should improve inhibitor solubility and increase its inhibitory effects. 
In total, future directions aim to systematically study poxvirus resolvase using 
biochemical and structural approaches.  These experiments will greatly enrich our understanding 
of the mechanism poxvirus resolvase uses to recognize and cleave of HJ DNA.  These studies 
will provide a platform to design and screen inhibitors against poxvirus infection which will be 
extremely useful in preventing the use of poxviruses in bio-terrorism.  
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CHAPTER 5: Metal&EDTA method to purify metal dependent proteins 
Abstract 
Poxvirus resolvases are a group of enzymes which specifically recognize and cleave 
four-way Holliday Junction DNA.  They use Mg2+ or Mn2+ ion as cofactor to carry out their 
enzymatic activity.  In this chapter, we developed one simple and efficient method to purify 
canarypox virus (CPV) resolvase.  The whole process needs two steps and only one SP-
sepharose chromatography column.  The first step is running linear salt gradient with buffer 
containing 5 mM of Mn2+, and the resolvase was eluted at about 0.6 M NaCl.  The second step is 
running linear salt gradient with buffer containing 0.5 mM EDTA, and the resolvase was eluted at 
about 0.3 M NaCl.  The final resolvase could reach 99% purity.  Surface property analysis 
indicates that CPV resolvase active sites comprise of negative charged residues, and are 
surrounded by positive residues.  When two active sites are neutralized by Mg2+ or Mn2+, CPV 
resolvase will bind SP-sepharose resin more tightly than it does in the presence of EDTA.  This 
method (Metal&EDTA) could be effectively used to purify E.coli RuvC and RNaseH.  Since most 
of the DNA and RNA polymerases, DNA and RNA nucleases, DNA and RNA ligases, and some 
metalloproteinase share the similar surface properties, and use Mg2+ or Mn2+ or other divalent 
ions as cofactor to carry out their biological functions, the use of Metal&EDTA method may be 
extended to purify these enzymes.  
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Introduction 
Poxviruses are a large group of viruses which infects a very broad range of eukaryotic 
hosts, including mammals, birds, reptiles and insects (1).  Poxviruses use a novel mechanism to 
replicate their genomes that involves formation of genome concatemers (141).  The poxvirus 
resolvases play an essential role in cleaving these concatemers and are therefore promising 
targets for antiviral drugs (6,7,21).  They function as a dimer, and have molecular weight around 
35 kDa (9).  The poxvirus resolvases use Mg2+ or Mn2+ as co-factor to carry out enzymatic activity 
(88).  We cloned the CPV resolvase gene to pET21a vector and over-expressed it in BL21(DE3) 
cell.  Through three chromatography separations, we purified the CPV resolvase to high purity.  
Resolvase crystals were obtained by micro-dialysis method and we were able to solve the three-
dimension structure (129), shown in figure 5-1.  In CPV resolvase structure, one Mg2+ was 
observed at the active site.  The Mg2+ ion forms direct interactions with Asp8 and Asp131, and 
indirect interactions with Asp130 and Asp134 through a water molecule.  CPV resolvase has the 
similar folding pattern to E.coli RuvC (24) and belongs to RNaseH super family (29). 
 
Figure 5-1.  Crystal structure of CPV resolvase.  A) shows the overall structure of CPV resolvase in cartoon.  B) shows the 
CPV resolvase active site.  Critical amino acids are shown as sticks; Mg2+ is shown as blue spheres; water molecules are 
shown as red spheres.  Hydrogen bonds and salt bonds are shown as dashed lines.  Figure B is not shown in the same 
orientation as figure A.  PDB access code: 5E6F. 
During our study of CPV resolvase, we found that resolvase crystals could be only 
obtained from wild form.  Any tags fusing with N- or C-terminal will lead the resolvase resistant to 
crystallize.  The original protocol needs three chromatography columns (SP-sepharose, MonoS, 
and Superdex-200) to get high purity resolvase.  When varying purification conditions, we 
developed a simple and efficient method to purify highly pure and wild form CPV resolvase.  The 
whole process was greatly simplified to two steps and only one chromatography column (SP-
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sepharose).  Since poxvirus resolvase share the similar surface property with other divalent ion 
dependent nucleic acid enzymes, the same protocol may be extended to purify these enzymes.  
We further realize that metalloproteinases, which comprise the largest protease family, also 
possess the similar the surface property as CPV resolvase and are divalent ion dependent, thus 
the use of divalent ion and EDTA method, may be extended to purify metalloproteinase as well. 
Results 
Regular method to purify CPV resolvase 
To carry out biochemical and structural study of poxvirus resolvase, we cloned canarypox 
virus resolvase (CPV) gene to pET21a vector, and over expressed CPV resolvase in BL21(DE3) 
cell.  CPV resolvase functions as a dimer.  It has a molecular weight about 35 KDa and pI of 8.5.  
We worked out one protocol to purify CPV resolvase by combination of two ion-exchange and 
one gel-filtration chromatography.  This protocol will give us the CPV resolvase about 99% of 
purity.  The results are in shown in figure 3-2. 
The first step to purify CPV resolvase is running SP-sepharose chromatography.  We 
found that CPV resolvase could be effectively bonded to the column and eluted at about 0.3 M 
NaCl during linear NaCl gradient elution.  At this stage, the CPV resolvase is about 70 percent 
purity.  The results are shown in figure 3-2A and 3-2B.  Next, we collected CPV resolvase peak 
fractions and diluted by adding one volume of buffer A1 to decrease the NaCl concentration.  
Then the diluted CPV resolvase peak fraction was loaded to MonoS chromatography column for 
further separation.  The CPV resolvase peak was eluted at about 0.35 M NaCl.  Most of impurity 
bands are removed, but several minor bands with molecular weight between 25~100 kDa could 
be detected on the SDS-PAGE gel.  The purity reach 95% purity and these results are shown in 
figure 3-2C and 3-2D.  Finally, CPV resolvase peak was pooled, concentrated and loaded to 
Superdex-200 for final purification.  After gel-filtration, only one minor band with molecular weight 
between 25 and 30 kDa could be detected, and the CPV resolvase is over 99% purity, shown in 
figure 3-2E and 3-2F.  The resolvase peak fractions from Superdex-200 elution were collected 
and concentrated by 10 kDa MWCO Centricon tube to 30~50 mg/ml and flashed frozen in liquid 
nitrogen and keep at -80°.  We also tested the Hydroxyapatite (HAP) separation effect following 
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SP-sepharose, the result showed that HAP could not separate CPV resolvase band from other 
proteins (Appendix B). 
 
Figure 5-2.  Regular protocol to purify CPV resolvase.  A) and B) show the results of SP-sepharose chromatography.  A) 
shows the salt elution profile.  B) shows the SDS-PAGE results of different fractions.  Lane1: Ladder marker; Lane 2: 
lysate; Lane 3: pellet; Lane4: supernatant; Lane 5: flow through; Lane 6: 48ml; Lane 7: 52ml; Lane 8: 56ml; Lane 9: 60ml; 
Lane 10: 64ml; Lane 11: 68ml; Lane12: 72ml; Lane 13: 76ml; Lane 14: 80ml; Lane 15: 84ml.  C) and D) show the results 
of MonoS chromatography.  C) shows the salt elution profile.  D) shows the SDS-PAGE results of different fractions.  
Lane1: Ladder marker; Lane 2: CPV resolvase peaks pooled from SP-sepharose elution; Lane 3: 25ml; Lane 4: 26ml; 
Lane 5: 27ml; Lane 6: 28ml; Lane 7: 29ml; Lane 8: 30ml; Lane 9: 31ml; Lane 10: 32ml; Lane 11: 33ml; Lane 12: 34ml; 
Lane 13: 35ml; Lane 14: 36ml.  E) and F) show the results of gel-filtration chromatography.  E) shows the gel-filtration 
elution profile.  F) shows the SDS-PAGE results of different fractions.  Lane1: Ladder marker; Lane 2: CPV resolvase 
peaks pooled from MonoS elution; Lane 3: 15ml; Lane 4: 16ml; Lane 5: 17ml; Lane 6: 18ml; Lane 7: 19ml; Lane 8: 20ml. 
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Purify CPV resolvase with Mg2+ and EDTA 
We tried other methods to improve CPV resolvase purification efficiency.  We realized 
that in the SDS-PAGE of regular method to purify CPV resolvase, considerable amount of CPV 
resolvase are in the pellet when spin down the lysate.  If we add Mg2+ to the culture media and 
purification buffer to stabilize CPV resolvase, CPV resolvase may increase its stability, thus we 
could improve final yield.  Therefore for 5 mM Mg2+ was added to culture media and lysis buffer.  
5 mM MgCl2 was also added to the chromatography buffer A1 and B1 to make buffer A2 and B2.  
We run SP-sepharose chromatography by same linear salt gradient as in regular method.  The 
SDS-PAGE indicates that there is still large amount of CPV resolvase in the pellet suggesting 
adding MgCl2 to the culture media and purification buffers doesn’t improve CPV resolvase 
stability.  However, to our surprise, we found that CPV resolvase peak elution volume is delayed 
by about 13 ml, corresponding of NaCl concentration of 0.4 M.  And the CPV resolvase peak 
fractions are much purer than CPV resolvase in figure 5-2B.  Considerable amount of impurity 
was removed from CPV resolvase peak, especially the protein molecular weight between 
30~100kDa.  These results are shown in figure 5-3A and 5-3B. 
The CPV resolvase peak shifted its elution volume.  It renders us to think that the elution 
volume may shift back to original position if we add EDTA to chelate Mg2+.  The elution volume 
difference may remove some impurity bands in CPV resolvase peak fractions if we run SP-
sepharose chromatography again.  Therefore, 0.5 mM EDTA was added to buffer A1 and B1 to 
make buffer A3 and B3.  We collected CPV resolvase peak fractions and diluted by adding two 
volume of buffer A1 to decrease the NaCl concentration.  A similar salt gradient was run through 
SP-sepharose chromatography column with buffer A3 and B3.  The results are exactly as we 
expected, and CPV resolvase peak shifts back to the original elute volume, as shown in figure 5-
3C.  The SDS-PAGE (Figure 5-3D) result shows that most the impurity bands were removed from 
CPV resolvase.  The impurities are concentrated in the later fractions and well separated from 
major peak fractions. 
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Figure 5-3.  Purification of CPV resolvase with Mg2+ and EDTA.  A) and B) show the results of SP-sepharose 
chromatography of CPV resolvase with 5mM MgCl2.  A) shows the salt gradient elution profile.  B) shows the SDS-PAGE 
results of different fractions.  Lane1: Ladder marker; Lane 2: lysate; Lane 3: pellet; Lane 4: supernatant; Lane 5: flow 
through; Lane 6: 60ml; Lane 7: 64ml; Lane 8: 68ml; Lane 9: 72ml; Lane 10: 76ml; Lane 11: 80ml; Lane 12: 84ml; Lane 13: 
88ml; Lane 14: 92ml; Lane 14: 96ml.  C) and D) show the results of SP-sepharose chromatography purification of CPV 
resolvase with EDTA.  C) shows the salt gradient elution profile.  Figure D) shows the SDS-PAGE results of different 
fractions.  Lane1: Ladder marker; Lane 2: CPV resolvase peaks pooled from SP-sepharose elution; Lane 3: 52ml; Lane 4: 
56ml; Lane 5: 60ml; Lane 6: 64ml; Lane 7: 68ml; Lane 8: 72ml; Lane 9: 76ml; Lane 10: 80ml. 
Purify CPV resolvase with Mn2+ and EDTA 
The purification of CPV resolvase by Mg2+ and EDTA gave us better results than regular 
method.  However, there are still some impurity bands in the CPV resolvase fractions.  Mn2+ has 
similar chemical properties as Mg2+, and most of nucleic acid enzymes could replace by Mn2+ with 
Mg2+.  Furthermore, fowlpox virus resolvase shows high activity when Mn2+ replaces Mg2+ as 
cofactor (88).  Therefore, we tested purification of CPV resolvase by adding Mn2+ to 
chromatography buffer.  5 mM of MnCl2 was added to the chromatography buffer A1 and B1 to 
make buffer A4 and buffer B4.  A salt gradient SP-sepharose chromatography was run using 
buffer A4 and B4.  We are excited to find that Mn2+ further delays the elute volume of CPV 
resolvase than Mg2+.  The elute volume shift from 66 to 102 ml, and the NaCl concentration 
corresponds 0.6 M.  After first step of purification, the resolvase is about 80% purity.  These 
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results are shown in figure 5-4A and 5-4B.  
 
Figure 5-4.  Purification of CPV resolvase with Mn2+ and EDTA.  A) and B) show the results of SP-sepharose 
chromatography of CPV resolvase with 5 mM MnCl2.  A shows the salt gradient elution profile.  Figure B show the SDS-
PAGE results of different fractions.  Lane1: Ladder marker; Lane 2: lysate; Lane 3: pellet; Lane 4: supernatant; Lane 5: 
flow through; Lane 6: 84ml; Lane 7: 88ml; Lane 8: 92ml; Lane 9: 96ml; Lane 10: 100ml; Lane 11: 104ml; Lane 12: 108ml; 
Lane 13: 112ml; Lane 14: 116ml; Lane 14: 120ml; Lane 15: 124ml.  C) and D) show the results of SP-sepharose 
chromatography purification of CPV resolvase.  C shows the salt gradient elution profile.  Figure D shows the SDS-PAGE 
results of different fractions.  Lane1: Ladder marker; Lane 2: CPV resolvase peaks pooled from SP-sepharose elution; 
Lane 3: 56ml; Lane 4: 60ml; Lane 5: 64ml; Lane 6: 68ml; Lane 7: 72ml; Lane 8: 76ml; Lane 9: 80ml; Lane 10: 84ml. 
Then we collected the CPV resolvase peak and add 2 equal volume of buffer A3 to 
decrease the NaCl concentration.  A salt gradient was run using buffer A3 and B3.  SDS-PAGE 
show very nice results.  The CPV resolvase peak could be fully separated from other impurity 
bands.  There is only one impurity band located at the later peak factions.  The earlier and 
majority peaks are almost 100% pure.  These results are shown in figure 5-4C and 5-4D. 
ITC experiment on titration of CPV resolvase with Mn2+ or Mg2+  
Mn2+ greatly delays the CPV resolvase retention volume.  It is necessary to know where 
and how many Mn2+ ions bind to CPV resolvase.  In our former paper, we identified one Mg2+ at 
each active site.  We also found that Mg2+ and Mn2+ do not bind resolvase aside from active site 
(129).  The Mg2+ was assigned based on the electron density size and surrounding environment.  
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However, Mg2+ and water molecules don’t have differences when judged by the size of electron 
density.  The exact stoichiometry of CPV resolvase and metal ion should be determined by ITC 
experiment. 
The titration of CPV resolvase to Mg2+ was performed, but the Kd value could not be 
exactly determined because of the low affinity.  Thus, we fixed N at 2, and let the software to 
determine the Kd value.  We estimated that the Kd value of CPV resolvase to Mg2+ is around 100 
mM.  As an alternative, we titrated wild CPV resolvase with Mn2+, and the results are shown in 
figure 5-5.  Mn2+ has a stoichiometry of 2.42:1 to CPV resolvase dimer.  It suggests one CPV 
resolvase dimer bind two Mn2+ ions, which mean one active site binds one Mn2+.  Kd value is 
1.185 mM, suggesting Mn2+ will saturate CPV resolvase during our purification (5 mM).  This 
experiment is carried out by lowering CPV resolvase concentration to 17.5 mg/ml (0.5 mM) and 
increasing Mn2+ to 50 mM to make sure that ITC results could be close to basal level at the end of 
titration. 
 
Figure 5-5.  Titration of CPV resolvase with Mg2+ and Mn2+.  A) shows the result of CPV resolvase titrated with Mg2+.  B) 
shows the result of CPV resolvase titrated with Mn2+. 
Purify Tri-Mut CPV resolvase with Mn2+ and EDTA 
Divalent ion (Mg2+ or Mn2+) and EDTA could increase the purification efficiency.  We 
speculate that binding of Mn2+ or Mg2+ to the CPV resolvase active site, neutralizes the negatively 
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charged residues and thus increases the CPV resolvase binding affinity to SP-sepharose resin.  If 
negatively charged residues are mutated to alanine, same surface electrostatic property could be 
achieved as binding of divalent ions.  In crystal structure of CPV resolvase, one Mg2+ ion is 
observed in the active site.  The Mg2+ ion directly interacts with Asp8 and Asp131, and indirectly 
interacts with Asp130, Asp134 mediated by one water molecule (Figure 5-1B).  Therefore, 
mutation of Asp130, Asp131, and Asp134 should abolish the metal binding ability of CPV 
resolvase.  In the light of this idea, we made D130A-D131A-D134A CPV resolvase construct, and 
tested its binding affinity to SP-sepharose in the presence of Mn2+ and EDTA.  These results are 
shown in figure 5-6. 
TriMut CPV resolvase could be overexpressed in BL21 (DE3) cell, but it has a poor 
solubility, as it shown in figure 5-6D.  Only a small fraction of CPV resolvase is soluble.  Same 
protocol was run as purifying wild CPV resolvase with Mn2+ and EDTA.  Comparing the figure 5-
6C and 5-6D with 5-2A, it is clear that the TriMut peaks are eluted later than wild type in the 
presence of 5 mM Mn2+.  However, when Mn2+ was removed by EDTA, the TriMut elution volume 
is rough as the same position as eluted with Mn2+.  This experiment suggests that TriMut CPV 
resolvase binds SP-sepharose more tightly than wild form and Mn2+ doesn’t contribute to the 
binding affinity.  SDS-PAGE also shows that most impurity bands couldn’t be separated from 
CPV resolvase band; this is consistent with the figure 5-6A and 5-6B.  
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Figure 5-6.  Structure model of CPV resolvase active sites and purification of TriMut CPV resolvase with Mn2+ and EDTA.   
A) shows the structure model of CPV resolvase active site in the presence of 5mM of Mn2+.  B) shows the structure model 
of Tri-Mut CPV resolvase at the active site.  C) and D) show the results of SP-sepharose chromatography of CPV 
resolvase with 5mM MnCl2.  C) shows the salt gradient elution profile.  D)show the SDS-PAGE results of different 
fractions.  Lane1: Ladder marker; Lane 2: lysate; Lane 3: pellet; Lane 4: supernatant; Lane 5: flow through; Lane 6: 80ml; 
Lane 7: 84ml; Lane 8: 88ml; Lane 9: 92ml; Lane 10: 96ml; Lane 11: 100ml; Lane 12: 104ml; Lane 13: 108ml; Lane 14: 
112ml; Lane 15: 116ml.  E) and F) show the results of SP-sepharose chromatography purification of CPV resolvase.  E) 
shows the salt gradient elution profile.  F) show the SDS-PAGE results of different fractions.  Lane1: Ladder marker; Lane 
2: CPV resolvase peaks pooled from SP-sepharose elution; Lane 3: 80ml; Lane 4: 84ml; Lane 5: 88ml; Lane 6: 92ml; 
Lane 7: 96ml; Lane 8: 100ml; Lane 9: 14ml; Lane 10: 108ml; Lane 11: 112ml; Lane 12: 116ml. 
Purified CPV resolvase has no nuclease contamination 
One concern of using Mn2+ and EDTA method is whether contamination is in the final 
purified product.  Supercoiled plasmids or linear DNA fragment was mixed with CPV resolvase 
and incubated at 37 degree for 2 hours.  Electrophoresis results show both of supercoiled 
plasmids and linear DNA do not have migration difference before and after incubation.  The 
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electrophoresis results demonstrate that there is no contamination of other nucleic enzyme in 
purified poxvirus CPV resolvase.  These results are shown in figure 5-7.  
 
Figure 5-7.  Agarose gel electrophoresis to detect CPV resolvase contamination.  Plasmid lane was prepared by mixing 
plasmid with only CPV resolvase cleavage buffer.  Plasmid/Res lane was prepared by mixing plasmid with CPV resolvase.  
PCR lane was prepared by mixing linear DNA with only CPV resolvase cleavage buffer.PCR/Res lane was prepared by 
mixing plasmid with CPV resolvase. 
Purify E.coli RuvC by Mn&EDTA method. 
The Mn&EDTA method could be successfully used to purify CPV resolvase.  Most of the 
nucleic acid enzymes are divalent ions dependant, and they share the similar surface property as 
CPV resolvase.  We tested our idea on the E.coli RuvC.  Like CPV resolvase, RuvC is junction 
resolvase, which plays essential role in DNA recombination in bacteria (53).  As a prototype of 
junction resolvase, E.coli RuvC has been extensive studied (142).  RuvC has RNaseH folding 
pattern, and belong to RNaseH-integrase superfamily (24).  It needs high concentration of 
glycerol and salt to be stable (53,143).  Therefore, we used same buffer to purify RuvC as CPV 
resolvase.  The results are shown as Figure 5-8.   
We first run the salt gradient of SP-sepharose chromatography in the presence of 5 mM 
MnCl2.  The result is shown in figure 5-8C and 5-8D.  We run a linear salt gradient from 0.1 M to 
1.0 M NaCl.  RuvC could effectively bonds to SP-sepharose resin, and RuvC peak was eluted at 
79 ml, corresponding of 0.5 M NaCl.  The RuvC purity could reach 70 percent.  Then RuvC peak 
fractions were collected and diluted with one volume of Buffer A3, and loaded to SP-sepharose 
column for next step purification.  A second linear salt gradient was run from 0.1 M to 1.0 M NaCl 
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in the presence of 0.5 mM EDTA, and RuvC peak was eluted at 65 ml, corresponding of 0.35 M 
NaCl.  Most of the impurity bands eluted with RuvC in the first step were eluted much later than 
RuvC.  Only two minor impurity bands were observed with molecular weight around 58 kDa and 
25 kDa.  The overall RuvC peak purity reaches 98% purity, as shown in figure 5-8E and 5-8F. 
Figure 5-8.  E.coli RuvC structure and purify E.coli RuvC with Mn2+ and EDTA.  A) shows overall structure of RuvC (PDB: 
1HJR) and B) shows the active site of RuvC.  Critical amino acids are shown as sticks.  C) and D) show the results of SP-
sepharose chromatography of RuvC with 5 mM MnCl2.  C) shows the salt gradient elution profile.  D) shows the SDS-
PAGE results of different fractions.  Lane1: Ladder marker; Lane 2: lysate; Lane 3: pellet; Lane 4: supernatant; Lane 5: 
flow through; Lane 6: 58ml; Lane 7: 63ml; Lane 8: 66ml; Lane 9: 70ml; Lane 10: 72ml; Lane 11: 76ml; Lane 12: 80ml; 
Lane 13: 84ml; Lane 14: 88ml; Lane 14: 92ml; Lane 15: 96ml.  E) and F) show the results of SP-sepharose 
chromatography purification of RuvC.  E) shows the salt gradient elution profile.  F) shows the SDS-PAGE results of 
different fractions.  Lane1: Ladder marker; Lane 2: RuvC peaks pooled from SP-sepharoseMn2+ elution; Lane 3: 52ml; 
Lane 4: 56ml; Lane 5: 60ml; Lane 6: 64ml; Lane 7: 70ml; Lane 8: 74ml; Lane 9: 78ml; Lane 10: 82ml; Lane 11: 86ml; 
Lane 12: 90ml; Lane 13: 94ml; Lane 14: 96ml; Lane 14: 100ml; Lane 15: 104ml.  
We compared all available protocols to purify bacteria RuvC.  As the prototype and 
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critical member in DNA recombination, E.coli RuvC had been extensively studied in the 1990’s.  
Authors used very complicated protocol to purify RuvC.  These protocols are listed in figure 5-9A 
and 5-9B.  Both protocols have four steps to get highly pure RuvC (53,143).  It is not hard to image 
there should be huge amount work to prepare buffers, to run chromatography columns sequentially to 
obtain pure RuvC.  These protocols will also take long time.  It will take several days to finish all 
steps.  As a comparison, Mn&EDTA method provides simple and efficient method to purify E.coli 
RuvC, as shown in figure 5-9C. 
 
Figure 5-9.  Protocols used to purify Bacteria RuvC.  A) and B) show the protocols used to purify E.coli RuvC in 1990’s 
(53,143).  C) shows the protocol used in this study.  D) and E) show the protocols used to purify T.Th RuvC (62,63). 
More recently, RuvC from Thermus.Thermophilus has attracted researchers’ attention 
because of its unique features of stability under high temperature.  Authors used different 
protocols to purify T.Th RuvC.  One group took fully the advantage that T.Th RuvC is stable in 
high temperature.  They incubated cell lysate at 70 degree for 30min to precipitate most of 
bacteria protein.  And then one more step of Heparin-Sepharose will give highly pure T.Th RuvC 
(62), shown in figure 5-9D.  The other group fused a Histag at the N-terminal of RuvC.  They then 
purified it by affinity method with Ni-NTA column.  However, adding a Histag cause a problem for 
crystallization, and authors removed the Histag by protease cleavage.  Finally, Authors run a high 
resolution MonoS chromatography column to get pure RuvC (63), shown in figure 5-9E.  
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Comparing all these protocols to purify bacteria RuvC, we could draw the conclusion that 
Mn&EDTA method provides most simple and efficient way to purify RuvC. 
Mn&EDTA method to purify E.coli RNaseH 
We further tested purification of E.coli RNaseH with Mn&EDTA method.  E.coli RNaseH 
is the first enzyme possessing RNaseH folding pattern with the crystal structure determined.  
RNaseH cleaves RNA strand in the DNA/RNA duplex during DNA replication.  One Mg2+ ion was 
observed in the active site of RNase HI when crystals were grown in buffer containing 100 mM 
Mg2+ (144), while two Mn2+ were observed when crystals were grown in buffer containing 1mM 
Mn2+ (145).  We expect that E.coli RNase HI could be purified by Mn2+&EDTA method.   
We first tested to purify RNaseH by Mn2+ then followed by EDTA.  However, we found 
that bounded Mn2+ in the first step couldn’t be easily removed during second step purification.  
Therefore, we used a reversed protocol: using EDTA containing buffer to purify RNaseH first then 
followed by Mn2+ containing buffer.  The expression level of RNaseH in E.coli is so huge, that 
RNaseH fraction will saturate SP-sepharose column for about 30ml from one liter cell culture 
(Data is not shown).  In this experiment, only one fifth of RNaseH was used to test the purification. 
RNaseH could be overexpressed in BL21(DE3) cell strain.  Almost all RNaseH is in the 
supernatant after centrifugation.  We first run the 0.05 ~ 1.0 M NaCl gradient of SP-sepharose 
chromatography in the presence of 0.5 mM EDTA.  The result is shown in figure 5-10A and 5-10B.  
RNaseH could effectively bonds to SP-sepharose resin, and RNaseH peak was eluted at 55 ml, 
corresponding of 0.2 M NaCl.  The RNaseH purity reaches 80 percent.  Then RNaseH peak 
fractions were collected and diluted with one volume of Buffer A3, and loaded to SP-sepharose 
column for next step purification.  A second linear salt gradient was run from 0.05 M to 1.0 M 
NaCl in the presence of 5 mM Mn2+, and RNaseH peak was eluted at 68 ml, corresponding of 0.3 
M NaCl.  Most of the impurity bands eluted with RNaseH in the first step were eluted much later 
than RNaseH.  The overall RNaseH peak purity reaches 98% purity, and several minor impurity 
bands could be observed.  These results are shown in figure 5-10C and 5-10D. 
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Figure 5-10.  Purification of RNaseH with EDTA and Mn2+ by SP-sepharose.  A) and B) show the results of SP-sepharose 
chromatography of RNaseH with 0.5 mM EDTA.  A) shows the salt gradient elution profile.  B) show the SDS-PAGE 
results of different fractions.  Lane1: ladder marker; Lane 2: lysate; Lane 3: pellet; Lane 4: supernatant; Lane 5: flow 
through; Lane 6: 46ml; Lane 7: 48ml; Lane 8: 50ml; Lane 9: 52ml; Lane 10: 54ml; Lane 11: 56ml; Lane 12: 58ml; Lane 13: 
60ml; Lane 14: 62ml; Lane 14: 64ml; Lane 15: 66ml.  C) and D) show the results of SP-sepharose chromatography 
purification of RNaseH with  5mM MnCl2.  C) shows the salt gradient elution profile.  D) shows the SDS-PAGE results of 
different fractions.  Lane1: Ladder marker; Lane 2: CPV resolvase peaks pooled from SP-sepharose elution; Lane 3: 58ml; 
Lane 4: 60ml; Lane 5: 62ml; Lane 6: 64ml; Lane 7: 66ml; Lane 8: 68ml; Lane 9: 70ml; Lane 10: 72ml; Lane 11: 74ml; 
Lane 12: 76ml; Lane 13: 78ml.. 
We further purified RNaseH with MonoS chromatography column by Mn2+&EDTA method.  
RNaseH peak fraction from first step purification by SP-sepharose was loaded on MonoS column 
equilibrated with 5% buffer B5.  After washing, we run the 0.05 ~ 1.0 M NaCl gradient by six 
chromatography column volume (48ml) in the presence of 0.5 mM EDTA.  RNaseH peak was 
eluted at 22.5 ml, corresponding of 0.2 M NaCl. Most impurities bands are separated from 
RNaseH except one with molecular weight around 50 kDa. These results are shown in figure 3-
9A and 3-9B. Then, the RNaseH fractions were collected, diluted by equal volume of buffer A6 
and loaded to MonoS column for further purification. A 0.05 ~ 1.0 M NaCl gradient by six 
chromatography column volume (48ml) was run in the presence of 5 mM MnCl2. RNaseH peak 
was shift to 26.0 ml, corresponding of 0.25 M NaCl. The last impurity band was well separated 
from RNaseH, and RNaseH almost reach 100% pure. These results are shown in Figure 3-9C 
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and 3-9D.  
 
Figure 5-11. Purification of RNaseH with EDTA and Mn2+ by MonoS. A) and B) show the results of MonoS 
chromatography of RNaseH with 0.5 mM EDTA.  A) shows the salt gradient elution profile.  B) shows the SDS-PAGE 
results of different fractions. Lane1: Ladder marker; Lane 2: CPV resolvase peaks pooled from SP-sepharose elution; 
Lane 3: 20ml; Lane 4: 21ml; Lane 5: 22ml; Lane 6: 23ml; Lane 7: 25ml; Lane 8: 35ml. C) and D) show the results of 
MonoS chromatography purification of RNaseH with  5mM MnCl2. C) shows the salt gradient elution profile. D) shows the 
SDS-PAGE results of different fractions. Lane1: Ladder marker; Lane 2: RNaseH peaks pooled from MonoS elution with 
EDTA; Lane 3: 24ml; Lane 4: 25ml; Lane 5: 26ml; Lane 6: 27ml; Lane 7: 28ml; Lane 8: 29ml. 
Mn&EDTA method to purify T7 ligase 
We also tested purification of T7 ligase by Mn&EDTA method.  DNA ligases catalyze the 
formation of phosphodiester bonds at single-strand breaks between adjacent 3’-hydroxyl and 5’-
phosphate termini in double-stranded DNA (146).  Bacteriophage T7 encodes a DNA ligase, 
which can utilize ATP and Mg2+ as a cofactor to carry out the reaction (147,148).  T7 ligase could 
be overexpressed in BL21 (DE3) cell, and majority protein is in the supernatant.  However, when 
we directly loaded supernatant to SP-sepharose column, we found that the elution volume is so 
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early that T7 ligase couldn’t be separately from most cellular protein, thus only using SP-
sepharose could not obtain highly pure T7 ligase.  T7 ligase binds SP-sepharose column at about 
0.15 M NaCl.  Therefore, we used Heparin-Sepharose as pre-separation to remove the most of 
impurity.  These results are shown in figure 5-12A and 5-12B.  We run a linear salt gradient from 
0.1 M to 1.0 M NaCl.  T7 ligase binds to Heparin-Sepharose tightly.  To elute it from the column, 
the salt concentration need reach 0.6 M NaCl.  Most of impurity is removed after Heparin 
chromatography.  T7 ligase peaks were collected, and we did next step experiment with SP-
sepharose chromatography. 
We then diluted T7 ligase peaks with five volume of buffer A6, and load it to SP-
sepharose column.  A linear salt gradient was run from 0.05 to 1.0 M NaCl in the presence of 5 
mM MnCl2.  The majority peak was eluted at 61 ml and a minor peak around 45ml.  However, the 
SDS-PAGE result indicates both peaks are T7 ligase peak.  In all fractions, there is only a single 
band.  All impurities have been washed away in the flow through.  These results are shown in 
figure 5-12C and 5-12D.  Since binding of Mn2+ delay the elution volume, the first minor likely is 
the denatured T7 ligase, which loses bonding affinity to Mn2+.  
We also tested the purifying T7 ligase by SP-sepharose in the presence of EDTA.  T7 
ligase peaks collected from Heparin elution was diluted and loaded to SP-sepharose column.  A 
linear salt gradient was run from 0.05 to 1.0 M NaCl in the presence of 0.5 mM EDTA.  There is 
one peak showed in the elution at 51 ml.  Again, the SDS-PAGE result shows there is only a 
single band.  All impurities have been washed away in the flow through.  These results are shown 
in figure 5-12E and 5-12F.  Although only using SP-sepharose couldn’t obtain pure T7 ligase, the 
elution volume shift from 61 to 51 ml, suggesting binding of Mn2+ did change ligase surface 
property. 
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Figure 5-12.  Purification ofT7 ligase with Heparin and Mn2+&EDTA.  A) and B) shows the results of Heparin-Sepharose 
chromatography of T7 ligase.  A) shows the salt gradient elution profile.  B) shows the SDS-PAGE results of different 
fractions.  Lane1: Ladder marker; Lane 2: lysate; Lane 3: pellet; Lane 4: supernatant; Lane 5: flow through; Lane 6: 88ml; 
Lane 7: 92ml; Lane 8: 96ml; Lane 9: 100ml; Lane 10: 104ml; Lane 11: 108ml; Lane 12: 112ml; Lane 13: 116ml; Lane 14: 
120ml; Lane 14: 124ml; Lane 15: 128ml.  C) and D) show the results of SP-sepharose chromatography of T7 ligase with 5 
mM MnCl2.  (C) shows the salt gradient elution profile.  D) shows the SDS-PAGE results of different fractions.  Lane1: 
Ladder marker; Lane 2: T7 ligase pooled from Heparin elution; Lane 3: 44ml; Lane 4: 46ml; Lane 5: 48ml; Lane 6: 50ml; 
Lane 7: 52ml; Lane 8: 54ml; Lane 9: 56ml; Lane 10: 58ml; Lane 11: 60ml; Lane 12: 62ml; Lane 13: 64ml; Lane 14: 66ml; 
Lane 14: 7068ml; Lane 15: 70ml.  E) and F) show the results of SP-sepharose chromatography of T7 ligase with 0.5 mM 
EDTA.  E) shows the salt gradient elution profile.  F) shows the SDS-PAGE results of different fractions.  Lane1: Ladder 
marker; Lane 2: T7 ligase pooled from Heparin elution; Lane 3: 2538ml; Lane 4: 40ml; Lane 5: 42ml; Lane 6: 44ml; Lane 7: 
46ml; Lane 8: 48ml; Lane 9: 50ml; Lane 10: 52ml; Lane 11: 54ml; Lane 12: 56ml; Lane 13: 58ml; Lane 14: 60ml; Lane 14: 
62ml; Lane 15: 64ml.  
Discussion and future directions 
Nucleic acid enzymes play critical roles in genetic engineering.  Hundreds of DNA and 
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RNA enzymes have been commercialized by biotech companies.  However, most of these 
enzymes need several chromatography steps to get high purity.  It takes huge amount of work to 
purify these enzymes especially for small labs.  Developing a universal protocol to purify nucleic 
acid enzyme will greatly decrease the amount of work and benefit nucleic acid study. 
In this chapter, we developed one simple, efficient method to purify CPV resolvase.  
Comparing to regular method, Mn2+ and EDTA method has several advantages.  1). Simple and 
efficient.  The whole purification process is greatly simplified to two steps and only one 
chromatography column.  Comparing regular method, it will save enormous amount of time and 
efforts to make different buffers, to run multiple chromatography columns.  Most importantly, the 
final CPV resolvase has a high purity at least 98%.  2). High yield. The elution ion strength and 
retention time are so different in two purification steps that almost all the CPV resolvase eluted 
from first chromatography are recovered in the second chromatography, as shown in figure 5-4A.  
Only CPV resolvase could be eluted at two different ion strengths.  All the impurities are washed 
away either in first chromatography or in the second chromatography. 3). Wide form.  CPV 
resolvase is purified as wide form, thus will not have the side effect with an affinity tag, and could 
directly be used to crystallization trial.  4). Low cost. SP-sepharose is a cheap resin, which could 
often be disposable.  Comparing to resin with high resolution, such as MonoS chromatography 
column, the cost using Metal&EDTA method is much lower. 
 
Figure 5-13.  CPV resolvase elute volume change with divalent ion or EDTA.  A) shows the elute volume change in the 
presence of Mn2+ or EDTA.  B) shows the elute volume change in the presence of Mg2+ or EDTA.  
We can’t exclude tiny amount of DNA/RNA endo- or exo-nucleases still exist in the final 
purified CPV resolvase.  Even there is some contamination; their amount must be several orders 
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less than CPV resolvase.  Based on our contamination assay, contamination nucleases could be 
inactivated or ignored.  
In figure 5-13A, the CPV resolvase peak eluted form buffer containing Mn2+ is fully 
separated from CPV resolvase peak eluted from buffer containing EDTA.  However, in figure 5-
13B, the CPV resolvase peak eluted from buffer containing Mg2+ overlaps with CPV resolvase 
peak eluted from buffer containing EDTA, suggesting the resolvase active site is not fully 
occupied Mg2+.  It is consistent with the low bonding affinity of Mg2+.  It may need over hundred 
milli-molar of Mg2+ to get the same effect as Mn2+, making Mg2+ impropriate for CPV resolvase 
separation.  
It is very interesting that adding 5 mM Mg2+ or Mn2+ only contribute very little to the ion 
strength in the elution buffer.  Comparing to the elute volume shift; the divalent ion contribution 
could be ignored.  If adding Mn2+ doesn’t play other role, and only contributes ion strength in the 
buffer, CPV resolvase should be eluted a little bit earlier than without Mn2+.  This lead to the 
question how could small amount of divalent ion could generate so huge effect.  Since the SP-
sepharose is positively charged ion-exchange resin.  It binds to positive charged area of 
macromolecule.  We postulate that binding divalent metal ion changed CPV resolvase surface 
property.  As CPV resolvase using Mn2+ or Mg2+ as cofactor to carry out enzymatic activity, we 
conjectured that divalent ions may bind to the active site, thus neutralize the negatively charge 
amino in the active site.  Our ITC experiment on CPV resolvase and Mn2+ suggested that divalent 
ion bind to CPV resolvase with a stoichiometry 2:1 (one CPV resolvase dimer binds two divalent 
ion or one active site binds one divalent ion).  We generated the CPV resolvase electrostatic 
potential map and compared the difference with Mn2+ and without Mn2+, and the results are 
shown in figure 5-14.  
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Figure 5-14.  Electrostatic potential map of CPV resolvase.  Negatively charged areas are colored red while positively 
charged areas are colored blue.  A) shows the surface bearing the active sites.  B) shows the same orientation as (A), but 
with Mg2+ or Mg2+ bonded.  The map is calculated from D8A-D131A, which is equal to Mg2+ or Mn2+ neutralize Asp8 and 
Asp131 negative charges.  C) and D) show other side of CPV resolvase. 
In the CPV resolvase electrostatic potential map, charges are not evenly distributed.  One 
surface bearing the active sites is positive charge dominated, except the active site, while the 
other side is negatively charged dominated.  When the active site bind Mg2+ or Mn2+, they 
neutralize two negatively charge residues, making the negatively charged regions almost gone.  
As a result, CPV resolvase binds SP-sepharose resin more tightly in the presence of divalent ion 
than in the absence of divalent ion, it could be only eluted by high concentration of salt.  
Interestingly, similar results were observed in the B.Halodruans RNase H.  When critical amino 
acid D132 is mutated to asparagine, RNase H increases its binding affinity to RNA/DNA duplex 
(12).  It is likely caused by charge change at the active site.  D132N has less negatively charged 
surface, therefore could bind substrate more tightly than wild type.  
Some nucleic acid enzymes bind Mn2+ so tightly that it couldn’t be easily removed by just 
washing with EDTA containing buffer, such as RNaseH and T7 ligase.  This problem could be 
overcome by either buffer exchange with Millipore Centricon tube or reversing the elution 
sequence to EDTA followed by Mn2+ elution. 
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The potential application of Metal&EDTA method 
The binding of divalent ion, changed electrostatic potential of metal dependant nucleic 
acid enzymes, but we are still very surprised to find that the ion strength to elute enzyme are so 
different , that most of impurity could be effectively remove from first or second step.  If the 
method could only be applied to purify CPV resolvase, it doesn’t mean much for protein 
purification.  However, if this technique could be used to purify a large group of enzymes, it would 
be major contribution to the protein purification field.  Here I listed possible application of this 
method.  Since some enzymes use divalent ions other than Mg2+ or Mn2+, this method should be 
named to divalent ion and EDTA method (abbreviation: Metal&EDTA).  Could Metal&EDTA 
method be used to purify other nucleic acid enzymes? We selected typical enzymes and made 
their electrostatic potential map, including large fragment of E.coli DNA polymerase I (34), 
restriction enzyme BamHI (37) and T7 DNA ligase(42), as shown in figure 10.  We found that all 
of them have the similar properties.  The charged residues are not evenly distributed with one 
surface is positive charged residue dominated, and other side is negatively charged residue 
dominated (not shown).  One universal feature is that the active site is negatively charged 
surrounded by large area of positive residues.  When divalent ion binds to the active site, it will 
neutralize the negative charged residues, making the positively charged amino acid area wider.  
Most of the DNA and RNA polymerases, DNA and RNA nucleases, DNA and RNA 
ligases are Mg2+ or Mn2+ dependent.  These enzymes have the similar surface properties as CPV 
resolvase.  Therefore, the Mn2+ and EDTA method may be extended to purify these enzymes. 
1). Purify enzymes from RNaseH-Integrase family.  As just discussed, most RNaseH 
family members show high affinity to divalent ions, and have been crystals in the presence of 
Mg2+ or Mn2+ (149,150).  Although E.coli RNaseH crystals were obtained in 100 mM MgCl2, or 
1mM MnCl2 and some of them are soaked in 45 mM MnCl2, the real concentration to saturate 
active site of RNaseH family member may be not so high.  The high concentration of Mg2+ or 
Mn2+ are more likely to make sure the enzymes have a 100% of occupancy to obtain nice crystals.  
As we see that CPV resolvase has the affinity of 108 ± 26.7 mM to Mg2+, but 5 mM of MgCl2 still 
give a pretty nice result.  In fact, the metal affinity of some of RNaseH family to Mg2+ or Mn2+ has 
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been determined by ITC.  RNaseHII from Methanoccus Jannaschii has the affinity of 13 μM and 
141 μM to Mn2+ and Mg2+ respectively (108).  Junction resolvase Cce1 from Saccharomyces 
cerevisiae mitochondria has the affinity of 0.85 μM to Mg2+ (106).  These results strongly support 
Metal&EDTA method will give nice results when used to purify RNaseH-Integrase family 
members.  
2). Other Mg2+ dependent nucleases.  Some other members don’t have RNaseH-
integrase folding pattern, but also using two-metal-ion mechanism to carry out cleavage of nucleic 
acid substrate, and they also show high affinity to divalent metal ions.  They members include 
junction resolvase, such as T4 endo VII nuclease (87,151), T7 endo I nuclease (86,152), and 
eukaryote junction resolvase EME1 (112).  Especially T7 endo I nuclease has a affinity of 
0.58mM to Mn2+, which has been determined by ITC (107).  Double stranded RNA nuclease 
Dicer, which play an essential role in RNA interference is another candidate.  Human dicer has 
been crystallized in buffer containing 20 mM MgCl2, and two Mg ions were identified in each 
active site (92).  All restriction enzyme are good candidates for Metal&EDTA method, however, 
there is very limited data on the metal affinity of restriction enzymes.  
3). Nucleic acid polymerases and ligases.  These enzymes are divalent ion dependent, 
but they have some differences from nucleases.  Metal ions in the nuclease play the role to 
activate a water molecule, which in turn performs nucleophilic attack on the phosphate, thus 
breaks the di-ester bond between two neighbor nucleotides (14).  In polymerase and ligase, two 
divalent ions functions stabilizing the intermediate.  The nucleophile is 3’-hydroxy group from 
nucleotides (153).  Thus, the Metal&EDTA method may not get good results when directly used 
to purify polymerase and ligases, as we see in the purification of T7 ligase.  It may need pre-
purification before apply Metal&EDTA method. 
4). Aside from divalent ion dependent nucleic acid enzymes, we realize that some 
divalent ion dependent proteases also possess similar surface property as CPV resolvase.  
Figure 5-15 shows the electrostatic potential map of bovine pancreatic carboxypeptidase (BPC) 
with and without Zn2+ bonded.  Unlike nucleic acid enzymes, which use two metal ions at their 
active sites, metalloproteinases only need one divalent ion at their active sites(95).  Three critical 
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amino acids form active site.  One of them is glutamate, and the other two amino acids are 
histidines.  These three amino acids form one salt bond and two dipolar bonds Zn2+.  One water 
molecule also binds to Zn2+, and being activated by Zn2+, performs nucleophilic attach against 
carbon atom at protein backbone.  Most metalloproteinases use Zn2+ as their cofactor, but some 
metalloproteinases prefer to use other divalent ions, such as Mn2+, Cu2+, Co2+ based on the 
subtle difference at the active site (96).  Metalloproteinases have extremely high affinity to their 
cofactor, which often reach nano-molar level (97).  
The electrostatic potential map of bovine pancreatic carboxypeptidase is not evenly 
distributed.  One side bearing the active site is positive charge dominated, while the other side is 
negative charged dominated, as shown in figure 5-15D and 5-15E.  The surface property of BPC 
is similar to CPV resolvase, especially at the active site side: negative charged area is 
surrounded positively charged area.  When divalent ion binds, it neutralizes the negative charged 
area, shown in figure 5-15C.  We expect that Metal&EDTA method will get nice results to purify 
bovine pancreatic carboxypeptidase.  
Some of metalloproteinases may be not as typical as BPC.  If their surfaces are not 
evenly distributed, Hydroxyapatite (HAP) will be a powerful resin to purify protein.  HAP has been 
widely used to purified various protein (154).  The functional groups of Hydroxyapatite are Ca2+ 
and phosphate, thus it provides an excellent resin to purify protein whatever the overall charge is.  
We expect that metal bonded and metal free protease will make a difference for HAP column.  
One advantage for metalloproteinase purification is they have extremely high affinity to divalent 
metal ions (the affinity usually is below micro-molar level), and adding μM of divalent will not 
cause any negatively effect on enzymes or resin.  Therefore, it is worthy to test purifying 
metalloproteinase with HAP chromatography by Metal&EDTA method. 
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Figure 5-15.  Crystal structure and electrostatic potential map bovine pancreatic carboxypeptidase.  Negatively charged 
areas are colored red while positively charged areas are colored blue.  A) shows the overall crystal structure at 1.2 Å 
resolution (PDB: 1M4L).  B) shows the active site composition.  Salt bonds or dipolar bonds are shown as dashed lines.  
C) shows the surface bearing the active site with Zn2+ bonded.  The electrostatic potential map is calculated based on the 
E72K mutation, which is equal to with Zn2+ bonded.  D) shows the same orientation as C), but with Zn2+ removed.  E) and 
F) show other side of bovine pancreatic carboxypeptidase.   
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Future directions 
Metal&EDTA method provides a simple and efficient way to purify divalent ion dependent 
enzymes.  It has great advantages comparing to regular method to purify divalent ion dependent 
enzymes.  However, not all divalent ion dependent enzymes could use Metal&EDTA method and 
get good results, as we see T7 ligase could not get good separation if we only use Metal&EDTA 
method.  An extra pre-purification is required for Metal&EDTA method to obtain pure T7 ligase.  
So far, we only tested E.coli RuvC, RNaseH and phage T7 ligase.  RuvC and RNaseH shares 
high structural similarity with CPV resolvase, therefore, it is not surprising that Metal&EDTA 
method could be successfully used to purify RuvC and RNaseH.  Phage T7 ligase is very 
different from CPV resolvase structurally and functionally.  Although it uses Mg2+ as cofactor, the 
Mg2+ play different role in T7 ligase to CPV resolvase.  In CPV resolvase, Mg2+ is used to activate 
water molecule, which in turn functions as nucleophile to perform nucleophilic attach.  In T7 ligase, 
Mg2+ is used to stabilize the transition state, and 3’-hydroxy group of nucleic acid terminal.  This 
rule applies other ligases, DNA polymerases and RNA transcriptases.  However, Metal&EDTA 
method did make a difference when purify T7 ligase, as the elution volume shifts 10 ml when 
Metal&EDTA method, suggesting Metal&EDTA could help divalent ion dependent enzyme 
purification. 
In this chapter, we only tested Metal&EDTA method with SP-sepharose chromatography 
column.  We did not test the Mg2+ or Mn2+ effect on the Heparin-Sepharose and MonoS 
chromatography column.  Different chromatography column may have different bind affinities to a 
specific divalent ion dependent enzyme.  As we see in the purification of Phage T7 ligase, 
Heparin-Sepharose binds T7 ligase more tightly than SP-sepharose.  Therefore, negatively 
charged resins, such as Heparin-Sepharose, MonoS, SP-sepharose, Phosphate-cellulose and 
Hydroxyapatite should be tested to find one which gives best result. 
In discussion section, I listed possible application of Metal&EDTA method.  Most likely, 
RNaseH family members will get nice results when using Metal&EDTA method.  For 
Metalloproteinase family members, it will need to do further experiment to test this idea.  Bovine 
pancreatic carboxypeptidase shows similar electrostatic potential map as CPV resolvase.  It is 
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expected that using Metal&EDTA to purify BPC give nice result.  However, some other 
metalloproteinases surface charges are more evenly distributed (example human 
carboxypeptidase; data not shown).  It is questionable to get nice results to purify other 
metalloproteinases.  Therefore, it will need extra pre-purification such as, ammonium sulfate 
precipitation or other chromatography purification.  Hydroxyapatite chromatography could bind protein 
with acid or basic isoelectric point.  For restriction enzymes, they could be further divided to subgroups 
based on their active site composition(155).  Their bind affinities to chromatography column may 
be different.  It is necessary to test each subgroup whether they could be directly purified by one 
chromatography column like CPV resolvase or need combination of two chromatography columns 
like phage T7 ligase. 
In summary, it is necessary to develop a protocol to purify each type of divalent 
dependent enzymes using Metal&EDTA method.  
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Chapter 6: Serine recombinase introduction 
Large serine recombinases (LSRs) carry out site-specific recombination between short 
DNA sequences in prokaryotes that fulfill a variety of biological functions (156,157).  Most 
identified LSRs are bacteriophage integrases, but some catalyze the movement of antibiotic 
resistance genes by transposition (158,159) and other mobile elements (160), or carry out 
programmed DNA rearrangements (161).  The LSRs are named for their relationship with the 
well-studied serine recombinases, many of which function to resolve transposition intermediates 
or regulate gene expression by inversion of regulatory sequences (162).  Most 
resolvase/invertase enzymes have a catalytic domain of ~150 residues at their amino terminus, 
followed by a small, helix-turn-helix (HTH) DNA-binding domain (Figure 6-1B).  The LSRs share a 
similar amino-terminal catalytic domain, but have much larger carboxyl-terminal regions that 
range in size from ~300 residues for the bacteriophage R4 and A118 integrases to ~550 residues 
for the TnpX transposase (Figure 6-1A).  Here, we will refer to the resolvases and invertases as 
small serine recombinases.  Although the C-terminal region of the LSRs is comprised of multiple 
structural domains, we refer to this as the ‘‘C-terminal domain’’, or CTD, for consistency with the 
literature. 
 
Figure 6-1.  Large versus small serine recombinases.  A) LSR domain organization.  Some LSR enzymes have additional 
cysteine-rich domains at their carboxyl-terminal ends that are not shown here.  B) Small serine recombinase domain 
organization showing the similarity between the LSR enzymes and the well-studied resolvase/invertases.  Note that some 
serine recombinase superfamily members have domain arrangements different from those shown here (162).  
Abbreviations – cat: catalytic domain; RD: recombinase domain; ZD: zinc ribbon domain; CC: coiled coil motif; HTH: helix- 
turn-helix DNA-binding domain.  The helix (αE) that connects the catalytic domain to the RD or HTH domains is indicated.  
This figure is adapted from reference (163). 
The LSRs that function as bacteriophage integrases are often referred to as serine 
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integrases, emphasizing that they are serine recombinase family members and therefore carry 
out recombination by a series of transesterification reactions that use a conserved serine 
nucleophile.  The tyrosine recombinases, which include the well-studied integrase from 
bacteriophage λ and the Cre recombinase from bacteriophage P1, have structures that are 
unrelated to the serine recombinases and use a different overall mechanism that involves 
phosphoryl transfer with a tyrosine nucleophile (162).  The serine integrases utilize short, specific 
DNA sequences, or ‘‘attachment sites’’, in the virus (attP) and in the host (attB).  The LSRs that 
are not phage integrases use similar attachment sites to carry out what are essentially the same 
integration and/or excision reactions (157). 
The serine integrases have several important properties that distinguish them from the 
integrases related to phage λ.  The integration reaction can be carried out in vitro, with no 
requirement for accessory proteins, auxiliary DNA sequences or specific substrate topologies.  In 
addition, the attP and attB sites required are 40–50 bp in length, allowing for relatively simple 
manipulation of substrates.  Because of these properties, the attP x attB integration reaction can 
be performed with high specificity and directionality in inter- and intra- molecular contexts, and in 
a variety of eukaryotic cells (164-169).  The simplicity and highly directional nature of these 
systems has led to the use of serine integrases as powerful genome engineering tools (156,170).  
The bacteriophage φC31 integrase has also shown promise for use in gene therapy applications 
(171).  Serine integrases have also been used to design modules for data storage and 
construction of logic gates in biological systems (172,173). 
LSR structure 
The LSRs are composed of three primary structural domains: an amino-terminal catalytic 
domain similar to that found in the small serine recombinases, a DNA-binding ‘‘recombinase 
domain’’, and a DNA-binding zinc ribbon domain (Figure 6-2).  Each of the three domains is 
rather complex and the connectors between domains play important functional roles.  The crystal 
structures of catalytic domain and CTD domain have been determined separately, in which the 
CTD was determined as the complex with attP left half site (attPL).  Here, we describe the LSR 
structure using TP901 catalytic domain (PDB code 3BVP) and Listeria innocua (LI) integrase 
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CTD/attPL (from bacteriophage A118, Figure 6-2A) complex (PDB code 4KIS) as examples. 
 
Figure 6-2.  Typical LSR structure and attP sequence.  A)  A118 attP left half site, where the serine integrase binds is 
labeled.  B)  The LSR catalytic domain.  The structure of the TP901 integrase catalytic domain dimer is shown (PDB code 
3BVP).  Conserved catalytic residues are indicated as spheres at Cα and mark the location of the active site pocket.  
Ala117 corresponds to the position of Val129 in φC31 integrase.  Selected secondary structural elements are labeled.  C) 
Structure of the zinc ribbon domain core, with the extended αK and αL helices that make up the coiled-coil motif not 
shown.  Secondary structure elements and the RD–ZD linker are indicated.  The zinc ion is represented by a sphere and 
the zinc-coordinating cysteine residues are drawn as stick models.  The attP half site numbering follows that is shown in 
Figure A.  In contrast to the recombinase domain, the zinc ribbon domain extends across nine base-pairs of the major 
groove, where it interacts with the ‘‘ZD motif’’.  D) The LSR recombinase domain, represented by the LI integrase 
CTD/attP complex structure (PDB code 4KIS).  Secondary structure elements and the RD–ZD linker are indicated.  The 
attP half-site numbering corresponds to that used in Figure A.  Note that only the HTH motif from the recombinase domain 
interacts in the major groove.  All other RD–attP interactions involve the minor groove.  Figures B, C and D are adapted 
from reference (163).  
The catalytic domain The sequence similarity between the LSR and small serine 
recombinase catalytic domains suggested that these domains would be structurally similar.  The 
catalytic domain consists of a five-stranded β sheet surrounded by five α helices.  The crystal 
structure of the TP901 integrase catalytic domain confirmed that this was the case and revealed a 
number of small differences that exist between the two families (Figure 6-2B).  Most of these are 
simple insertions between structural elements that increase the average LSR catalytic domain 
size by 10–15 residues.  The serine nucleophile and three arginine residues that surround the 
scissile phosphate during catalysis (174) are strictly conserved (shown in figure 6-2B). 
The αE helix The αE helix connects catalytic domain and recombination domain.  It has 
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been crystallized in both structures of catalytic domain and CTD.  The αE helix plays a crucial 
role in the recombination pathway, mediating inter-subunit interactions involved in both LSR 
dimer formation and LSR tetramer formation.  This helix also plays an important role in the 
progression from synapsis of attachment sites to DNA cleavage, subunit rotation and DNA 
ligation to generate products (175). 
Recombination domain The middle domain in the LSRs has been termed the 
‘‘recombinase domain’’ based on LSR family member homology.  While there is no significant 
sequence similarity between the LSR RD and the HTH DNA-binding domain found in the small 
serine recombinases, it was expected that this domain would have a related function.  Indeed, the 
crystal structure of the LI integrase CTD-DNA complex revealed that the LSR recombinase 
domain does contain a structurally similar HTH motif (Figure 6-2D), .The LSR HTH subdomain 
(αF-αG-αH) is preceded by a pair of β-strands (β6–β7) and followed by a second pair of strands 
(β8–β9) and a fourth α-helix (αI).  Mutagenesis studies in the TnpX transposase (176) and LI 
integrase (114) have provided strong biochemical support for a role of this region in DNA binding. 
Zinc ribbon domain The zinc ribbon domain contains four highly conserved cysteine 
residues and it was inferred from early sequence analyses that a zinc-binding module was 
present in the LSRs.  The LI integrase structure revealed that residues 269–320 form a zinc 
ribbon (Figure 6-2C), which is typically defined as two b-hairpins with zinc-coordinating residues 
located near the base of the hairpins (177).  The four cysteine residues that coordinate zinc in the 
LSRs are almost completely conserved, but there do appear to be some exceptions with a 
histidine replacing cysteine.  The zinc ribbon domain has two important functions: DNA-binding 
and mediating interactions between integrase subunits.  This domain binds DNA by wrapping the 
β11–β12 hairpin and the β12–β12 segment around the major groove (Figure 6-2C), accounting 
for nine base-pairs of continuous contact at the outer ends of the attP site.  Deletion of the entire 
domain results in a dramatic reduction of DNA-binding affinity to attP and attB sites for the Bxb1 
and LI integrases (114,178).  It has been suggested that inter-subunit interactions are mediated 
by the coiled-coil (CC) motifs (179), but the nature of these interactions is not yet clear.  In LI 
integrase, the coiled-coil motif can be excised from the zinc ribbon domain with no effect on 
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integrase binding to attP and attB.  However, the resulting ∆ coiled-coil (∆CC) integrase loses the 
ability to carry out intermolecular recombination and to discriminate between sites during 
intramolecular recombination in vivo (114). 
LSR catalytic mechanism 
During the integration reaction, the serine integrase binds to attP and attB as a dimer, 
mediates association of the sites to form a tetrameric synaptic complex, and catalyzes strand 
exchange to generate an integrated prophage and new attachment sites, attL and attR.  The 
reverse reaction, where the prophage is excised by site-specific recombination between attL and 
attR sequences, does not occur in the absence of a phage-encoded recombination directionality 
factor (RDF).  The LSRs use the same mechanism to exchange strands as do the small serine 
recombinases (157,180).  This reaction is shown schematically in Figure 6-3, incorporating 
features recently proposed based on structural models (114). 
 
Figure 6-3.  The integration reaction catalyzed by large serine recombinases.  Integrase dimers bound to attP and attB 
associate to form a synaptic complex stabilized by interactions between catalytic domain dimers and by interactions 
involving the CC motifs.  Coordinated cleavage of all four DNA strands by the catalytic domains results in 5’-
phosphoserine linkages between the DNA and the protein subunits plus 3’-overhanging dinucleotides containing the site’s 
crossover sequence.  Rotation of subunit pairs about a horizontal axis results in formation of a strand-exchange 
configuration where ligation to form recombinant attL and attR products will occur efficiently if the unpaired dinucleotides 
are complementary.  The unique ZD arrangements on the resulting attL and attR sites promote an intramolecular 
interaction between CC motifs that inhibits the reverse excision reaction.  This figure is adapted from reference (163). 
Despite the similarity in mechanism of strand exchange, the small serine recombinases 
function under very different topological contexts and do not share the large C-terminal region 
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that is responsible for coordination of unique LSR activities.  LSR site-selectivity and directionality 
are regulated at the synapsis step of the recombination pathway (178,181) in a manner that 
involves the CTDs.  In this model, coiled-coil motif controls the integration directionality.  When 
LSR dimer forms complex with attP and attB, the coiled-coil motif prefer to form intermolecular 
interaction, thus promote formation of attP and attB synapsis and integration.  When LSR dimer 
forms complex with attL and attR, the coiled-coil motif prefers to form intramolecular interaction, 
thus inhibits formation of attL and attR synapsis and incision. 
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CHAPTER 7: The attP site in listeria bacteriophage integration 
This chapter incorporates all members’ work of the Van Duyne lab. Karen Rutherford purified 
∆CC-CTD protein, prepared attPL, obtained ∆CC-CTD•attPL crystal and collected diffraction data. 
Robert Sharp performed one of triplicate intermolecular recombination assay. Kushol Gupta 
performed the sedimentation equilibrium experiment and measured the oligomeric constant of LI 
integrase and ∆CC-Integrase. Gregory Van Duyne involved in all experiments in this study. 
Abstract 
Large serine recombinases (LSRs) catalyze the movement of DNA elements into and out 
of bacterial chromosomes using site-specific recombination between short DNA att sites.  LSR 
differs from serine recombinase (SR) by possessing a large C-terminal domain (CTD).  Crystal 
structure of CTD•attPL revealed that CTD contacts attPL from one side and forms numerous 
specific and non-specific interactions with attPL nucleotides.  In this chapter, we employed 
different approaches, including X-ray crystallography, DNA competition binding assay, 
intermolecular recombination assay and electrophoretic mobility shift assay, systematically 
studied the interaction between attP and Listeria innocua (LI) serine integrase.  Our results 
demonstrated that most nucleotides which form non-specific interactions could be mutated 
without affect binding affinity to LI integrase and recombination efficiency.  Nucleotides which 
form specific interaction showed decreased binding affinity to LI integrase and recombination 
efficiency.  The LI integrase or CTD has different affinities to attP site or half sites.   In general, 
attP has higher affinity to LI integrase/CTD than half attP sites and attPL has higher affinity to LI 
integrase/CTD than attPR.  These features likely adapts to LSR biological functions. 
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Introduction 
Listeria bacteriophage integration to and incision from Listeria DNA genome is a very 
complicated process.  The major players in the process are rather simple, for it only has two 
protein components (serine integrase and recombination directionality factor, and the later is only 
required during incision process), and four DNA fragments (attP, attB, attL and attR.  Two of them 
function simultaneously). Listeria integrase belong to large serine recombinase family, and it is a 
multi domain enzyme.  The different domains interact with the att DNA at different positions.  The 
LSR continuously switches its conformation, thus change its affinity to different fragment to fulfill 
different function in the bacteriophage life cycle. 
Dimerization of the small serine recombinases has been well established with firm 
biochemical and structural bases (162,175).  As expected, the Bxb1, φC31 and A118 integrases 
are also apparent dimers in solution based on size exclusion chromatography.  However, the 
issue of dimerization is more complicated for the LSRs since the coiled-coil region of the zinc 
ribbon domain is also thought to mediate integrase-integrase interactions (179).  Most LSR 
attachment sites are 40–50 bp in length, with attP generally 48-50 bp and attB 38-40 bp. 
 
Figure 7-1.  Large serine recombinase-attP site complexes.  A), schematic models of the LI integrase•attP complex.  B) 
shows the attP sequence of bacteriophage A118.  Nucleotides identical in the two half-sites are in bold and the central 
dinucleotide is colored red.  Base pairs in rectangle box shows attP left half site (attPL); other base pairs shows attP right 
site (attPR).  The regions contacted by the RD, the ZD and the RD–ZD linker are indicated.  C), the structural model was 
generated by combining two integrase CTD•attPL complexes (114), using the γδ-resolvase/DNA complex (182) as a 
guide.  The catalytic domains shown are also from the γδ-resolvase/DNA complex.  Figures  A and C are adapted from 
reference (163).  Figure B is adapted from reference (114). 
The multi-domain and flexible nature of serine integrase makes crystallization very 
difficult.  The conserved catalytic domain structure was first determined in 2008 (183).  Until very 
recently, CTD crystal structure was reported as complex with attP left site (114).  Schematic and 
structural representations of a LSR binding to its attP site are shown in Figure 7-1A.  Figure 7-1B 
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shows the attP site of bacteriophage A118.  The structure model of LSR•attP (Figure 7-1C) is 
based on the structure of the LI integrase CTD bound to an attP half-site.  Given the similarity 
between integrases at the domain level, this mode of binding is likely to be shared by most LSRs.  
The integrase domains are spread out across the attP half-site, where each structural component 
contacts a distinct surface on the site.  Together with αE, the recombinase domain contacts base 
pairs 0-12, the RD-ZD linker contacts base-pairs 13-15, and the ZD contacts base-pairs 16–24, 
where it recognizes a nine base-pair ‘‘ZD motif’’.  Overall, 25 base pairs of the A118 attP half-site 
are covered by the integrase.  Surprisingly, the vast majority of integrase-DNA contacts involving 
αE, the RD, and the RD-ZD linker are to the sugar-phosphate backbone and to bases in the 
minor groove.  The only major groove interactions are via αH from the HTH motif.  In addition, the 
majority of the contacts made by the zinc ribbon domain involve the major groove, where the β11-
β12 hairpin and the β12-β12 loop span nine base-pairs at the end of the site. 
Although considerable progresses have been made in LSR study, most available 
knowledge focuses on biochemical study.  The limited structural information is the major barrier to 
understand the LSR mechanism in detail.  The available structure of LI CTD•attPL provided 
critical information that it could nicely explain the LSR mechanism by switching intermolecular 
and intramolecular interaction of coiled-coil motif.  In this model, ZD domain goes into major 
groove of attPL site, thus likely forms interaction with bases and determines the attP sequences 
specificity.  However, the low resolution restricted our understanding of the detailed interaction 
network between ZD motif and attPL.  Therefore, it is necessary to obtain a higher resolution 
structure of CTD•attPL structure to visualize the interaction.   Meanwhile, performing biochemical 
assay using attP point mutations will help understand the detail CTD interacts with attP site. 
Another researching area on LSR is the attachment site binding energetics.  Scientists 
speculated there are affinity differences between LSR or CTD and attP, attB, attL and attR sites, 
and they contribute to integration and incision.  Surprisingly, the LSR shows similar range of 
affinity to att sites.  In addition, CTD alone shows similar range of infinity to att sites as LSR 
(178,184).  These results are quite confusing.  To further study the binding energetic of LSR/CTD 
to att sites and guide crystallization of LSR/CTD complex with att sites, it is necessary to study 
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binding affinity of LSR or CTD to attP or attP half sites.  In this chapter, we employed different 
approaches, including X-ray crystallography, DNA competition binding assay, intermolecular 
recombination assay and electrophoretic mobility shift assay to study the interaction attP and 
serine integrase. 
Material and Method 
Crystallization of ∆CC-CTD•attPL and solving the structure 
∆CC-CTD protein and attPL are prepared by Karen Rutherford.  AttPL was annealed by 
two DNA oligos to make 5’ overhang with G and C to facilitate crystallization. ( 
5’-GTTTAGTTCCTCGTTTTCTCTCGTT-3’, 5’-CAACGAGAGAAAACGAGGAACTAAA-3’).  ∆CC-
CTD•attPL complex was prepared in buffer (10mM Tris-HCl, pH 8.0, 150mM NaCl, 1mM TCEP) 
by molar ration 1:1.5 (30μM:45μM).  The ∆CC-CTD•attPL crystals was obtained in 0.1M Tris-HCl 
pH 7.5, 0.2M (NH4)2SO4, 25% PEG3350 by hanging drop evaporation method.  Crystals are 
cryo-protected in reservoir solution with 20 v/v glycerol.  The diffraction was collected at APS 
Beamline 23-IDD.  Crystallization and data collection are performed by Karen Rutherford, a 
former postdoc in the lab. Initial phasing information was solved by molecular replacement with 
CTD•attPL as searching model.  CCP4i package was used to refinement the crystal structure and 
Coot software package was used to perform structure adjustment. 
Intermolecular recombination assay 
AttP mutants are amplified by PCR with plasmid (pGV2345, a plasmid harboring wild attP 
sequence) as templates and further purified, quantified.  Supercoiled attB plasmid pGV1741 are 
freshly purified, quantified and aliquoted to keep at -20°C. Both attP mutants and attB plasmid are 
dissolved in buffer (10 mM Tris, pH 8.5, 0.5 mM EDTA). LI Integrase was prepared at 2.5μM in 
buffer containing 20 mM Tris pH 8, 150 mM NaCl, 50 μg/ml BSA, 10% glycerol, 2 mM DTT. 
Reactions were carried out in the PCR tube by mixing of 4μl of 5X reaction buffer (100 
mM Tris pH 8, 750 mM KCl, 5 mM spermidine HCl, 10 mM DTT, 25 mM MgCl2, 125 μg/ml BSA, 
25% glycerol), 7.5μl sterile water, 2.5 μl supercoiled plasmid (500ng/μl), 2 μl integrase and 4μl of 
attP mutant (25ng/μl).  The mixtures were incubated at 32°C for 20min.  10ul of reaction products 
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were loaded to agarose gel (0.8% in 1X TAE buffer with 0.5ug/ml ethidium bromide) and run in 
buffer (1X TAE with 0.5ug/ml ethidium bromide) at 50V for 2 hours and 30minutes.  These 
experiments are carried out as triplicate or more.  The electrophoresis results are photographed 
by Kodak image workstation 4000, and quantified by QUANTIUM5.0 
Integrase DNA-binding competition assay 
Linear attP was cut from attP-harboring plasmid, gel purified, quantified and radio labeled 
with 32P.  Linear attP mutants: attP mutants are amplified by PCR with plasmid (pGV2345, a 
plasmid harboring wild attP sequence) as templates.  PCR products were purified, quantified. 
Both attP and attP mutants are dissolved in 1X TE buffer.  PAGE gel was prepared at 6%, using 
37.5:1 acrylamide mixture in 1X TE buffer (25mM Tris, 192mM glycine).  
2μl attP mutants (25nM), 8μl attP* (1nM in 1X binding buffer containing 2 mM Tris pH 7.4, 
150 mM KCl, 2 mM DTT, 25 μg/ml BSA, 25 μg/ml salmon DNA, 105% glycerol, 0.02% 
bromophenol blue), 10μl Integrase at 32 nM in 1X bind buffer were added to PCR tube, mix 
briefly, spin down, and incubate in the 32°C  heat block for 30 min.  Load 10 μl per lane and run 
the gel in 1X TE buffer at 200V for 2.5 hours, 10°C.  Dry the gel for 1 hour at 70°C deg.  Expose 
overnight for phosphorimager analysis.  Scan the gel and save the image for analysis.  These 
experiments are carried out as triplicate or more. 
Electrophoresis mobility shift assay to study attP affinity to LSR/CTD 
Linear attP was cut from attP-harboring plasmid, gel purified, quantified.  Linear attPL or 
attPR was synthesized as DNA oligo, and annealed with complimentary oligos.  All linear 
attP/attPL/attPR oligos are quantified, radio labeled with 32P. DNA (attP, attPL, attPR) dissolving 
buffer: 10 mM Tris, pH 8.5, 0.5 mM EDTA 
LI Integrase was prepared at 400nM in 1X binding buffer, and sequentially diluted by 
factor of 2 to 200, 100, 50, 25, 12.5, 6.3, 3.1, 1.6, 0.8, 0.4, 0.2, 0.1nM.  CTD was prepared at 
6400nM in 1X binding buffer, and sequentially diluted by factor of 2 to 3200, 1600, 800, 400, 200, 
100, 50, 25, 12.5, 6.3, 3.1, 1.6nM. 
All other steps are same as Integrase DNA-binding competition assay. 
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Results 
∆CC-CTD•attPL structure 
The first experiment we performed is obtaining the high resolution crystal structure of 
CTD•attPL.  Our lab has solved the crystal structure of CTD•attPL at 3.2Å using CTD of Listeria 
innocua prophage and left half site of attP (attPL) of bacteriophage A118 (114).  There are four 
CTD•attPL molecules in one asymmetric unit and coiled-coiled (CC) motifs adopt different 
conformations.  We speculate that if the CC motif is truncated from CTD, the CTD will become 
structurally homogenous and may help to obtain high quality crystals.  In the light of this idea, we 
make truncated version of ∆CC-CTD (residue 342-416 are truncated), and co-crystallized with 
attPL.  These crystals are obtained in distinct condition to CTD•attPL, belong to different space 
group and diffract to 2.8Å.  Each asymmetric unit has only one ∆CC-CTD•attPL molecule. 
We solved the structure with molecular replacement with full length CTD•attPL as 
searching model.  Table I shows the statistics of data collection and refinement of ∆CC-
CTD•attPL.  The overall structure of ∆CC-CTD•attPL is similar to CTD/attPL, with an overall rmsd 
of 1.087Å.  When aligned as Cα, it has an rmsd of 1.016Å, suggesting that the coiled-coil motif 
doesn’t change the overall CTD structure. 
∆CC-CTD is located at one side of attPL, and spreads on whole attPL, as shown in 
Figure 7-2A.  Briefly, αE helix contacts with minor groove of 0-3 base pair.  Recombination 
domain crosses cover major groove of 4-12 base pair.  Linker region between recombination 
domain and Zinc finger binding domain contacts with minor groove of 13-15 base pair.  The zinc 
finger binding domain makes extensive contacts with major groove of 16-24 base pair, in which 
zinc finger motif interacts with 16-20 base pairs and β11-β12 motif run through major groove of 
19-24, making extensive contacts with nucleo bases to determine the sequence specificity. 
The contacts between ∆CC-CTD and attPL could be divided to two categories.  One 
category is non-specific contacts between ∆CC-CTD and attPL phosphate and sugar backbones, 
which constitute the majority interactions.  The other category is sequence specific contacts 
between ∆CC-CTD and attPL nucleo bases, which constitute the minority interactions.  The 
detailed contacts between CTD and attPL have been described (114).  There is no considerable 
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difference between CTD•attPL an ∆CC-CTD•attPL, I will not repeat description here. 
Table 7-I.  Summary of data collection and refinement statistics 
 
Rmerge=Σ|Ih - <Ih>|Σ Ih, where <Ih> is the average intensity over symmetry 
equivalent measurements; R-factor, Σ|Fobs – Fcalc|/ ΣFobs, where summation is data 
used in refinement.  Numbers in parentheses represent values in the highest 
resolution shell.  *Rfree was calculated with 5% of the data. 
We carefully examined specific contacts between ∆CC-CTD and attPL.  Three regions 
are observed to form specific contacts, shown in figure 7-2.  The first region is located at the 
major groove of 5-10 base pairs.  αH helix goes into the major groove (Figure 7-2B).  ND2 and 
OD1 atoms of Asn208 side chain interact with both nucleosides of base pair 9.  Interestingly, the 
recombination motif adopts a shape of bridge, hanging over major groove of 5-10 base pairs, with 
only αH helix goes into the major groove.  The second specific contact is located at the linker 
region between recombination domain and zinc binding domain (Figure 7-2D).  Both atoms of 
nitrogen (ND2) and oxygen (OD1) of Asn259 side chain interact with nucleo base pair at 15th 
position.  The last specific contact is located at the zinc binding domain (Figure 7-2C).  β11 strand 
goes in to the major groove of base pair 18-24. Oxygen atom of Asp287 side chain and main 
Crystal ∆CC-CTD•attPL 
Space Group P212121 
Unit Cell a=48.3Å, b=57.1Å, c=167.9Å 
 α=β=γ=90° 
Wavelength (Å) 0.97919 
Resolution (Å) 57.11-2.85 
Completeness (%) 98.5(98.8) 
Rmerge 0.057(0.99414) 
Mean I/σ 14.9(2.3) 
Redundancy 3.0(3.1) 
Unique Reflections 10662 
Molecular replacement  
Model 4KIS 
Resolution (Å) 3.2 
Refinement  
Rfree* 0.282 
Rwork 0.202 
Number of atoms  
Protein 1921 
DNA 1020 
Zn2+ 2 
Solvent 12 
RMSD  
Bond length (Å) 0.012 
Bond Angles (°) 1.764 
Ramachandran plot (%)  
Favored 94.4 
Allowed 5.6 
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chain oxygen atoms of Asp287, Thr288 and Val289 form hydrogen bond net with base pair 20-23. 
 
Figure 7-2.  Crystal structure of ∆CC-CTD•attPL and specific contacts between ∆CC-CTD and attPL.  A) shows the 
overall structure of ∆CC-CTD•attPL complex.  Figures B, C and D show detailed specific contacts between ∆CC-CTD and 
attPL at different regions.  In all Figure B, D and D, hydrogen bonds are shown as dashed lines.  Non specific contacts are 
not showed. 
LI Integrase competition assay 
To study the contribution of each nucleo base pair of attP to form complex with LI 
integrase, we designed binding competition assay.  In this assay, wild attP was radio labeled.  
AttP mutants were used to bind LI integrase competing with wild attP.  If the base pair mutation 
weakens the interaction with LI integrase, more fraction of wild attP will bind LI integrase.  The 
fraction of radio labeled wild attP could be detected by EMSA.  Quantifying the ratio between 
radio labeled attP alone band and attP•integrase complex band will show the contribution of 
specific base pair.  We designed 79 attP mutants and studied their effects on forming complex 
with LI integrase.  Table 7-II shows the sequences of 79 mutants.  
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Table 7-II. List of attP mutants used in this study 
 
Nucleotides which have been mutated are shown in lowercase and bold with grey background.  
Number name Sequences 
0 lip 5’-TTGTTTAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCAAAAAT 
1 lip1A 5’-TTGTTTAGTATCTCGTTATCTCTCGTaGGtGGGAGAAGAAACGGGATACCAAAAAT 
2 lip1G 5’-TTGTTTAGTATCTCGTTATCTCTCGTgGGcGGGAGAAGAAACGGGATACCAAAAAT 
3 lip1C 5’-TTGTTTAGTATCTCGTTATCTCTCGTcGGgGGGAGAAGAAACGGGATACCAAAAAT 
4 lip2A 5’-TTGTTTAGTATCTCGTTATCTCTCGaTGGAtGGAGAAGAAACGGGATACCAAAAAT 
5 lip2T 5’-TTGTTTAGTATCTCGTTATCTCTCGtTGGAaGGAGAAGAAACGGGATACCAAAAAT 
6 lip2G 5’-TTGTTTAGTATCTCGTTATCTCTCGgTGGAcGGAGAAGAAACGGGATACCAAAAAT 
7 lip2C 5’-TTGTTTAGTATCTCGTTATCTCTCGcTGGAgGGAGAAGAAACGGGATACCAAAAAT 
8 lip3A 5’-TTGTTTAGTATCTCGTTATCTCTCaTTGGAGtGAGAAGAAACGGGATACCAAAAAT 
9 lip3T 5’-TTGTTTAGTATCTCGTTATCTCTCtTTGGAGaGAGAAGAAACGGGATACCAAAAAT 
10 lip3G 5’-TTGTTTAGTATCTCGTTATCTCTCgTTGGAGcGAGAAGAAACGGGATACCAAAAAT 
11 lip3C 5’-TTGTTTAGTATCTCGTTATCTCTCcTTGGAGgGAGAAGAAACGGGATACCAAAAAT 
12 lip4A 5’-TTGTTTAGTATCTCGTTATCTCTaGTTGGAGGtAGAAGAAACGGGATACCAAAAAT 
13 lip4T 5’-TTGTTTAGTATCTCGTTATCTCTtGTTGGAGGaAGAAGAAACGGGATACCAAAAAT 
14 lip4G 5’-TTGTTTAGTATCTCGTTATCTCTgGTTGGAGGcAGAAGAAACGGGATACCAAAAAT 
15 lip5A 5’-TTGTTTAGTATCTCGTTATCTCaCGTTGGAGGGtGAAGAAACGGGATACCAAAAAT 
16 lip5G 5’-TTGTTTAGTATCTCGTTATCTCgCGTTGGAGGGcGAAGAAACGGGATACCAAAAAT 
17 lip5C 5’-TTGTTTAGTATCTCGTTATCTCcCGTTGGAGGGgGAAGAAACGGGATACCAAAAAT 
18 lip6A 5’-TTGTTTAGTATCTCGTTATCTaTCGTTGGAGGGAtAAGAAACGGGATACCAAAAAT 
19 lip6T 5’-TTGTTTAGTATCTCGTTATCTtTCGTTGGAGGGAaAAGAAACGGGATACCAAAAAT 
20 lip6G 5’-TTGTTTAGTATCTCGTTATCTgTCGTTGGAGGGAcAAGAAACGGGATACCAAAAAT 
21 lip7A 5’-TTGTTTAGTATCTCGTTATCaCTCGTTGGAGGGAGtAGAAACGGGATACCAAAAAT 
22 lip7G 5’-TTGTTTAGTATCTCGTTATCgCTCGTTGGAGGGAGcAGAAACGGGATACCAAAAAT 
23 lip7C 5’-TTGTTTAGTATCTCGTTATCcCTCGTTGGAGGGAGgAGAAACGGGATACCAAAAAT 
24 lip8A 5’-TTGTTTAGTATCTCGTTATaTCTCGTTGGAGGGAGAtGAAACGGGATACCAAAAAT 
25 lip8T 5’-TTGTTTAGTATCTCGTTATtTCTCGTTGGAGGGAGAaGAAACGGGATACCAAAAAT 
26 lip8G 5’-TTGTTTAGTATCTCGTTATgTCTCGTTGGAGGGAGAcGAAACGGGATACCAAAAAT 
27 lip8C 5’-TTGTTTAGTATCTCGTTATcTCTCGTTGGAGGGAGAgGAAACGGGATACCAAAAAT 
28 lip9A 5’-TTGTTTAGTATCTCGTTAaCTCTCGTTGGAGGGAGAAtAAACGGGATACCAAAAAT 
29 lip9T 5’-TTGTTTAGTATCTCGTTAtCTCTCGTTGGAGGGAGAAaAAACGGGATACCAAAAAT 
30 lip9G 5’-TTGTTTAGTATCTCGTTAgCTCTCGTTGGAGGGAGAAcAAACGGGATACCAAAAAT 
31 lip9C 5’-TTGTTTAGTATCTCGTTAcCTCTCGTTGGAGGGAGAAgAAACGGGATACCAAAAAT 
32 lip10A 5’-TTGTTTAGTATCTCGTTaTCTCTCGTTGGAGGGAGAAGtAACGGGATACCAAAAAT 
33 lip10T 5’-TTGTTTAGTATCTCGTTtTCTCTCGTTGGAGGGAGAAGaAACGGGATACCAAAAAT 
34 lip10G 5’-TTGTTTAGTATCTCGTTgTCTCTCGTTGGAGGGAGAAGcAACGGGATACCAAAAAT 
35 lip10C 5’-TTGTTTAGTATCTCGTTcTCTCTCGTTGGAGGGAGAAGgAACGGGATACCAAAAAT 
36 lip11A 5’-TTGTTTAGTATCTCGTaATCTCTCGTTGGAGGGAGAAGAtACGGGATACCAAAAAT 
37 lip11G 5’-TTGTTTAGTATCTCGTgATCTCTCGTTGGAGGGAGAAGAcACGGGATACCAAAAAT 
38 lip11C 5’-TTGTTTAGTATCTCGTcATCTCTCGTTGGAGGGAGAAGAgACGGGATACCAAAAAT 
39 lip12A 5’-TTGTTTAGTATCTCGaTATCTCTCGTTGGAGGGAGAAGAAtCGGGATACCAAAAAT 
40 lip12G 5’-TTGTTTAGTATCTCGgTATCTCTCGTTGGAGGGAGAAGAAcCGGGATACCAAAAAT 
41 lip12C 5’-TTGTTTAGTATCTCGcTATCTCTCGTTGGAGGGAGAAGAAgCGGGATACCAAAAAT 
42 lip13A 5’-TTGTTTAGTATCTCaTTATCTCTCGTTGGAGGGAGAAGAAAtGGGATACCAAAAAT 
43 lip13T 5’-TTGTTTAGTATCTCtTTATCTCTCGTTGGAGGGAGAAGAAAaGGGATACCAAAAAT 
44 lip13C 5’-TTGTTTAGTATCTCcTTATCTCTCGTTGGAGGGAGAAGAAAgGGGATACCAAAAAT 
45 lip14A 5’-TTGTTTAGTATCTaGTTATCTCTCGTTGGAGGGAGAAGAAACtGGATACCAAAAAT 
46 lip14T 5’-TTGTTTAGTATCTtGTTATCTCTCGTTGGAGGGAGAAGAAACaGGATACCAAAAAT 
47 lip14G 5’-TTGTTTAGTATCTgGTTATCTCTCGTTGGAGGGAGAAGAAACcGGATACCAAAAAT 
48 lip15A 5’-TTGTTTAGTATCaCGTTATCTCTCGTTGGAGGGAGAAGAAACGtGATACCAAAAAT 
49 lip15T 5’-TTGTTTAGTATCtCGTTATCTCTCGTTGGAGGGAGAAGAAACGaGATACCAAAAAT 
50 lip15G 5’-TTGTTTAGTATCgCGTTATCTCTCGTTGGAGGGAGAAGAAACGcGATACCAAAAAT 
51 lip15C 5’-TTGTTTAGTATCcCGTTATCTCTCGTTGGAGGGAGAAGAAACGgGATACCAAAAAT 
52 lip16A 5’-TTGTTTAGTATaTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGtATACCAAAAAT 
53 lip16T 5’-TTGTTTAGTATtTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGaATACCAAAAAT 
54 lip16G 5’-TTGTTTAGTATgTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGcATACCAAAAAT 
55 lip17A 5’-TTGTTTAGTAaCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGtTACCAAAAAT 
56 lip17G 5’-TTGTTTAGTAgCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGcTACCAAAAAT 
57 lip17C 5’-TTGTTTAGTAcCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGgTACCAAAAAT 
58 lip18T 5’-TTGTTTAGTtTCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGAaACCAAAAAT 
59 lip18G 5’-TTGTTTAGTgTCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGAcACCAAAAAT 
60 lip18C 5’-TTGTTTAGTcTCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGAgACCAAAAAT 
61 lip19A 5’-TTGTTTAGaATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATtCCAAAAAT 
62 lip19G 5’-TTGTTTAGgATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATcCCAAAAAT 
63 lip19C 5’-TTGTTTAGcATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATgCCAAAAAT 
64 lip20A 5’-TTGTTTAaTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATAtCAAAAAT 
65 lip20T 5’-TTGTTTAtTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATAaCAAAAAT 
66 lip20C 5’-TTGTTTAcTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATAgCAAAAAT 
67 lip21A 5’-TTGTTTaGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACtAAAAAT 
68 lip21T 5’-TTGTTTtGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACaAAAAAT 
69 lip21G 5’-TTGTTTgGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACcAAAAAT 
70 lip21C 5’-TTGTTTcGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACgAAAAAT 
71 lip22A 5’-TTGTTaAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCtAAAAT 
72 lip22G 5’-TTGTTgAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCcAAAAT 
73 lip22C 5’-TTGTTcAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCgAAAAT 
74 lip23A 5’-TTGTaTAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCAtAAAT 
75 lip23G 5’-TTGTgTAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCAcAAAT 
76 lip23C 5’-TTGTcTAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCAgAAAT 
77 lip24A 5’-TTGaTTAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCAAtAAT 
78 lip24G 5’-TTGgTTAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCAAcAAT 
79 lip24C 5’-TTGcTTAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCAAgAAT 
109 
 
The attP mutant competition assay results are shown in Figure 7-3.  These mutants cover 
all base pairs 1-24.  Most attP base pairs have palindrome structures; therefore we test other 
three type nucleoside.  For those positions are not palindrome structures, we make them to 
palindrome structure and test each of four types of base pairs. 
 
Figure 7-3.  attP mutation effect on LI integrase binding.  Figure A-E shows the EMSA results of competition.  Figure A 
from left to right: attP control; attP mutant 1-19.  Figure B: attP control; attP mutant 20-38.  Figure C: attP mutant 39, attP 
control; attP mutant 40-57.  D: attP mutant 58-59, attP control; attP mutant 60-76.  E: attP mutant 77-79, wild attP.  Figure 
F shows the quantified results. 
The DNA binding competition assays indicated that most attP mutants had similar binding 
affinity as wild attP.  Base pair mutations at positions 20 and 23 greatly affect binding efficiency, 
for any mutation will weak attP binding to LI integrase, showed Figure in 7-3F.  Some mutants, 
such as at positions 2, 9, 14, 15 and 19, have negative effects when mutated to specific base pair. 
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These results are showed in Figure 7-3F.  I will discuss these results in the discussion section. 
Intermolecular recombination assay 
The second experiment we did was measuring the recombination efficiency of attP 
mutants when each base pair was mutated.  In this experiment, mutant attPs were used to 
recombine with attB.  After recombination, it will linearize circular plasmids harboring the attB 
sequences.  By comparing the intensity ratio between linear and circular plasmid band, we could 
infer the attP mutation on recombination effects.  These results are shown Figure 7-4. 
 
Figure 7-4.  attP mutation effect on recombination.  Figure A-D shows the EMSA results of competition.  Figure A from left 
to right: attP mutant 1-24.  Figure B from left to right:  attP mutant 25-48.  Figure C from left to right: attP mutant 49-64.  D 
from left to right: attP mutant 65-79, wild attP control; Figure E shows the quantified results. 
The intermolecular recombination results showed that most attP mutants have similar 
recombination efficiency as wild attP, as shown in Figure 7-4E.  Only several mutants located at 
111 
 
position 2, 9, 15 and 20 has low recombination efficiency than wild attP.  Especially mutant at 
position 20, all mutants showed low recombination efficiency.  I will discuss this in the discussion 
section. 
AttP affinity to LI integrase and CTD  
The last experiment we did was the measuring the affinities between attP and LI 
integrase.  These assays included: LI integrase to attP, attPL and attPR; CTD to attP, attPL and 
attPR.  The results are shown in Figure 7-5. 
 
Figure 7-5.  The affinity of attP sites to LI integrase and CTD.  Figures A, B and C show LI integrase affinities to attP, 
attPL and attPR.  Figures D, E and F show CTD affinities to attP, attPL and attPR.  In all figures, the first lanes are radio-
labeled attP, attPL or attPR alone.  In Figures A, B and C, integrase concentrations from left to right are: 400, 200, 100, 50, 
25, 12.5, 6.3, 3.1, 1.6, 0.8, 0.4, 0.2, 0.1nM.  In Figures D, E and F, CTD concentrations from left to right are: 6400, 3200, 
1600, 800, 400, 200, 100, 50, 25, 12.5, 6.3, 3.1, 1.6nM.  Arrows in Figure B and C point to bands corresponding Integrase 
monomer and attPL (attPR) complex.  Arrows in Figure D, E and F point to bands corresponding CTD dimer and attP 
(attPL or attPR) complex. 
From these figures, we could estimate that the Kd values of LI integrase or CTD to attP, 
attPL or attPR.  These values are summarized in following Table 7-III.  The affinities of LI 
integrase to attP, attPL and attPR are different.  It is expected that attP has the highest affinity of 
6nM.  Interestingly, the affinities of LI integrase to attPL and attPR are different, even though 
attPL and attPR have same size and similar sequence.  CTD has different patterns to bind attP, 
attPL and attPR.  Surprisingly, attP and attPL bind CTD with almost same affinity.  CTD only has 
very weak affinity to attPR. 
Table 7-III: Summary of attP sites to LI integrase affinity 
 attP attPL attPR 
LI Integrase 6nM 50nM ~400nM 
CTD 100nM 150nM 4800nM 
In Figure 7-5B and 7-5C, we found that there are weak bands below the In•attPL or 
In•attPR bands (Shown as arrows).  These bands likely correspond to LI integrase 
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monomer•attPL or attPR.  In Figure 7-5D, there are weak band (shown as arrow) above the major 
band: these bands likely correspond to one attP binding CTD dimer molecules.  In Figures 7-5E 
and 7-5F, the weak bands (shows as arrows) likely correspond to one attPL or attPR binding CTD 
dimer molecules. 
Discussion 
In this chapter, we determined the crystal structure of ∆CC-CTD•attPL complex.  ∆CC-
CTD•attPL has similar structure to CTD•attPL except truncation of coiled-coil motif.  The non-
specific contacts comprise the majority interactions between ∆CC-CTD and attPL.  The specific 
contacts only constitute a small fraction of interactions between ∆CC-CTD and attPL.   
In the attP competition and intermolecular recombination assays, most attP mutants have 
no distinctive effect on LI integrase binding and recombination. This could be explained by the 
fact that these mutants only form non-specific interactions with LI integrase. They only contact LI 
integrase by backbone sugar and phosphate moieties. Nucleoside mutation does not change the 
non-specific interaction with LI integrase.  
However, we noticed that some attP mutants have weaker binding affinity than wild attP, 
and these attP mutants are located at positions 2, 9, 14, 15, 19, 20 and 23. In addition, some attP 
mutants have lower recombination efficiency than wild attP, and these attP mutants are located at 
positions 2, 9, 15, 20. These results indicate that LI integrase and attP binding affinity closely 
relates with attP recombination efficiency. When binding affinity drops, attP likely has decreased 
recombination efficiency. AttP mutants which possesses low binding affinity and low 
recombination efficiency are not randomly distributed. In fact, nucleosides at these positions 
interact with LI integrase and forms specific interaction. Mutations at these positions will abolish 
the specific interaction between LI integrase and attP, therefore they will have weak binding 
affinity which leads to low recombination efficiency.   
Interestingly, none of attP mutant completely abolishes the attP binding and 
recombination. It suggests that all specific and non-specific interaction between attP and LI 
integrase play important roles in the process of attP binding and recombination. Multiple attP 
mutations may be required to cause a severe effect on its binding to Integrase and recombination. 
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The affinity of att sites to full-length SR or CTD is a hot research area in serine 
recombination study.  Among the LSR systems where attachment site binding has been studied 
quantitatively, there is a general consensus that integrase dimers bind within a similar range of 
affinities to attP, attB, attL and attR sites (163).  Scientists pay less attention to the LSR affinity to 
half att sites than full att sites.  We, for the first time, carried out experiments and symmetrically 
studied the LSR affinity to half attP sites. 
There is a long puzzling question in LSR study.  The affinities of LSR to att sites and CTD 
to att sites are in the same range.  As pointed out by Ghosh et al (178), the similar net DNA-
binding affinities observed for the full-length integrase and single CTD constructs imply that a 
significant energetic cost is associated with an integrase dimer binding to its attachment sites.  
Indeed, if the CTD interaction energies were additive, the net affinity expected for an integrase 
dimer binding to att-site DNA would amount to a Kd of about 10-14 M.  One interpretation is that 
the free integrase dimers adopt stable configurations that need to be disrupted in order to bind an 
attachment site and that the cost of doing so is approximately that of a single CTD-half site 
interaction (163). 
We noted one weak band below the integrase•attPL (or attPR) strong band.  The 
following discussion refers to attPL.  The weak band clearly exists and it could not be ignored.  
There are two explanations of the weak and strong bands.  One explanation is: the top band is 
dimer integrase and two attPL; the low band is dimer integrase and one attPL.  The alternative 
explanation is: the top band is dimer integrase and one attPL; the low band is monomer integrase 
and one attPL.  We believe the second explanation is the truth.  Two arguments support this 
conclusion.  One arguments is that there is much more integrase than attPL in the experiment.  
Two attPL molecules will choose to bind two integrase dimers (one attPL binds one integrase 
dimer) rather than bind one integrase dimer.  The other argument is that if the top band is two 
attPL and one integrase dimer, it should have similar mobility rate to dimer integrase•attP.  
Compared to Figure 7-5A, the top band migration is faster than dimer integrase•attP, thus it 
support the top band is dimer integrase•attPL complex.  In the same way, the top band in Figure 
7-5C correspond to dimer integrase•attPR. 
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Now, it leads to another question: could integrase dissociate to monomer at the 
concentration level of 400nM.  This observation is contradictory to the conclusion that SR and 
LSR are stable dimers (163).  According to our unpublished data (performed by Kushol Gupta 
and me), Listeria integrase is a stable dimer with Kd < 1nM, but also is a weak tetramer with Kd of 
45.5 μM.  The ∆CC-Integrase behavior is very different.  It is a stable dimer with Kd of 20nM.  This 
result indicates coiled-coiled motif contributes to integrase oligomeric formation: the 
intramolecular interaction of coiled-coil make dimer much more stable and also contribute form 
weak tetramer.  According to the LSR mechanism proposed by Rutherford et al (114), coiled-coil 
motif could not form intramolecular interaction.  Therefore, it is reasonable to assume that the Kd 
value of integrase dimerization in intergrase•attPL is around 20nM.  Integrase monomer could 
easily fall off from dimer integrase•attPL complex, thus monomer integrase•attPL will show as 
weak band in Figure 7-5B. 
The fact that the affinities of LSR to att sites and CTD to att sites are in the same range is 
better explained by an alternative way.  LSR has a Kd of dimerization around 10-8 M when forms 
complex with attP.  EMSA assay could not measure the affinity when LSR concentration closes to 
10-8 M.  However, if one intermolecular disulfide bond is introduced at αE helix, make the LSR as 
dimer much more stable when the concentration less than 10-8 M, the much high Kd could 
obtained.  The proper Kd value of monomer-dimer are likely adopts LSR function.  Higher Kd of 
dimerization may help bonding LSR to att sites, but make the rotation much difficult after 
cleavage.  Lower Kd of dimerization will cause more serious problem, since it will abolish the 
binding of LSR to att sites. 
There are weak bands above the strong shift bands in Figures 7-5D, E and F.  Based on 
the same fact that CTD amount is much more than attP (attPL or attPR), the weak should 
correspond to two CTD and one attP (attPL or attPR).  Comparing the weak band in figure 7-5D 
and E, CTD•attP is much stronger than CTD•attPL.  These results could be explained by CTD 
dimerization promote attP.  In the process of CTD dimer binding to attP, one CTD monomer binds 
to attP half site first.  After first CTD monomer binding, the second CTD monomer binding to 
leftover attP half site is boosted by two factors: first CTD monomer brings the second CTD 
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monomer to vicinity and the latter has tendency to bind attP.  In contrast, the second CTD 
monomer is not boosted by binding to attPL in the process forming CTD dimer and attP complex. 
CTD has a much stronger affinity to attPL than to attPR (150nM vs 4800nm).  This 
observation is consistent with our crystallization study.  CTD•attPL crystals could be obtained 
while CTD•attPR could not.  In our crystallization condition, the final CTD•attPL concentration is 
17.5μM.  At this condition, over 99% of CTD and attPL exist as complex.  At same concentration, 
about 30% of CTD and attPR do not form complex.  To get CTD•attPL, it is necessary to try high 
concentration of CTD•attPR complex or introduction artificial crosslink between CTD and attPR. 
In summary, this study provides detailed information to understand the interaction 
between attP site and Integrase.  The affinity differences between integrase, CTD and attP, attP 
half sites are likely adapted to LSR biological functions.  Similar experiments should be performed 
to study LSR interaction with attB, attL and attR sites and carry out crystallization trials. 
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APPENDIX A: Chapter 2&3 
Material and Methods 
Chemicals: acetate acid, acrylamide, agarose, ammonium persulfate, bisacrylamide, boric acid, 
EB (Ethidium Bromide), EDTA (Ethylenediaminetetraacetic acid), glycerol, HCl, protease inhibitor 
mixture, IPTG(Isopropyl β-D-1-thiogalactopyranoside), magnesium chloride, manganese 
chlorides, NaN3, PMSF(phenylmethanesulfonylfluoride), sodium chloride, se-methionine, sodium 
potassium tartrate, sucrose, TEMED (tetramethylethylenediamine), SDS (sodium dodecyl sulfate), 
Tris (tris(hydroxymethyl)aminomethane). 
Vector: pET21a 
Expression plasmids: Wild type resolvase, D130A, D132A, E59A, E59A-D130N, D130A-
D131A-D134A, D130A-D131A-D134A, ∆7 (97-103 deletion). 
Media: LB (Lysogeny broth), EZ Rich methionine-free medium (Teknova) 
Cell strain: DH5α, BL21(DE3). 
Chromatography Column: SP-sepharose, Mono-S, Superdex-200. 
Buffers: 
1). Buffers used to purify CPV resolvase: 
20 mM Tris, pH 7.4, 15% glycerol, 0.01%NaN3; 
20 mM Tris, pH 7.4, 15% glycerol, 0.01%NaN3, 0.2 M NaCl; 
20 mM Tris, pH 7.4, 15% glycerol, 0.01%NaN3, 1.0 M NaCl; 
2). Buffer used to dissolve DNA oligos: 
10 mM Tris, pH 8.5, 0.5 mM EDTA; 
3). Buffer used to anneal DNA duplex or HJ: 
20 mM Tris, pH8.0, 100 mM NaCl; 
4). Buffers used to run DNA electrophoresis: 
1x TAE buffer: 40 mM Tris-acetate and 1 mM EDTA, pH 8.3; 
0.5x TBE buffer: 45 mM Tris borate, 1 mM EDTA, pH 8.3; 
5). Buffer used to run SDS-PAGE: 
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 4x Resolving buffer: 1.5 M Tris-HCl, pH 8.8, 0.4% SDS; 
 4x Stacking buffer: 0.5 M Tris-HCl, pH6.8, 0.4% SDS; 
 1x Running buffer: 25 mM Tris, 192 mM Glycine, 0.1% SDS; 
 5x Loading buffer: 250 mM Tris, pH 6.8, 10% v/v SDS, 0.05% w/v Bromophenol blue, 44% 
  v/v glycerol; 
 Staining buffer: 10% w/v Ammonium Sulfate, 0.12% w/v Commassie blue, 10% v/v 
 Phosphoric acid, 20% v/v Methanol. 
Resolvase expression and purification 
The resolvase gene of canarypox virus was codon-optimized and synthesized by IDT 
(Appendix B).  The gene was inserted into pET21a vector between NdeI and BamHI restriction 
sites.  The plasmid was transformed into BL21(DE3) cell and grown on LB plate with ampicillin.  A 
single colony was inoculated into 30 ml of LB with 100 μg/ml of ampicillin and grown overnight at 
37° and 250 rpm.  The next morning, 10 ml of overnight culture was inoculated into 1 L LB media 
with ampicillin.  When OD600 reached 0.6, IPTG (Isopropyl β-D-1-thiogalactopyranoside) was 
added into the media at final concentration of 0.1 mM.   The temperature was adjusted to 18° 
degree and cells continued to grow overnight.   
The cell pellet was spun down at 8,000 rpm for 10 minutes and was resuspended in lysis 
buffer containing 20 mM Tris-HCl (pH 7.4), 15% glycerol (v/v), 0.2 M NaCl, 0.01% NaN3.  The 
cells  were lysed in two passes with an Avestin EmulsiFlex-C3  homogenizer, and the lysate was 
spun at 16,000rpm at 4° for 20 minutes.  The supernatant was filtered with Whatman paper and 
loaded onto a SP-sepharose column (24 ml bed volume) equilibrated with lysis buffer.  The lysis 
buffer was continued to run until the baseline was flat.  A linear gradient was run from 0.2 M to 
1.0 M NaCl in 20 mM Tris-HCl (pH 7.4), 15% glycerol (v/v), 0.01% NaN3 buffer by 5 column 
volumes (120 ml).  The resolvase peak was eluted roughly at the ionic strength of 0.3 M NaCl.  At 
this stage, the resolvase was about 80% purity.  
 The resolvase peak (24 ml) was pooled and diluted with an equal volume (24 ml) of 
buffer containing 20 mM Tris-HCl (pH7.4), 15% glycerol, 0.01% NaN3.  Then, 16 ml of resolvase 
peak fraction was loaded onto a MonoS column (8 ml bed volume) for further purification.  The 
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same gradient was run from 0.2 M to 1.0 M NaCl in 20 mM Tris-HCl (pH 7.4), 15% glycerol (v/v), 
0.01% NaN3 buffer in 6 column volumes (48 ml).  The resolvase peak fractions were pooled 
again, resulting in about 95% purity. Resolvase was purified in a total of three injections on 
MonoS and concentration with 10 kDa MWCO Centricon devices (Millipore) to 2 ml. Four injection 
of 0.5 ml were loaded onto a Superdex-200 10/230 column (24 ml bed volume) for final 
purification.  The running buffer for gel-filtration chromatography contained 20 mM Tris-HCl (pH 
7.4), 15% glycerol, 1 M NaCl and 0.01% NaN3.  After gel-filtration, the resolvase purity reached 
nearly 100%.  The resolvase peak fractions were collected and concentrated by using 10 kDa 
MWCO Centricon devices to 30~50 mg/ml and frozen in liquid nitrogen, and keep at -80° for 
future use. 
Resolvase mutant constructs were generated using the Quickchange site-directed 
mutagenesis procedure, and mutant resolvases were expressed and purified as wild type 
resolvase.  Selenomethionine-substituted protein was overexpressed using the methionine 
auxotroph B834(DE3) grown in EZ Rich methionine-free medium (Teknova) supplemented with 
100 mg/L of  D/L-selenomethionine.  Selenomethionine resolvase was expressed and purified 
using the same protocols as native resolvase. 
Crystallization and diffraction data 
CPV resolvase crystals were obtained by microdialysis, where 10 μl of 10 mg/ml protein 
in 20 mM Tris-HCl (pH 7.4), 15% glycerol, 1 M NaCl and 0.01% NaN3 was dialyzed against 1.5 ml 
of 50 mM Tris-HCl (pH 8.5), 180 mM MgCl2, 150 mM sodium-potassium tartrate, 0.35-0.50 M 
NaCl at 22°C using 10 μl dialysis buttons (Hampton Research) and 8 kDa MWCO dialysis 
membrane.  Crystals generally appeared after one week and continued to grow for another week 
to typical dimensions of 0.1 x 0.1 x 0.5 mm.  The crystals were cryo-protected by gradually 
increasing the sucrose concentration from 0-50% by dialysis.   
The crystals are tetragonal, P43212, with one resolvase dimer in the asymmetric unit and 
diffract to 2.6 Å.  Native resolvase diffraction data were collected at the NECAT beam line 24-ID-
E and processed with XDS package (185).  The native resolvase diffraction data exhibited 
anisotropy with diffraction limits of 2.3 Å along c* but 2.7 Å along a* and b*.  The data were 
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ellipsoidally truncated, anisotropically scaled, and an isotropic B of -20.61 Å was applied using 
the UCLA Diffraction Anisotropy Server (186).  Diffraction data for SeMet resolvase were 
measured at the Advanced Photon Source (APS) beam line 23-ID-D, and processed with 
HKL2000 (187).  SeMet peak dataset was collected at 0.97947Å with 1° oscillation. Translation of 
SeMet resolvase crystal along longest dimension was employed to decrease diffraction decay. 
Structure determination 
SHELXD (188) was used to locate both internal Se sites at 5 Å from the anomalous 
difference data, but the resulting SAD-phased map could not be readily interpreted (R=0.55).  
HHpred was used to search for homologous proteins (189) and produced three potential models 
in the RuvC family for molecular replacement: PDB codes 4EP4, 1HJR, and 1KCF.  Phased 
molecular replacement was performed using MOLREP (190) to place each model into the SAD-
phased map with scores of 0.131, 0.109, and 0.134, respectively.  The last model (1KCF; 21% 
identical to CPV resolvase) was combined with the Se-Met phases using Phaser (191).  This 
resulted in a the model with Rwork=0.43 and Rfree=0.49.  Several rounds of phase combination 
between the Se-SAD data and native dataset dropped the Rwork below 0.40.  The resulting 
model was used to refine against the native data and the data extend to 2.6 Å.   Another several 
rounds of model building with COOT (192) and refinement with CNS (193)  improved the structure 
to Rwork=0.223 and Rfree=0.264.  Residues 114-127 of both subunits are disordered, but were 
fit into weak density to provide approximate locations for modeling studies. 
Resolvase kinetic experiments 
Bulged DNA substrates are efficiently cleaved by resolvase and the products dissociate 
rapidly form the enzyme.  In this study, we used synthetic bulged DNA as substrates to perform 
kinetic measurements.  The bulged DNA sequence and all the reaction protocols were exactly 
same as described by Culyba (21).  DNA oligos were purchased form IDT and FPLC purified.  
Unlabeled DNA oligos were mixed at equal molar ratio at 100uM in 10 mM Tris-HCl, 0.1 M NaCl, 
boiled for 5 min and slowly cooled down to room temperature.  Fluorescein labeled substrate was 
mixed at a 2:1 molar ratio of unlabeled to 6-Carboxfluorescein labeled DNA oligo. 
Reactions for kinetic analysis were carried out in 100 μl buffer, containing 25 mM Tris-
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HCl (pH 8.0), 100 mM NaCl, 5 mM MgCl2 (or 0.5 mM MnCl2),  at 37° for 30 minutes.  The final 
resolvase concentration was 10 nM; fluorescein labeled bulged DNA concentration was fixed at 2 
nM and unlabeled DNA substrate concentration was varied from 0 to 1920 nM.  Fluorescein 
polarization signal was recorded every 60 seconds by a Beacon 2000 fluorescence polarization 
system (Invitrogen).  The percentage of cleavage was calculated by the formula: (FP level - Basal 
FP level)/(Initial FP - Basal FP) *100%.  Each experiment was done in triplicate to calculate a 
standard deviation.  Initial velocities were calculated from non-linear regression fits of the kinetic 
data using an exponential decay model in the Prism software package.  Km and Vmax were 
calculated using the Michaelis-Menten model in Prism. 
To measure the Km values of metal ions, experiments were carried out and analyzed as 
described above, with the following modifications.  Bulged DNA concentrations were fixed at their 
Km value for Mg2+ and Mn2+ respectively.  Mg2+ concentration was varied from 0.25 mM to 13 mM, 
while Mn2+ concentration was varied from 0.012 mM to1.3 mM. 
Holliday junction cleavage assays 
The HJ substrate was prepared by mixing four DNA oligos at equal molar ratio (100uM) 
(Appendix A, one of them is 6-fluoresencin labeled) in 10 mM Tris-HCl (pH8.0), 100 mM NaCl.  
The mixture was boiled for 5 minutes and then slowly cooled down to room temperature in a 
water bath. 
The cleavage buffer contained 20 mM Tris-HCl (pH8.0), 100 mM NaCl, 1% glycerol.  
CPV resolvase and HJ substrate concentrations were 100 nM and 10 nM respectively.  Final 
metal ion concentrations of Mg2+, or Mn2+ or combinations of Mg2+ and Mn2+ are specified in 
relevant figures.  20μl reactions were incubated at 37°C for 30 min and then stopped by adding 
5x stop solution (100 mM EDTA, 5% SDS, 30% glycerol and 0.1% bromophenol blue).  The 
reaction products were separated on 10% polyacrylamide gels by electrophoresis in 0.5x TBE 
buffer.  The fluorescein label was visualized with a Typhoon instrument (GE healthcare). 
Isothermal titration calorimetry 
For CPV resolvase binding experiments, resolvase was in buffer containing 20 mM Tris 
(pH7.4), 1 M NaCl, 15% glycerol and concentration of 45mg/ml (1.3 mM).  The titration metal ion 
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(Mg2+ or Mn2+) was 30 mM in same buffer (prepared by mixing 0.203g MgCl2*6H2O or 0.198g 
MnCl2*4H2O, 20 μl 1M Tris, pH 7.4, 0.2 ml 5M NaCl, 0.3ml 50% glycerol (v:v), adding distilled 
water to 1ml ).  The ITC experiment was carried out by injecting metal ion into resolvase solution 
and measure the heat change.  In total, there were 20 injections and each injection was 2 μl.  
There were 3 minutes intervals between injections. Control experiments was performed by 
titration of Mg2+ (Mn2+) to buffer (used to dissolve CPV resolvase), and the enthalpy change was 
subtracted in calculation Mg2+ (Mn2+)•CPV resolvase enthalpy change. 
For metal binding to resolvase•HJ experiments, the HJ was prepared by mixing equal 
molar ratios of four oligos in buffer containing 10 mM Tris, pH7.4, 100 mM NaCl.  The mixture 
was boiled for 5 minutes and slowly cooled down to room temperature.  Resolvase mutants and 
DNA HJ was mixed at a 1: 1 molar ration, and dialysis against buffer (10 mM Tris-HCl, pH7.4, 
100 mM NaCl) to remove the glycerol and high concentration of NaCl.  The resolvase•HJ 
complex concentration was adjusted to 0.1 mM.  MgCl2 and MnCl2 are also dissolved at 2 mM in 
same buffer.  The experiments were carried out using the same protocol as for titration of 
resolvase with divalent ion.  All titrations were repeated three or more times and data was 
processed with the ITC-200 origins package. The stoichiometry and binding constants of Mn2+ to 
apo resolvase and resolvase•HJ complex were automatically determined, while the stoichiometry 
of Mg2+ was fixed at 2 and binding constants to apo resolvase, and mutant resolvase•HJ were 
automatically determined. 
Construction of CPV resolvase•HJ model 
The T.thermophilus RuvC•HJ complex (PDB code 4LD0) was first modified as follows.  
The terminal base-pairs and/or hairpin nucleotides were removed on each junction arm and the 
arms were extended to 10-bp in length by overlap superposition of idealized B-DNA duplex 
segments.  The HJ core where RuvC binds was not changed.  A CPV resolvase•HJ model was 
then constructed by superposition of the resolvase dimer onto the RuvC dimer using the Cα 
positions of conserved catalytic residues.  The side chain dihedral angles of several amino acids 
at the protein-DNA interface were adjusted to avoid steric clashes.  The only steric overlap 
between the resolvase main chain and the HJ DNA involved the disordered loop connecting α4 
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and α5, which was not experimentally well-defined but may become ordered upon substrate 
binding.  We did not attempt to model a DNA-binding conformation for this loop.  
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Data files 
CPV resolvase gene and protein sequence 
Codon optimized DNA sequence of canarypox virus resolvase: 
ATG•ACC•ATC•ATC•TGC•TCT•GTA•GAC•ATT•GGC•ATC•AAA•AAC•CCG•GCA•TAC•ACC• 
ATC•TTT•CGT•TAC•GAA•GAT•TCT•AAA•GTC•TCC•CTG•ATC•GCA•ATC•GAG•AAA•TCC• 
GAC•TGG•TCT•GAC•AAC•TGG•GAA•TAC•AAC•GTG•ACT•AAA•GAT•CTG•ACT•AAA•TAT• 
AAC•CCG•GAC•ATC•ATC•GTG•CTG•GAA•AAA•CAG•GGT•TAC•CGT•TCT•CCG•AAT•GCT• 
AAA•ATC•ATT•TAC•TTC•ATC•AAA•GGT•TTC•TTC•TAT•AAT•ACC•AAC•ACT•TCC•GTG• 
ATC•GTT•CGT•AAT•CCG•ACT•TTC•CAA•GGC•GGT•TCC•TAC•TCT•GAC•CGT•AAA•AAA• 
CAG•TCT•GTT•ATC•ACC•TTC•ATG•GAC•AAA•CTG•AGC•CGT•TAC•TCT•GAT•CAC•ATC• 
GAC•GAC•ATT•CTG•TCT•AGC•TTC•ACT•AAA•CTG•GAC•GAC•ATC•GCG•GAC•TCT•TTC• 
AAC•CTG•GGT•ATC•GCG•TAC•ATC•GAA•TCC•ACG•TTC•AAA•AAA•AAC•GTT•AAA•TAA 
 
Primary sequence of canarypox virus resolvase: 
MTIICSVDIGIKNPAYTIFRYEDSKVSLIAIEKSDWSDNWEYNVTKDLTKYNPDIIVLEKQGYRSPNA 
KIIYFIKGFFYNTNTSVIVRNPTFQGGSYSDRKKQSVITFMDKLSRYSDHIDDILSSFTKLDDIADSF 
NLGIAYIESTFKKNVK 
 
Codon changed sequence 
ATG•ACC•ATC•ATC•TGC•TCT•GTA•GAC•ATT•GGC•ATC•AAA•AAC•CCG•GCA•TAC•ACC• 
ATC•TTT•CGT•TAC•GAA•GAT•TCT•AAA•GTC•TCC•CTG•ATC•GCA•ATC•GAG•AAA•TCC• 
GAC•TGG•TCT•GAC•AAC•TGG•GAA•TAC•AAC•GTG•ACT•AAA•GAT•CTG•ACT•AAA•TAT• 
AAC•CCG•GAC•ATC•ATC•GTG•CTG•GAA•AAA•CAG•GGT•TAC•CGT•TCT•CCG•AAT•GCT• 
AAA•ATC•ATT•TAC•TTC•ATC•AAA•GGT•TTC•TTC•TAT•AAT•ACC•AAC•ACT•TCC•GTG• 
ATC•GTT•CGT•AAT•CCG•ACT•TTC•CAA•GGC•GGT•TCC•TAC•TCT•GAC•CGT•AAA•AAA• 
CAG•TCT•GTT•ATC•ACC•TTC•ATG•GAC•AAA•CTG•AGC•CGT•TAC•TCT•GAT•CAC•ATC• 
GAC•GAC•ATT•CTG•TCT•AGC•TTC•ACT•AAA•CTG•GAC•GAC•ATC•GCG•GAC•TCT•TTC• 
AAC•CTG•GGT•ATC•GCG•TAC•ATC•GAA•TCC•ACG•TTC•AAG•AAG•AAC•GTT•AAA•TAA 
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CPV resolvase properties 
        10         20         30         40         50         60  
MTIICSVDIG IKNPAYTIFR YEDSKVSLIA IEKSDWSDNW EYNVTKDLTK YNPDIIVLEK  
        70         80         90        100        110        120  
QGYRSPNAKI IYFIKGFFYN TNTSVIVRNP TFQGGSYSDR KKQSVITFMD KLSRYSDHID  
       130        140        150  
DILSSFTKLD DIADSFNLGI AYIESTFKKN VK 
 
Number of amino acids: 152 
Molecular weight: 17560.9 
Theoretical pI: 7.72 
Amino acid composition: 
Ala (A)   5   3.3% 
Arg (R)   5   3.3% 
Asn (N)  10   6.6% 
Asp (D)  14   9.2% 
Cys (C)   1   0.7% 
Gln (Q)   3   2.0% 
Glu (E)   5   3.3% 
Gly (G)   6   3.9% 
His (H)   1   0.7% 
Ile (I)  19  12.5% 
Leu (L)   7   4.6% 
Lys (K)  15   9.9% 
Met (M)   2   1.3% 
Phe (F)   9   5.9% 
Pro (P)   4   2.6% 
Ser (S)  16  10.5% 
Thr (T)  10   6.6% 
Trp (W)   2   1.3% 
Tyr (Y)  10   6.6% 
Val (V)   8   5.3% 
 
Total number of negatively charged residues (Asp + Glu): 19 
Total number of positively charged residues (Arg + Lys): 20 
 
Atomic composition: 
Carbon    C  799 
Hydrogen  H  1231 
Nitrogen  N  199 
Oxygen    O  240 
Sulfur    S  3 
 
Formula: C799H1231N199O240S3 
Total number of atoms: 2472 
 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water. 
Ext. coefficient    25900 
Abs 0.1% (=1 g/l)   1.475, assuming all pairs of Cys residues form cystines 
Ext. coefficient    25900 
Abs 0.1% (=1 g/l)   1.475, assuming all Cys residues are reduced 
 
Estimated half-life: 
The N-terminal of the sequence considered is M (Met). 
The estimated half-life is: 30 hours (mammalian reticulocytes, in vitro). 
                            >20 hours (yeast, in vivo). 
                            >10 hours (Escherichia coli, in vivo). 
 
Instability index: 
The instability index (II) is computed to be 28.49 
This classifies the protein as stable. 
 
Aliphatic index: 85.26 
Grand average of hydropathicity (GRAVY): -0.351  
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List of residues involved in interface interaction of CPV resolvase 
Residue Number Chain  Complex 
ASA* (Å2) 
Free ASA 
(Å2) 
Buried (ASA) 
Interface (Å2) 
Buried ASA 
% 
TRP  40 A 36.2 51.21 15.01   29.31 
GLU  41 A 43.43 82.07 38.64   47.08 
TYR  42 A 139.33 154.53 15.2    9.84 
THR  45 A 13.98 26.89 12.91   48.01 
ARG  64 A 117.51 202.97 85.46   42.10 
SER  65 A 20.46 27.17 6.71   24.70 
PRO  66 A 65.97 106.73 40.76   38.19 
LYS  69 A 51.61 95.76 44.15   46.10 
TYR  72 A 51.25 141.75 90.5   63.84 
PHE  73 A 0.07 58.77 58.7   99.88 
LYS  75 A 42.24 77.64 35.4   45.60 
GLY  76 A 0.0 53.48 53.48 100.00 
PHE  77 A 45.12 92.88 47.76   51.42 
TYR  79 A 52.93 160.48 107.55   67.02 
ASN  80 A 122.3 135.48 13.18    9.73 
TRP  40 B 33.54 49.07 15.53   31.65 
GLU  41 B 37.54 88.47 50.93   57.57 
TYR  42 B 129.04 145.20 16.16   11.13 
THR  45 B 9.66 26.26 16.6   63.21 
TYR  63 B 93.32 176.35 83.03   47.08 
ARG  64 B 150.05 201.98 51.93   25.71 
LYS  69 B 50.98 93.24 42.26   45.32 
TYR  72 B 31.18 118.16 86.98   73.61 
PHE  73 B 0.35 51.96 51.61   99.33 
LYS  75 B 51.34 80.82 29.48   36.48 
GLY  76 B 0.22 51.32 51.1   99.57 
PHE  77 B 44.77 93.11 48.34   51.92 
TYR  79 B 66.66 174.33 107.67   61.76 
ASN  80 B 131.71 140.51 8.8    6.26 
*ASA: accessible surface area 
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Summary of CPV-resolvase dimerization interface interaction 
Buried area upon the complex formation (Å2) 1325.9 
Buried area upon the complex formation (%)   8.92 
Interface area (Å2) 662.95 
Interface area MolA (%)   8.55 
Interface area MolB (%)   9.31 
POLAR Buried area upon the complex formation (Å2) 989.1 
POLAR Buried area upon the complex formation (%)  74.60 
POLAR Interface area (Å2) 494.55 
NO POLAR Buried area upon the complex formation (Å2) 336.7 
NO POLAR Buried area upon the complex formation (%)  25.39 
NO POLAR Interface area (Å2) 168.35 
Residues at the interface_Total: 29 
Residues at the interface_MolA: 15 
Residues at the interface_MolB: 14 
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List of residues involved in interface interaction of E.coli RuvC 
Residue Number Chain 
ID 
Complex ASA 
Å2 
Free ASA 
Å2 
Buried (ASA) 
Interface Å2 
Buried ASA 
% 
LEU  40 A 29.39 68.15 38.76   56.87 
PRO  41 A 30.4 95.67 65.27   68.22 
LEU  44 A 5.08 45.93 40.85   88.94 
LYS  45 A 74.76 125.05 50.29   40.22 
TYR  48 A 21.44 65.78 44.34   67.41 
VAL  68 A 42.06 67.80 25.74   37.96 
PHE  69 A 137.47 159.71 22.24   13.93 
ALA  71 A 42.53 53.28 10.75   20.18 
LYS  72 A 175.29 190.76 15.47    8.11 
ALA  74 A 21.02 83.23 62.21   74.74 
ALA  77 A 3.49 46.83 43.34   92.55 
LEU  78 A 13.67 119.17 105.5   88.53 
LEU  80 A 51.09 55.87 4.78    8.56 
GLY  81 A 0.0 41.00 41.0 100.00 
GLN  82 A 11.97 64.01 52.04   81.30 
ARG  84 A 9.42 43.86 34.44   78.52 
GLY  85 A 0.0 35.05 35.05 100.00 
VAL  86 A 0.0 24.41 24.41 100.00 
ILE  88 A 0.0 38.70 38.7 100.00 
VAL  89 A 0.0 56.75 56.75 100.00 
VAL  92 A 29.11 86.13 57.02   66.20 
ASN  93 A 50.54 91.46 40.92   44.74 
VAL  98 A 22.43 42.51 20.08   47.24 
GLU  100 A 48.53 78.46 29.93   38.15 
LEU  40 B 28.84 66.29 37.45   56.49 
PRO  41 B 16.27 95.59 79.32   82.98 
LEU  44 B 3.0 46.67 43.67   93.57 
LYS  45 B 59.27 116.19 56.92   48.99 
TYR  48 B 27.06 65.13 38.07   58.45 
VAL  68 B 61.83 77.52 15.69   20.24 
ALA  71 B 23.27 45.40 22.13   48.74 
LYS  72 B 131.53 139.36 7.83    5.62 
ALA  74 B 16.45 88.18 71.73   81.34 
ASP  75 B 59.62 85.81 26.19   30.52 
ALA  77 B 3.4 35.72 32.32   90.48 
LEU  78 B 10.5 110.73 100.23   90.52 
LEU  80 B 44.59 49.09 4.5    9.17 
GLY  81 B 0.0 36.36 36.36 100.00 
GLN  82 B 4.25 51.13 46.88   91.69 
ARG  84 B 8.96 42.25 33.29   78.79 
GLY  85 B 0.0 35.35 35.35 100.00 
VAL  86 B 0.0 22.01 22.01 100.00 
ILE  88 B 0.85 40.91 40.06   97.92 
VAL  89 B 0.03 62.88 62.85   99.95 
VAL   92 B 32.77 76.48 43.71   57.15 
ASN  93 B 59.81 100.50 40.69   40.49 
VAL  98 B 27.51 51.25 23.74   46.32 
GLU  100 B 55.89 78.41 22.52   28.72 
ASA: accessible surface area  
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Summary of E.coli RuvC dimerization interface interaction 
Buried area upon the complex formation (Å2) 1905.7 
Buried area upon the complex formation (%)  10.71 
Interface area (Å) 952.85 
Interface area MolA (%)  10.59 
Interface area MolB (%)  10.83 
POLAR Buried area upon the complex formation (Å) 1476.9 
POLAR Buried area upon the complex formation (%)  77.50 
POLAR Interface area (Å) 738.45 
NO POLAR Buried area upon the complex formation (Å) 428.8 
NO POLAR Buried area upon the complex formation (%)  22.50 
NO POLAR Interface area (Å) 214.4 
Residues at the interface_Total: 48 
Residues at the interface_MolA: 24 
Residues at the interface_MolB: 24 
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Primary sequence alignment of poxvirus resolvases 
                        *        20         *        40         *        60         *        
Penguinpox   : ------------------MRKSIMIICSVDIGIKNPAYTIFNYDK---------DNSTIKLIAIEKSDWS- :  43 
Pigeonpox    : -----------------------MIICSVDIGIKNPAYTIFNYDK---------DNSTIKLIAIEKSDWS- :  38 
Fowlpox      : -----------------------MIICSVDIGIKNPAYAIFNYDN---------TSNTIKLIAIEKSDWT- :  38 
Canarypox    : ----------------------MTIICSVDIGIKNPAYTIFRYE-----------DSKVSLIAIEKSDWS- :  37 
Vaccinia     : METLTSSSQSLMSSPMSKKDYSSEIICAFDIGAKNPARTVLEVK----------DNS-VRVLDISKLDWS- :  59 
Camelpox     : -----------MSSPMSKKDYSSEIICAFDIGAKNPARTVLEVK----------DNS-VRVLDISKLDWS- :  48 
Cowpox       : METLTSSSQSLMPLPMSKKDYSSEIICAFDIGAKNPARTVLEVK----------DNS-VRVLDISKLDWS- :  59 
Monkeypox    : ---------------MSKKDYSSEIICAFDIGAKNPARTVLEVK----------DNS-VRVLDISKLDWS- :  44 
Taterapox    : METLTSSSQSLMSSPISKKDYSSEIICAFDIGAKNPARTVLEVK----------DNS-VRVLDISKLDWS- :  59 
Crocodilepox : -----------------------MIIAAIDPGTRNPAVAWIEVVPGAGDGVGTAAAARVRLRALRRCDWSG :  48 
Smallpox     : METLTSSSQSLISSPMSKKDYSSEIICAFDIGAKNPARTVLEVK----------DNS-VRVLDISKLDWS- :  59 
Yokapox      : METSVNLSQSLTHSQMLKRDSNSEIICAFDIGAKNPARTILEVR----------GQE-VRIIDISKLDWS- :  59 
Goatpox      : ----------MSNNHC-LKHIKKEVICAFDIGAKNPARTVLEIE----------SNN-IKIIDISKLDWS- :  48 
Sheeppox     : ----------MSNNHC-LKNIKKEVICAFDIGAKNPARTILEIE----------SNN-IKIIDISKLDWS- :  48 
Tanapox      : ----------------------MEIVCAFDLGKKNPARTIFEID----------GNG-IKLIDISKLDWS- :  37 
Deerpox      : ----------MSKNYYNAPTEQKEVICAFDIGAKNPARTIIEVY----------NNNSIKILDISKLDWS- :  50 
Swinepox     : ----------MSNNHY-----RKEIICAFDIGAKNPARTILEIE----------NNI-IRIIDISKLDWS- :  44 
Squirrelpox  : -------MPKRRARRPATRDGCRRVVSAFDIGAKNPARTVLEVS----------GDS-VRVLDVSKLDWS- :  52 
 
                      80         *       100         *       120         *       140         
Penguinpox   : KNWERSVAKDLTSYN----PDVVILEKQGFKSPNSKIIYFIKGFFYNTN--TKVIVRNPTFKGGSYRNRKK : 108 
Pigeonpox    : KNWERSVAKDLTSYN----PDVIILEKQGFKSPNSKIIYFIKGFFYNTN--TKVIVRNPTFKGGSYRNRKK : 103 
Fowlpox      : KNWERSVARDLTRYN----PDVVILEKQGFKSPNSKIIYFIKGFFYNSN--TKVIVRNPTFKGGSYRNRKK : 103 
Canarypox    : DNWEYNVTKDLTKYN----PDIIVLEKQGYRSPNAKIIYFIKGFFYNTN--TSVIVRNPTFQGGSYSDRKK : 102 
Vaccinia     : SDWERRIAKDLSQYE----YTTVLLERQPRRSPYVKFIYFIKGFLYHTS-AAKVICVSPVMSGNSYRDRKK : 125 
Camelpox     : SDWERRIAKDLSQYE----YTTVLLERQPRRSPYVKFIYFIKGFLYHTS-AAKVICVSPVMSGNSYRDRKK : 114 
Cowpox       : SDWERRIAKDLSQYE----YTTVLLERQPRRSPYVKFIYFIKGFLYHTS-ATKVICVSPVMSGNSYRDRKK : 125 
Monkeypox    : SDWERRIAQDLSQYE----YTTVLLERQPRRSPYVKFIYFIKGFLYHTS-AAKVICVSPVMSGNSYRDRKK : 110 
Taterapox    : SDWERRIAKDLSQYE----YTTVLLERQPRRSPYVKFIYFIKGFLYHTS-AAKVICVSPVMSGNSYRDRKK : 125 
Crocodilepox : RDWQRRVAADLLDPARAPRPDLVVVEKQGRGSRLARIVYFVQGLVWPRA-----AVRNPSFRGGRYADRKA : 114 
Smallpox     : SDWERRIAKDLSQYE----YTTVLLERQPRRSPYVKFIYFIKGFLYHTS-AAKVICVSPVMSGNSYRDRKK : 125 
Yokapox      : SDWEKRIAKDLSQYE----YNTVLLERQPRRSPYVKFIYFIKGFLYHNSSNIKVICVSPVMSGNSYRDRKK : 126 
Goatpox      : CKWEEQVAKDLFQHN----YNYVLLEQQSKRSPYIKFIHFIKGLLYNSD--TKVISVSPVMVGCSYKDRKK : 113 
Sheeppox     : CKWEEQVAKDLFQHN----YNYVLLERQSKRSPYIKFIHFIKGLLYNSD--TKVISVSPVMVGYSYKDRKK : 113 
Tanapox      : TNWEKKVADDISKYN----YTSVLLERQPKRSPYVKFIYFIKGFLYNTF--TKVICVSPVMNGKSYKDRKK : 102 
Deerpox      : TDWEKRIARDISQYD----YKFVLLERQPRRSPYVKFIYFIKGFLYHSH--TKVICVSPVMTGNSYKDRKR : 115 
Swinepox     : TDWEKKVARDISQYD----YTSVLLERQPRRSPYVKIIYFIKGYLYNTR--SKVICVSPVMTGDSYRERKR : 109 
Squirrelpox  : ADWESRVARDVAAFD----ADTVLLETQPRGSPHARFVYFIRGVLHGNR---RVLCVAPAMRGNSYRWRKR : 116 
                                                                                           
                      *       160         *       180         *       200         *        
Penguinpox   : QSVDTFIQKISEYSEYKNDILNKYTKLDDIADSFNLGLSYMESLLKKCKISKD---------------- : 161 
Pigeonpox    : QSIDTFIQKISEYSEYKNDILNKYTKLDDIADSFNLGLSYMESLIKKCKISKD---------------- : 156 
Fowlpox      : QSIDVFIQKISEYTDYKNDILNKYTKLDDIADSFNLGLSYMESLLKKCKISKD---------------- : 156 
Canarypox    : QSVITFMDKLSRYSDHIDDILSSFTKLDDIADSFNLGIAYIESTFKKNVK------------------- : 152 
Vaccinia     : RSVEAFLDWMDTFG--LRNSVPDRRKLDDVADSFNLAMRYVLDKWNTNYTPYN-RCKSRNYIKKM---- : 187 
Camelpox     : RSVEAFLDWMDTFG--LRDSVPDRRKLDDVADSFNLAMRYVLDKWNTNYTPYN-RCKSRNYIKKMY--- : 177 
Cowpox       : RSVEAFLDWMDTFG--LRDSVPDRRKLDDVADSFNLAMRYVLDKWNTNYTPYN-RCKSRNYIKKM---- : 187 
Monkeypox    : RSVEAFLDWMDTFG--LRDSVPDRRKLDDVADSFNLAMRYVLDKWNTNYTPYN-RCKYRNYIKKM---- : 172 
Taterapox    : RSVEAFLDWMDTFG--LRDSVPDRRKLDDVADSFNLAMRYVLDKWNTNYTPYN-RCKSRNYIKKM---- : 187 
Crocodilepox : RSVRLFRRRAALLG---VPATALTGKLDDLADSLNLALAAAAELKFDSV-------------------- : 160 
Smallpox     : RSVEAFFDWMDIFG--LRDSVPDRRKLDDVADSFNLAMRYVLDKWNTNYTHYN-RCKSRNYIKKM---- : 187 
Yokapox      : RSVEAFLDWMNAFG--MRDYVPDRRKLDDVADSFNLAMRYVLDKWNTNYIPYN-KYRCKNYIKNM---- : 188 
Goatpox      : KSTESFLNWMKVFG--LVNSIPKGKKIDDVADSFNIALRFVLDKWDINYIPYK-KNKKIVKKPFKNNNG : 179 
Sheeppox     : KSTESFLNWMKVFG--LVNSIPKGKKIDDVADSFNIALRFVLDKWDINYIPYK-KIKK----------- : 168 
Tanapox      : RSIEVFLNWMTVFG--LKKNIPK-RKLDDVADSFNLAMRYILNKWKISYKPYI-KNKKN---------- : 157 
Deerpox      : RSIETFLNWMSIFG--LIDFIPIRRKLDDVADSFNLAMRYVLDKWNINHAPYV-KHKSIKKCKIDDNSI : 181 
Swinepox     : RSVETFLNWMNVFG--IMDFIPDRRKLDDVADSFNIAMRYILDKLNIKYYSYINRYKKM---------- : 166 
Squirrelpox  : VSVRRFLSWMDMFG--LRDSVPDRRKLDDVADSFNIAMRFVLTRL------------------------ : 159 
 
Characters in black rectangle are the five conserved amino acids in the active pocket. 
Virus name Genebank access code 
Penguinpox: NP_039150 
Pigeonpox: YP_00946184 
Fowlpox: NP_039150 
Canarypox:   NP_955284 
Vaccinia:  CAM58313 
Camelpox: AAG37631 
Cowpox: AGY98876 
Monkeypox:  AAY97133 
Taterapox:  YP_717451 
Virus name Genebank access code 
Crocodilepox:  YP_784335 
Smallpox:  NP_042170 
Yokapox:  YP_004821479 
Goatpox:  AGZ95429 
Sheeppox: NP_659686 
Tanapox:  YP_001497109 
Deerpox:   YP_227498 
Swinepox:  NP_570271 
Squirrelpox: YP_008658536  
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Oligonucleotides used for the assay substrates 
Substrate Oligonucleotides use 
Sub A 
 
5’-AGCTTCTGTGCAGCAGCTGCTCTCAACTGCAGTCTAGACT-3’ 
5’-AGTCTAGACTGCAGTTGAGAGCTTGCTAGGACGGATCCCT-3’ 
5’-AGGGATCCGTCCTAGCAAGCTTTTTGTTTTGATTGCGAGG-3’ 
5’-CCTCGCAATCAAAACAAAAAGCAGCTGCTGCACAGAAGCT-3’-F 
Enzymatic 
study 
Sub B 
 
5’-AGCTTCTGTGCAGCAGCTGCTCTCAACTGCAGTCTAGACT-3’ 
5’-AGTCTAGACTGCAGTTGAGAGCTTGCTAGGACGGATCCCT-3’ 
5’-AGGGATCCGTCCTAGCAAGCTTTTTGTTTTGATTGCGAGG-3’ 
5’-CCTCGCAATCAAAACAAAAAGCAGCTGCTGCACAGAAGCT-3’ 
Enzymatic 
study 
Sub C 5’-TCCGTCCTAGCAAGCCGCTGCTACCGGAAG-3’ 
5’-CTTCCGGTAGCAGCGAGAGCGGTGGTTGAA-3’ 
5’-TTCAACCACCGCTCTTCTCAACTGCAGTCT-3’ 
5’-AGACTGCAGTTGAGAGCTTGCTAGGACGGA-3’ 
ITC study 
Sub D 5’-TCCTACCACCAGATACACGCCACAGTTTTTTTTTTGATTA-3’-F 
5’-TAATCTTTTTTTTTTCTGTGGCGTGTATCTGGTGGTAGGA-3’ 
Bulged 
substrate 
Sub E 5’-TCCTACCACCAGATACACGCCACAGTTTTTTTTTTGATTA-3’ 
5’-TAATCTTTTTTTTTTCTGTGGCGTGTATCTGGTGGTAGGA-3’ 
bulged 
substrate 
Sub F 5’-CCTCGCAATCAAAACAAAAAGCAGCTGCTGCACAGAAGCT-3’-F 
5’-AGCTTCTGTGCAGCAGCTGCTTTTTGTTTTGATTGCGAGG-3’ 
Duplex DNA 
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Enzymatic activity of wild resolvase and mutants 
 
Enzymatic activities of wild resolves and mutant were determined by measuring fluorescence 
polarization change. The experiment is described in the resolvase kinetic study. 
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Appendix B: CHAPTER 5 
Material and Methods 
Primers 
Primers used to clone D130A-D131A-D134A CPV resolvase 
1). 5’-CTAGCTTCACTAAACTGGCAGCAATCGCGGCATCTTTCAACCTGGGTATCG-3’ 
2). 5’-CGATACCCAGGTTGAAAGATGCCGCGATTGCTGCCAGTTTAGTGAAGCTAG-3’ 
Primers used to clone E.coli RuvC 
1). 5’-TATACCATGGCTATTCTCGGCATTGATCCGGGTTCGC-3’ 
2). 5’-ATTCGGATCCTTAACGCAGTCGCCCTCTCGCCAGGTTCAG-3’ 
3). 5’-CACCTTGCTGAAACTGCCCGCTAATCCAC-3’ 
4). 5’-GTGGATTAGCGGGCAGTTTCAGCAAGGTG-3’ 
Primers used to clone E.coli RNaseH 
1). 5’- GTCAGTCATATGCTTAAACAGGTAGAAATTTTCACCG-3’ 
2). 5’- GTCAGTAAGCTTAAACTTCAACTTGGTAGCCTGTATC-3’ 
Vector: pET21a, pET33b,  
Plasmids: Wild CPV resolvase in pET21a, D130A-D131A-D134A CPV resolvase in pET21a, 
RuvC in pET33b, RNaseH in pET21a 
Media: LB (Lysogeny broth) 
Cell strain: DH5α, BL21(DE3). 
Chromatography columns: SP-sepharose, Mono-S, Superdex-200, Heparin-Sepharose, 
Hydroxyapatite. 
Buffers:  
1). Buffers used to purify CPV resolvase and E.coli RuvC:  
Lysis buffer: 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3, 0.2 M NaCl;  
Buffer A1: 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3;  
Buffer B1: 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3, 1.0 M NaCl; 
Buffer A2: 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3, 5 mM MgCl2; 
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Buffer B2: 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3, 1.0 M NaCl, 5 mM MgCl2; 
Buffer A3: 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3, 0.5 mM EDTA; 
Buffer B3: 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3, 1.0 M NaCl, 0.5 mM EDTA; 
Buffer A4: 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3, 5 mM MnCl2; 
Buffer B4: 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3, 1.0 M NaCl, 5 mM MnCl2; 
2). Buffers used to purify E.coli RNaseH:  
Lysis buffer: 20 mM Tris-HCl, pH 7.4, 10% Glycerol, 0.01% NaN3, 0.05 M NaCl;  
Buffer A5: 20 mM Tris-HCl, pH 7.4, 10% Glycerol, 0.01% NaN3, 0.5 mM EDTA; 
Buffer B5: 20 mM Tris-HCl, pH 7.4, 10% Glycerol, 0.01% NaN3, 1.0 M NaCl, 0.5 mM EDTA; 
Buffer A6: 20 mM Tris-HCl, pH 7.4, 10% Glycerol, 0.01% NaN3, 5 mM MnCl2; 
Buffer B6: 20 mM Tris-HCl, pH 7.4, 10% Glycerol, 0.01% NaN3, 1.0 M NaCl, 5 mM MnCl2; 
3). Buffers used to purify phage T7 ligase:  
Lysis buffer: 20 mM Tris-HCl, pH 7.4, 0.01% NaN3, 0.2M NaCl; 
Buffer A7: 20 mM Tris-HCl, pH 7.4, 0.01% NaN3; 
Buffer B7: 20 mM Tris-HCl, pH 7.4, 0.01% NaN3, 1.0 M NaCl; 
Buffer A8: 20 mM Tris-HCl, pH 7.4, 0.01% NaN3, 5 mM MnCl2; 
Buffer B8: 20 mM Tris-HCl, pH 7.4, 0.01% NaN3, 1.0 M NaCl, 5 mM MnCl2; 
Buffer A9: 20 mM Tris-HCl, pH 7.4, 0.01% NaN3, 0.5 mM EDTA; 
Buffer B9: 20 mM Tris-HCl, pH 7.4, 0.01% NaN3, 1.0 M NaCl, 0.5 mM EDTA; 
4). Buffer used to dissolve DNA oligos:  
10 mM Tris-HCl, pH 8.5, 0.5 mM EDTA. 
5). Buffer used to anneal DNA duplex:   
20 mM Tris-HCl, pH 8.0, 100 mM NaCl. 
6). Buffers used to run DNA electrophoresis:  
1x TAE buffer: 40 mM Tris-acetate and 1 mM EDTA, pH 8.3. 
0.5x TBE buffer: 45 mM Tris borate, 1 mM EDTA, pH 8.3. 
7). Buffers used to run SDS-PAGE:  
4x resolving buffer: 1.5 M Tris-HCl, pH 8.8, 0.4% SDS 
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4x stacking buffer: 0.5 M Tris-HCl, pH6.8, 0.4% SDS 
1x running buffer: 25 mM Tris, 192 mM Glycine, 0.1% SDS 
5x loading buffer: 250 mM Tris, pH 6.8, 10% v/v SDS, 0.05% w/v Bromophenol blue, 44%  
v/v Glycerol. 
8). Staining buffer: 10% w/v Ammonium sulfate, 0.12% w/v Commassie blue,  
9). Distain buffer: 10% v/v Phosphoric acid, 20% v/v Methanol. 
CPV resolvase cell culture and expression 
The CPV resolvase gene was codon optimized and synthesized by IDT (Integrated DNA 
Technologies) and inserted into pET21a vector (Novagen) between NdeI and BamHI restriction 
sites.  CPV resolvase was expressed in strain BL21 (DE3) by LB (Lysogeny broth) media at 18°C 
upon induction with 0.1 mM IPTG (isopropyl β-D-1-thiogalactopyranoside) when the cells reached 
an optical density of 0.6 at 600 nm.  After 16 hours, the bacteria cells were collected by 
centrifugation and resuspended in lysis buffer (20 mM Tris-HCl, pH 7.4, 15% Glycerol (v:v), 0.2 M 
NaCl, 0.01% NaN3).  The resuspended cell pellets are either flashed frozen in liquid nitrogen for 
long term storage or directly go to the next stage for purification.  Resolvase mutant construct 
(D130A-D131A-D134A, Tri-Mut) was generated by Quick-change site-directed mutagenesis kit 
(Strategene).  Same cell culture and purification protocols were applied to Tri-Mut CPV resolvase. 
Regular method to purify CPV resolvase 
One liter resuspended cell pellet was lysed at high pressure using an Avestin EmulsiFlex-
C3, clarified by centrifugation, and filtered before loading to 24 ml SP-sepharose chromatography 
column (GE Healthcare) equilibrated with lysis buffer.  After washing, a linear salt gradient was 
run from 0.2 M to 1.0 M NaCl in 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3 buffer by 5 
volume of SP column (120 ml).  The salt gradient buffer was mixed from buffer A1 (20 mM Tris-
HCl, pH 7.4, 15% Glycerol, 0.01% NaN3) and buffer B1 (20 mM Tris-HCl, pH 7.4, 15% Glycerol, 
0.01% NaN3, 1 M NaCl).  The resolvase peak (24 ml) was pooled and diluted with equal volume 
of buffer A1.  Then 16 ml of resolvase peak fraction was loaded onto 8 ml MonoS column (GE 
Healthcare) for further purification.  A salt linear gradient chromatography was run from 0.25 M to 
0.55 M NaCl in 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3 buffer in 6 volume of MonoS 
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chromatography column (48 ml).   Then resolvase peak fractions were pooled from MonoS 
elution and concentrated by 10 kDa MWCO Centricon tube (Millipore) to 2 ml and 0.5 ml was 
loaded to 23 ml Superdex-200 10/230 column (GE Healthcare) for final purification.  The running 
buffer for gel-filtration chromatography contains is Buffer B1.  The resolvase peak fractions from 
Superdex-200 elution were collected and concentrated by 10 kDa MWCO Centricon tube to 
30~50 mg/ml and flashed frozen in liquid nitrogen and keep at -80°.  Multiple runs and injections 
(for MonoS and gel-filtration) are required to purify one liter CPV resolvase cell pellet.  CPV 
resolvase purity was quantified by Quantum. 
Metal&EDTA method to purify CPV resolvase 
Filtered supernatant from one liter cell culture was loaded to 24 ml SP-sepharose column 
(GE Healthcare) equilibrated with lysis buffer.  After washing, a linear salt gradient 
chromatography was run from 0.2 M to 1.0 M NaCl in 20 mM Tris-HCl (pH 7.4), 15% Glycerol, 5 
mM MgCl2, 0.01% NaN3 buffer by 5 volume of SP-sepharose column (120 ml).  The salt gradient 
buffer was mixed from buffer A2 (20 mM Tris-HCl, pH 7.4, 15% Glycerol, 5mM MgCl2, 0.01% 
NaN3) and buffer B2 (20 mM Tris-HCl, pH 7.4, 15% Glycerol, 5mM MgCl2, 0.01% NaN3, 1M 
NaCl).  Resolvase peak fractions were pooled and diluted with two volume of buffer A3 (20 mM 
Tris-HCl, pH 7.4, 15% Glycerol, 0.5 mM EDTA, 0.01% NaN3) and loaded again to SP-sepharose 
chromatography column for next step purification.  A linear salt gradient chromatography was run 
from 0.2 M to 1.0 M NaCl in 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3 and 0.5 mM 
EDTA buffer by 5 volume of SP column (120ml).  The salt gradient buffer was mixed from buffer 
A3 and buffer B3 (20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.5mM EDTA, 0.01% NaN3, 1.0 M 
NaCl).  Resolvase peaks were collected, concentrated to 30~50 mg/ml and flashed frozen in 
liquid nitrogen and kept at -80°.  
The protocol using Mn2+ and EDTA to purify CPV resolvase was same as Mg2+ and 
EDTA except the first chromatography using buffer A4 (20 mM Tris-HCl, pH 7.4, 15% Glycerol, 5 
mM MnCl2, 0.01% NaN3) and buffer B4 (20 mM Tris-HCl, pH 7.4, 15% Glycerol, 5 mM MnCl2, 
0.01% NaN3, 1M NaCl).  A linear salt gradient chromatography was run from 0.2 M to 1.0 M NaCl 
by mixing Buffer A4 and B4. 
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ITC experiment to determine the metal affinity to CPV resolvase 
CPV resolvase was dissolved in buffer containing 20 mM Tris-HCl (pH 7.4), 1 M NaCl, 15% 
Glycerol at concentration of 17.5 mg/ml (dimer concentration: 0.5 mM).  The titration Mn2+ or Mg2+ 
was 50 mM in same buffer.  The ITC experiment was carried out by injecting metal ion into CPV 
resolvase solution and measure the heat change.  All experiments are performed at 25°C.  
Totally, there are 27 injections and each injection is 1.5 μl (except first inject 1.0 μl).  There is 3 
minutes interval between two injections.  Final data was processed with the ITC-200 ORIGINS 
package.  Stoichiometry of CPV resolvase to Mg2+ is fixed at 1:2.  
These experiments are also performed with high concentration of CPV resolvase (1.34 
mM, 47 mg/ml) and low concentration of Mg2+ or Mn2+ (30 mM). 
Contamination assay 
Super-coiled pET21a plasmid harboring the CPV resolvase gene was used as circular 
DNA.  Linear DNA is prepared by purification of PCR (Polymerase chain reaction) product of CPV 
resolvase gene.  Super-coiled plasmid or linear DNA (final concentration: 50 μg/ml) was mixed 
with CPV resolvase at mass ratio 1:1 in buffer containing 25 mM Tris-HCl, pH 8.0, 5 mM MgCl2 
and 1% Glycerol.  We incubated the reaction mixture for 2 hours at 37°C.  The incubation product 
was added equal volume of buffer containing 10% Glycerol, 2% SDS and 0.04% bromophenol 
blue.  10 μl of product was loaded to 1% agarose for electrophoresis analysis.  
Metal&EDTA method to purify E.coli RuvC 
The E.coli RuvC gene was amplified by PCR from BL21(DE3) cell strain and inserted into 
pET33b vector (Novagen) between NdeI and BamHI restriction sites.  RuvC was over-expressed 
in strain BL21 (DE3) by LB (Lysogeny broth) media at 20°C upon induction with 0.1 mM IPTG 
when the cells reached an optical density of 0.6 at 600nm.  After 16 hours, the bacteria cells were 
collected by centrifugation and resuspended in lysis buffer (20 mM Tris-HCl, pH 7.4, 15% 
Glycerol (v:v), 0.15 M NaCl, 0.01% NaN3).  The resuspended cell pellets are either flashed frozen 
in liquid nitrogen for long term storage or directly go to the next stage for purification. 
Two liter resuspended cell pellet was lysed at high pressure using an Avestin EmulsiFlex-C3, 
clarified by centrifugation, and filtered before loading to 24 ml SP-sepharose chromatography 
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column (GE Healthcare) equilibrated with lysis buffer.  After washing, a linear salt gradient 
chromatography was run from 0.15 M to 1.0 M NaCl in 20 mM Tris-HCl (pH 7.4), 15% Glycerol, 5 
mM MnCl2, 0.01% NaN3 buffer by 5 volume of SP-sepharose column (120 ml).  The salt gradient 
buffer was mixed from buffer A2 and buffer B2.  RuvC peak fractions were pooled and diluted 
with two volume of buffer A3 and loaded again to SP-sepharose chromatography column for next 
step purification.  A linear salt gradient chromatography was run from 0.15 M to 1.0 M NaCl in 20 
mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3 and 0.5 mM EDTA buffer by 5 volume of SP 
column (120ml).  The salt gradient buffer was mixed from buffer A3 and buffer B3.  In both steps 
of chromatography, RuvC purity was monitored by SDS-PAGE.  RuvC peaks were collected, 
concentrated and flashed frozen in liquid nitrogen and kept at -80°.  
Metal&EDTA method to purify E.coli RNaseH 
 The E.coli RNaseH gene was amplified by PCR from genomic DNA of DH5α strain and 
inserted into pET21a vector (Novagen) between NdeI and HindIII restriction sites.  RNaseH was 
over-expressed in strain BL21(DE3) by LB (Lysogeny broth) media at 15°C upon induction with 
0.1 mM IPTG when the cells reached an optical density of 0.6 at 600nm.  After 16 hours, the 
bacteria cells were collected by centrifugation and resuspended in lysis buffer (20 mM Tris-HCl, 
pH 7.4, 15% Glycerol (v:v), 0.05 M NaCl, 0.01% NaN3).  The resuspended cell pellets are either 
flashed frozen in liquid nitrogen for long term storage or directly go to the next stage for 
purification. 
One liter resuspended cell pellet was lysed at high pressure using an Avestin EmulsiFlex-
C3, clarified by centrifugation, and filtered.  One fifth of supernatant was loaded to 24 ml SP-
sepharose chromatography column (GE Healthcare) equilibrated with lysis buffer.  After washing, 
a linear salt gradient chromatography was run from 0.05 M to 1.0 M NaCl in 20 mM Tris-HCl (pH 
7.4), 10% Glycerol, 0.5 mM EDTA, 0.01% NaN3 buffer by 5 volume of SP-sepharose column 
(120 ml).  The salt gradient buffer was mixed from buffer A5 and buffer B5.  RNaseH peak 
fractions were pooled and diluted with two equal volume of buffer A3 and loaded again to SP-
sepharose chromatography column for next step purification.  A linear salt gradient 
chromatography was run from 0.05 M to 1.0 M NaCl in 20 mM Tris-HCl, pH 7.4, 10% Glycerol, 
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0.01% NaN3 and 5 mM MnCl2 buffer by 5 volume of SP column (120ml).  The salt gradient buffer 
was mixed from buffer A6 and buffer B6.  
RNaseH peak fractions from first step are further purified by MonoS chromatography 
column (8ml, GE Healthcare).   MonoS column was equilibrated with 5% buffer B5, and RNaseH 
peak fractions collected from SP-sepharose was loaded to MonoS column.  After washing, a 
linear salt gradient chromatography was run from 0.05 M to 1.0 M NaCl in 20 mM Tris-HCl (pH 
7.4), 10% Glycerol, 0.5 mM EDTA, 0.01% NaN3 buffer by 6 volume of MonoS column (48 ml).  
The salt gradient buffer was mixed from buffer A5 and buffer B5.RNaseH peak fractions were 
pooled and diluted with two volume of buffer A6 and loaded again to MonoS chromatography 
column for next step purification.  A linear salt gradient chromatography was run from 0.05 M to 
1.0 M NaCl in 20 mM Tris-HCl, pH 7.4, 10% Glycerol, 0.01% NaN3 and 5 mM MnCl2 buffer by 5 
volume of MonoS column (120ml).  The salt gradient buffer was mixed from buffer A6 and buffer 
B6.In both steps of chromatography, RNaseH purity was monitored by SDS-PAGE.  
Metal&EDTA method to purify Phage T7 ligase 
Plasmid (pET28b) harboring Phage T7 ligase gene is kept by our lab.  RuvC was over-
expressed in strain BL21(DE3) by LB media at 37°C upon induction with 0.1 mM IPTG when the 
cells reached an optical density of 0.6 at 600nm.  It continued for another three hours, and the 
bacteria cells were collected by centrifugation and resuspended in lysis buffer (20 mM Tris-HCl, 
pH 7.4, 0.2 M NaCl, 0.01% NaN3).  The resuspended cell pellets directly go to the next stage for 
purification or by adding 15% glycerol at final concentration and flashed frozen in liquid nitrogen 
for long term storage. 
One liter resuspended cell pellet was lysed at high pressure using an Avestin EmulsiFlex-
C3, clarified by centrifugation, and filtered before loading to 24 ml SP-sepharose chromatography 
column (GE Healthcare) equilibrated with lysis buffer.  After washing, a linear salt gradient 
chromatography was run from 0.2 M to 1.0 M NaCl in 20 mM Tris-HCl (pH 7.4), 0.01% NaN3 
buffer by 5 volume of Heparin-Sepharose column (120 ml).  The salt gradient buffer was mixed 
from buffer A5 (20 mM Tris-HCl (pH 7.4), 0.01% NaN3) and buffer B5 (1.0 M NaCl in 20 mM Tris-
HCl, pH 7.4, 0.01% NaN3).  T7 ligase peak fractions were pooled (total 24 ml).   
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4 ml of the peak was diluted with five volume of buffer A5 and loaded again to SP-
sepharose chromatography column for next step purification.  A linear salt gradient 
chromatography was run from 0.05 M to 1.0 M NaCl in 20 mM Tris-HCl, pH 7.4, 0.01% NaN3 and 
5 mM MnCl2 buffer by 5 volume of SP column (120 ml).  The salt gradient buffer was mixed from 
buffer A6 (20 mM Tris-HCl (pH 7.4), 5 mM MnCl2, 0.01% NaN3) and buffer B6 (20 mM Tris-HCl 
(pH 7.4), 5 mM MnCl2, 0.01% NaN3, 1.0 M NaCl).  T7 ligase peak pooled from Heparin-
Sepharose was also further purified by EDTA method.   
4 ml of the peak was diluted with five volume of buffer A5 and loaded again to SP-
sepharose chromatography column for next step purification.  A linear salt gradient 
chromatography was run from 0.05 M to 1.0 M NaCl in 20 mM Tris-HCl, pH 7.4, 0.01% NaN3 and 
0.5 mM EDTA buffer by 5 volume of SP column (120 ml).  The salt gradient buffer was mixed 
from buffer A7 (20 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 0.01% NaN3) and buffer B7 (20 mM Tris-
HCl, pH 7.4, 0.5 mM EDTA, 0.01% NaN3, 1.0 M NaCl).  In all steps of chromatography, Phage 
T7 ligase purity was monitored by SDS-PAGE.  
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Data files 
E.coli RuvC gene and protein primary sequences 
RuvC gene and protein sequence (cloned from BL21(DE3)): 
Gene sequence of E.coli RuvC: 
ATG•GCT•ATT•ATT•CTC•GGC•ATT•GAT•CCG•GGT•TCG•CGC•GTG•ACC•GGC•TAC•GGC• 
GTC•ATC•CGC•CAG•GTA•GGT•AGG•CAA•CTG•TCC•TAC•CTG•GGT•AGC•GGA•TGC•ATC• 
CGC•ACC•AAA•GTG•GAT•GAT•TTA•CCG•TCT•CGT•CTG•AAA•CTC•ATC•TAT•GCG•GGC• 
GTG•ACG•GAA•ATC•ATC•ACC•CAG•TTC•CAG•CCT•GAT•TAT•TTC•GCC•ATT•GAA•CAA• 
GTC•TTT•ATG•GCA•AAG•AAC•GCT•GAC•TCA•GCC•CTG•AAA•CTG•GGC•CAG•GCG•CGC• 
GGC•GTG•GCG•ATT•GTG•GCG•GCG•GTG•AAT•CAG•GAG•TTG•CCA•GTA•TTT•GAA•TAC• 
GCG•GCA•CGT•CAG•GTA•AAG•CAA•ACG•GTG•GTA•GGT•ATT•GGC•AGT•GCC•GAA•AAA• 
AGC•CAG•GTG•CAG•CAT•ATG•GTC•CGC•ACC•TTG•CTG•AAA•CGG•CCC•GCT•AAT•CCA• 
CAG•GCG•GAT•GCC•GCC•GAT•GCG•CTG•GCG•ATT•GCT•ATC•ACC•CAC•TGC•CAC•GTT• 
AGT•CAG•AAT•GCG•ATG•CAG•ATG•AGC•GAA•TCG•CGG•CTG•AAC•CTG•GCG•AGA•GGG• 
CGA•CTG•CGT•TAA 
 
Primary sequence of E.coli RuvC: 
MAIILGIDPGSRVTGYGVIRQVGRQLSYLGSGCIRTKVDDLPSRLKLIYAGVTEIITQFQPDYFAIEQ 
VFMAKNADSALKLGQARGVAIVAAVNQELPVFEYAARQVKQTVVGIGSAEKSQVQHMVRTLLKRPANP 
QADAADALAIAITHCHVSQNAMQMSESRLNLARGRLR 
 
Gene sequence of E.coli RuvC (consistent with E.coli RuvC: NP_416377.1) 
ATG•GCT•ATT•ATT•CTC•GGC•ATT•GAT•CCG•GGT•TCG•CGC•GTG•ACC•GGC•TAC•GGC• 
GTC•ATC•CGC•CAG•GTA•GGT•AGG•CAA•CTG•TCC•TAC•CTG•GGT•AGC•GGA•TGC•ATC• 
CGC•ACC•AAA•GTG•GAT•GAT•TTA•CCG•TCT•CGT•CTG•AAA•CTC•ATC•TAT•GCG•GGC• 
GTG•ACG•GAA•ATC•ATC•ACC•CAG•TTC•CAG•CCT•GAT•TAT•TTC•GCC•ATT•GAA•CAA• 
GTC•TTT•ATG•GCA•AAG•AAC•GCT•GAC•TCA•GCC•CTG•AAA•CTG•GGC•CAG•GCG•CGC• 
GGC•GTG•GCG•ATT•GTG•GCG•GCG•GTG•AAT•CAG•GAG•TTG•CCA•GTA•TTT•GAA•TAC• 
GCG•GCA•CGT•CAG•GTA•AAG•CAA•ACG•GTG•GTA•GGT•ATT•GGC•AGT•GCC•GAA•AAA• 
AGC•CAG•GTG•CAG•CAT•ATG•GTC•CGC•ACC•TTG•CTG•AAA•CTG•CCC•GCT•AAT•CCA• 
CAG•GCG•GAT•GCC•GCC•GAT•GCG•CTG•GCG•ATT•GCT•ATC•ACC•CAC•TGC•CAC•GTT• 
AGT•CAG•AAT•GCG•ATG•CAG•ATG•AGC•GAA•TCG•CGG•CTG•AAC•CTG•GCG•AGA•GGG• 
CGA•CTG•CGT•TAA 
 
Primary sequence of codon changed E.coli RuvC): 
MAIILGIDPGSRVTGYGVIRQVGRQLSYLGSGCIRTKVDDLPSRLKLIYAGVTEIITQFQPDYFAIEQ 
VFMAKNADSALKLGQARGVAIVAAVNQELPVFEYAARQVKQTVVGIGSAEKSQVQHMVRTLLKLPANP 
QADAADALAIAITHCHVSQNAMQMSESRLNLARGRLR  
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E.coli RuvC properties 
        10         20         30         40         50         60 
MAIILGIDPG SRVTGYGVIR QVGRQLSYLG SGCIRTKVDD LPSRLKLIYA GVTEIITQFQ  
        70         80         90        100        110        120 
PDYFAIEQVF MAKNADSALK LGQARGVAIV AAVNQELPVF EYAARQVKQT VVGIGSAEKS  
       130        140        150        160        170 
QVQHMVRTLL KLPANPQADA ADALAIAITH CHVSQNAMQM SESRLNLARG RLR  
 
Number of amino acids: 173 
Molecular weight: 18746.7 
Theoretical pI: 9.59 
Amino acid composition:
Ala (A)  22   12.7% 
Arg (R)  12  6.9% 
Asn (N)  5  2.9% 
Asp (D)  7  4.0% 
Cys (C)  2  1.2% 
Gln (Q)  14  8.1% 
Glu (E)  6  3.5% 
Gly (G)   13  7.5% 
His (H)    3  1.7% 
Ile (I)   13  7.5% 
Leu (L)   16  9.2% 
Lys (K)    7  4.0% 
Met (M)    5  2.9% 
Phe (F)    4  2.3% 
Pro (P)   6  3.5% 
Ser (S)   10  5.8% 
Thr (T)   7  4.0% 
Trp (W)   0  0.0% 
Tyr (Y)   5  2.9% 
Val (V)  16  9.2% 
 
Total number of negatively charged residues (Asp + Glu): 13 
Total number of positively charged residues (Arg + Lys): 19 
 
Atomic composition: 
Carbon      C       826 
Hydrogen    H      1359 
Nitrogen    N       241 
Oxygen      O       241 
Sulfur      S         7 
 
Formula: C826H1359N241O241S7 
Total number of atoms: 2674 
 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water. 
Ext. coefficient     7575 
Abs 0.1% (=1 g/l)   0.404, assuming all pairs of Cys residues form cystines 
Ext. coefficient     7450 
Abs 0.1% (=1 g/l)   0.397, assuming all Cys residues are reduced 
 
Estimated half-life: 
The N-terminal of the sequence considered is M (Met). 
The estimated half-life is: 30 hours (mammalian reticulocytes, in vitro). 
>20 hours (yeast, in vivo). 
>10 hours (Escherichia coli, in vivo). 
Instability index: 
The instability index (II) is computed to be 34.35 
This classifies the protein as stable. 
 
Aliphatic index: 104.91 
Grand average of hydropathicity (GRAVY): 0.085  
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E.coli RNaseH properties 
        10         20         30         40         50         60 
MLKQVEIFTD GSCLGNPGPG GYGAILRYRG REKTFSAGYT RTTNNRMELM AAIVALEALK  
        70         80         90        100        110        120 
EHCEVILSTD SQYVRQGITQ WIHNWKKRGW KTADKKPVKN VDLWQRLDAA LGQHQIKWEW  
       130        140        150 
VKGHAGHPEN ERCDELARAA AMNPTLEDTG YQVEV  
 
Number of amino acids: 155 
Molecular weight: 17596.9 
Theoretical pI: 8.43 
Amino acid composition: 
Ala (A)  14  9.0% 
Arg (R)  10  6.5% 
Asn (N)  7  4.5% 
Asp (D)  7  4.5% 
Cys (C)  3  1.9% 
Gln (Q)  8  5.2% 
Glu (E)  12  7.7% 
Gly (G)   14  9.0% 
His (H)    5  3.2% 
Ile (I)    7  4.5% 
Leu (L)   12  7.7% 
Lys (K)   11  7.1% 
Met (M)    4  2.6% 
Phe (F)    2  1.3% 
Pro (P)    5  3.2% 
Ser (S)    4  2.6% 
Thr (T)   10  6.5% 
Trp (W)    6  3.9% 
Tyr (Y)    5  3.2% 
Val (V)    9  5.8% 
 
Total number of negatively charged residues (Asp + Glu): 19 
Total number of positively charged residues (Arg + Lys): 21 
 
Atomic composition: 
Carbon      C       776 
Hydrogen    H      1215 
Nitrogen    N       227 
Oxygen      O       228 
Sulfur      S         7 
 
Formula: C776H1215N227O228S7 
Total number of atoms: 2453 
 
Extinction coefficients: 
Ext. coefficient    40450 
Abs 0.1% (=1 g/l)   2.299, assuming all Cys residues are reduced 
 
Estimated half-life: 
The N-terminal of the sequence considered is M (Met). 
The estimated half-life is: 30 hours (mammalian reticulocytes, in vitro). 
>20 hours (yeast, in vivo). 
>10 hours (Escherichia coli, in vivo). 
Instability index: 
The instability index (II) is computed to be 17.12 
This classifies the protein as stable. 
 
Aliphatic index: 73.68 
Grand average of hydropathicity (GRAVY): -0.631  
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Phage T7 ligase properties 
        10         20         30         40         50         60 
MMNIKTNPFK AVSFVESAIK KALDNAGYLI AEIKYDGVRG NICVDNTANS YWLSRVSKTI  
        70         80         90        100        110        120 
PALEHLNGFD VRWKRLLNDD RCFYKDGFML DGELMVKGVD FNTGSGLLRT KWTDTKNQEF  
       130        140        150        160        170        180 
HEELFVEPIR KKDKVPFKLH TGHLHIKLYA ILPLHIVESG EDCDVMTLLM QEHVKNMLPL  
       190        200        210        220        230        240 
LQEYFPEIEW QAAESYEVYD MVELQQLYEQ KRAEGHEGLI VKDPMCIYKR GKKSGWWKMK  
       250        260        270        280        290        300 
PENEADGIIQ GLVWGTKGLA NEGKVIGFEV LLESGRLVNA TNISRALMDE FTETVKEATL  
       310        320        330        340        350 
SQWGFFSPYG IGDNDACTIN PYDGWACQIS YMEETPDGSL RHPSFVMFRG TEDNPQEKM  
 
Number of amino acids: 359 
Molecular weight: 41133.0 
Theoretical pI: 5.27 
Amino acid composition:  
Ala (A)  18   5.0% 
Arg (R)  13   3.6% 
Asn (N)  18   5.0% 
Asp (D)  22   6.1% 
Cys (C)   6   1.7% 
Gln (Q)  11   3.1% 
Glu (E)  32   8.9% 
Gly (G)  28   7.8% 
His (H)   9   2.5% 
Ile (I)  20   5.6% 
Leu (L)  33   9.2% 
Lys (K)  28   7.8% 
Met (M)  14   3.9% 
Phe (F)  16   4.5% 
Pro (P)  14   3.9% 
Ser (S)  16   4.5% 
Thr (T)  17   4.7% 
Trp (W)   9   2.5% 
Tyr (Y)  13   3.6% 
Val (V)  22   6.1% 
 
Total number of negatively charged residues (Asp + Glu): 54 
Total number of positively charged residues (Arg + Lys): 41 
 
Atomic composition: 
Carbon    C   1847 
Hydrogen  H   2846 
Nitrogen  N     482 
Oxygen    O  543 
Sulfur    S   20 
 
Formula: C1847H2846N482O543S20 
Total number of atoms: 5738 
 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water. 
Ext. coefficient    69245 
Abs 0.1% (=1 g/l)   1.683, assuming all pairs of Cys residues form cystines 
Ext. coefficient    68870 
Abs 0.1% (=1 g/l)   1.674, assuming all Cys residues are reduced 
 
Estimated half-life: 
The N-terminal of the sequence considered is M (Met). 
The estimated half-life is: 30 hours (mammalian reticulocytes, in vitro). 
>20 hours (yeast, in vivo). 
>10 hours (Escherichia coli, in vivo). 
Instability index: 
 
The instability index (II) is computed to be 40.00 
This classifies the protein as stable. 
  
Aliphatic index: 80.36 
Grand average of hydropathicity (GRAVY): -0.400  
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Using hydroxyapatite chromatography to purify CPV resolvase 
After first step of regular protocol, the CPV resolvase peak fractions were pooled (total 24ml). 12 
ml of them was diluted with equal volume of buffer A1 and loaded to the HAP chromatography 
column. After washing, a linear phosphate gradient was run from 0.05 to 1.0 M in 6 volume of 
column volume (48ml). The CPV peak was eluted at 34 ml, corresponding of 0.3M phosphate. 
Most of impurity bands appear in the later fraction, but a few bands are co-eluted with CPV 
resolvase peak. These results are shown in following figure A and B. 
 
HAP chromatography to purify CPV resolvase. (A)shows the phosphate gradient elution profile. (B) shows the SDS-PAGE 
results of different fractions. Lane1: Ladder marker; Lane 2: CPV resolvase peaks pooled from SP-sepharose elution; 
Lane 3 to 14 are evenly sampled from 32 ml to 54 ml. 
 
Buffer A: 15% Glycerol, 10mM Na/K phosphate, pH 7.0. 
Buffer B: 15% Glycerol, 1.0M Na/K phosphate, pH 7.0  
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Typical nucleic acid enzymes and their divalent ion binding sites* 
Enzymes M2+ binding sites Enzymes M2+ binding sites 
Taq DNA polymerase 2 Restriction enzymes 4 
Pfu DNA polymerase 4 Ligase (dimer) 4 
E.coli DNA polymerase I 6 RNaseH 2 
Poxvirus DNA polymerase 4 Cas9 4 
Retroviral transcriptase 6 Argonaute 4 
Retroviral integrase 4 Dicer 4 
RNA polymerase 2   
* Only divalent ion binds to active sites are counted. Divalent ions number is calculated by active 
sites multiplying by two. Divalent ions, such as Zn2+ forming Zinc finger, which don’t bind at the 
active sites and only play a role to stabilize the protein structure, are not included in the 
calculation.   
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